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Abstract 
 
Non-infectious uveitis is a clinically heterogenous disease, which can cause 
chronic relapsing and remitting chorioretinal inflammation and vision loss. 
The disease is incurable but long-term clinical remission of inflammation may 
be induced with high dose ‘blockbuster’ systemic immunosuppression, which 
has multiple side effects. Personalised immunosuppressive therapy is 
currently not feasible, partly due to limitations in disease phenotyping.  
The aims of this thesis were to individualise management of patients with 
sight-threatening non-infectious uveitis by investigating: 
1. Clinical phenotypes of two similar subtypes of sight-threatening non-
infectious uveitis: multifocal choroiditis (MFC) and punctate inner 
choroidopathy (PIC). 
2. Immunological phenotypes of patients with sight-threatening non-
infectious uveitis. 
3. Perspectives of patients with sight-threatening retinal disease. 
Clinical and imaging data from 343 eyes of 185 subjects with MFC and PIC 
were found have some significant differences, with PIC showing a greater 
predilection for young, myopic women and tendency to secondary choroidal 
neovascularisation. Fifty patients with intermediate uveitis, posterior uveitis 
and panuveitis and 10 control subjects were prospectively recruited for 
immunological analysis of blood samples. Patients in clinical remission had 
significantly higher levels of Treg, polarised towards TIGIT and T-bet, 
associated with higher serum cytokine levels of IL-10 of TGF-β, and 
significantly lower methylation levels at key Treg epigenetic sites, compared 
to active patients and controls. Qualitative data was collected from patients 
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with sight-threatening retinal disease and used to design a pilot intervention 
to increase subjects’ capability and opportunity for healthy lifestyle change. 
 
Results suggest that the phenotyping of non-infectious uveitis could be 
improved and that immunological biomarkers could assist in disease 
management. The visual and psychosocial consequences of sight-
threatening retinal disease may also be addressed with tailored behavioural 
interventions. These findings could improve management of patients with 
uveitis by supporting the transition towards a more individualised therapeutic 
approach. 
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Impact Statement 
 
The impact of the research contained within this thesis is pertinent to the 
development of patient-centred therapies as we enter an era of 
‘personalised’ or ‘stratified’ approaches to disease management. 
Individualised treatment approaches to inflammatory disease are, in theory, 
favourable to standard ‘blockbuster’ systemic immunosuppression 
approaches (which have significant associated morbidity). In order to best 
utilise the increasing range of targeted immunomodulating drugs coming to 
market, it is important to have methods of disease phenotyping which are 
supported by scientific evidence and are relevant to outcomes prioritised by 
patients. The results of the clinical and laboratory studies, outlined in this 
thesis, contribute to the body of knowledge within this specialist area of sight-
threatening non-infectious uveitis. 
The results of the lab-based immunology study, in particular, provide 
evidence that the T-cell surface-expressed coinhibitory molecule, TIGIT, has 
utility as a marker of functional Treg, and that low levels of TIGIT may be a 
biomarker for increased risk of disease relapse of sight-threatening non-
infectious uveitis. This could help to individualise patient treatment by 
assisting in determining whether systemic immunosuppressive drugs are 
inducing functionally suppressive Treg, and by helping to inform clinical 
decision-making about tapering off immunosuppression. These data are also 
relevant to the recent interest in quantitative identification and isolation of 
viable, functional Treg for downstream clinical purposes, which includes their 
generation ex vivo for immunomodulating therapies.  
The public engagement and qualitative analysis project presented in this 
thesis involved engagement with patients who have sight-threatening,  
progressive retinal disease. The project identified an interventional approach 
 
 
9 
 
 
 
 
which has the potential to increase an individual’s sense of agency and self-
efficacy in the context of this type of chronic sight-threatening disease; and 
possibly improve their experience of the disease. This project demonstrated 
how public engagement might help to guide research, by developing the 
interface between healthcare/research institutions and their local 
communities.   
A final important impact of this thesis is the example of interdisciplinary 
thinking applied to a medical problem, in order to facilitate patient-centred 
solutions. Scientific and medical collaborations with teams specialising in 
rheumatology and cancer epigenetics, for example, were formed to assist in 
the design and conduct of this clinical ophthalmology and immunology 
research. Furthermore, social science theory and methods were explored in 
addition to conventional biomedical theory and quantitative methods. I 
believe that the value of drawing upon diverse expertise, in the development 
of individualised therapeutic approaches for sight-threatening non-infectious 
uveitis, has been demonstrated in this PhD thesis. 
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Chapter 1 Background and Introduction 
 
1.1 Definition of uveitis and anatomy of the uveal tract 
 
Uveitis is a term that refers to inflammation of the uveal tract, which is the 
highly vascular pigmented middle layer of the three concentric layers that 
make up the eye (Figure 1). The uvea lies between the sclera (superficial to 
it) and the retina (deep to it). The uveal tract is composed of the iris and 
ciliary body anteriorly and the choroid posteriorly (Foster and Vitale 2002).  
 
 
Figure 1: The uveal tract, consisting of the iris, ciliary body and choroid (highlighted 
in red) (Hu 2009) 
 
The term ‘uveitis’ may derive from the Latin ūva, meaning grape, possibly 
because of the deep purple/ pigmented appearance which characterises 
uveal tissue. The term ‘uveitis’ has now become almost synonymous in 
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ophthalmic clinical practice with any inflammation involving structures inside 
the eye, including vitreous gel and the retina. When the posterior uvea is 
inflamed there is a high likelihood of developing sight-threatening ‘retinitis’, 
defined as follows: 
‘Retinitis is an inflammation of the retina, most commonly related either to an 
infectious or an inflammatory cause. It is a nonspecific sign that 
accompanies many diverse causes of ocular inflammation and indicates the 
inflammation is involving the retina, either in isolation or in association with 
other structures, such as the choroid (chorioretinitis) or the optic nerve 
(neuroretinitis).’ (Gilbert, et al. 2016a) 
Therefore, sight-threatening posterior uveitis may also be referred to as 
‘choroiditis’, ‘retinitis’, ‘chorioretinitis’ or ‘neuroretinitis’ and these terms are 
sometimes used interchangeably.  
1.2 Classification of uveitis  
Uveitis is a clinically heterogenous disease: at least 150 disorders are known 
to be associated with intraocular inflammation. Individually, these disorders 
have a relatively low prevalence. In order to gain understanding of 
commonalities between subtypes the uveitis and develop uniformity in 
clinical research, diagnosis and management, the International Uveitis Study 
Group (IUSG) developed clinical criteria for classifying uveitis (Bloch-Michel 
and Nussenblatt 1987). In 2004, the Standardization of Uveitis Nomenclature 
(SUN) workshop analysed the IUSG criteria, found them very useful and 
added criteria for onset, duration and course of the disease.  
The SUN classification, as is it now known, is the most commonly used 
classification system for uveitis (Jabs, et al. 2005b). It classifies uveitis 
according to the anatomical location of intraocular inflammation, as follows 
(with a visual depiction of this shown in Figure 2): 
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1. Anterior 
2. Intermediate 
3. Posterior  
4. Pan uveitis  
 
Figure 2 SUN Working Group anatomic classification of uveitis (Jabs, Nussenblatt, 
Rosenbaum, et al., 2005) 
 
The SUN group also recommended consistent terminology to grade 
intraocular inflammation in the anterior chamber (AC), which presents as 
floating cells or ‘flare’ in the anatomical area of the AC. This may be graded 
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on a scale of 0 to 4, according to its severity (Tables 1-2) (Jabs, et al. 
2005b). Cells or cloudiness (haze) within the vitreous gel may be graded in a 
similar way to AC activity, although this is not currently part of the SUN 
classification (Davis, et al. 2010; Nussenblatt, et al. 1985). The clinical 
presentation of uveitis will be described in more detail, later in this chapter. 
 
Table 1 SUN working group classification of anterior chamber cells 
Grade  Number of AC cells 
0 <1  
0.5+ 1-5 
1+ 6-15 
2+ 16-25 
3+ 26-50 
4+ >50 
 
 
Table 2 SUN working group classification of anterior chamber flare 
Grade  Anterior chamber flare 
0 None  
1+ Faint 
2+ Moderate (iris and lens details clear) 
3+ Marked (iris and lens details hazy)  
4+ Intense (fibrin or plastic aqueous)  
 
Whilst the SUN criteria have been helpful for anatomically sub-classifying  
uveitis and grading active inflammation in clinical and research contexts, they 
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are not comprehensive clinical criteria. Therefore, uveitis is often further 
classified according to the clinical course of the inflammation, that is, into 
acute or chronic and, according to aetiology, that is, into infectious or non-
infectious.  
 
1.3 Epidemiology of uveitis 
In the Western world, the current incidences of uveitis vary between 38 and 
200 per 100,000 (Sangwan 2010; Williams, et al. 2007). Uveitis can affect 
people of all ages but occurs most frequently in the working age population 
(20 to 50 years), with 35% affected remaining visually disabled and resulting 
in a socio-economic impact comparable to diabetic retinopathy (Suttorp-
Schulten and Rothova 1996). A population-based study from the United 
States (US) reported three-fold increment in the incidence of uveitis, 
especially in the older age group, compared to the previous studies. The 
same study reported higher prevalence of uveitis in females compared to 
males (Gritz and Wong 2004). Anterior uveitis is the most common type of 
uveitis followed by pan uveitis, posterior uveitis and, finally, intermediate 
uveitis (Foster, et al. 2016a). Many cases of uveitis are chronic and may lead 
to numerous sight-threatening complications, which have been historically 
underestimated due of the paucity of data concerning their incidence. 
 
1.4 Prevalence and causes of vision loss in uveitis 
Uveitis is thought to be responsible for around 10-15% of all causes of vision 
loss worldwide and up to 22% of legal blindness in the UK (Durrani, et al. 
2004). Uveitis causes visual loss from direct inflammation, but also 
substantially from macular oedema, epiretinal membrane, cataract (opacity 
of the crystalline lens), glaucoma (optic neuropathy with characteristic visual 
field defect), choroidal neovascular membrane (CNV) and retinal 
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detachment. A recent study from Brazil found that uveitis was the second 
most common cause of vision impairment (15.7%) (Silva, et al. 2013) and, in 
Singapore, 7.5% of uveitis patients had severe vision loss, most commonly 
from cataract and glaucoma (Yeo, et al. 2013). In a recently published study 
of the causes of visual impairment in England and Wales, ‘uveitis’ did not 
feature as a distinct category (Quartilho, et al. 2016). The current UK 
Certificate of Vision Impairment (CVI) registration form, which formally 
certifies someone as visually impaired and functions as a record of data 
about visual impairment, contains only ‘chorioretinitis (unspecified) H30.9’, as 
a specific uveitis category. It has been noted that in addition to the 0.43% of 
patients in the UK recorded in this study with chorioretinitis (Quartilho, et al. 
2016), “many other patients with visual loss from uveitis are ‘hiding in plain 
sight’ within ‘secondary glaucoma’, ‘cataract’, ‘other retinal disorders’ and 
other categories” (Jones 2016). It was also observed that in a recent large 
study from a tertiary centre in Manchester, only 671 of 3000 uveitis patients 
(21%) could be labelled as having chorioretinitis, if severely affected (Jones 
2015; Jones 2016).  
‘At a time when great advances in the control of uveitis by 
immunosuppression and biologic therapy are being thwarted by funding 
restrictions, it would mean a disservice to affected patients if their disease 
cannot be adequately represented in vision impairment statistics.’ (Jones 
2016).  
Another study of uveitis patients attending a specialist clinic at Moorfields 
Eye Hospital indicates that vision loss was noted in 19.2% of eyes with 
uveitis, with chronic cystoid macular oedema being the most common cause 
of ‘moderate’ vision loss (3.55%) and macular scarring, the most common 
cause for irreversible ‘severe’ visual loss (4%) (Table 3) (Tomkins-Netzer, et 
al. 2014). Other causes of vision loss from uveitis include retinal vasculitis 
with or without ischaemia, retinopathy, hypotony (an eye with intraocular 
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pressure (IOP) of 5 mm Hg or less) and phthisis bulbi (an atrophic, non-
functional eye as a result of chronic inflammation) (Daniel, et al. 2012; 
Foster, et al. 2016a) 
Table 3 Causes of vision loss among all patients with uveitis attending a specialist at 
a tertiary centre in London (moderate vision loss corresponded to a best corrected 
Snellen visual acuity (BCVA) of 20/50 to 20/120 and severe vision loss to a BCVA of 
20/200) (Tomkins-Netzer et al., 2014). 
 
1.5 Visual impairment, disability and stereotypes 
Eye disease may lead to visual impairment and/ or disability.  Reduced visual 
acuity and reduced visual contrast sensitivity, in particular, have been found 
to be independently associated with self-reported difficulty with a wide variety 
of everyday visual activities and an increase in overall vision disability score 
(RUBIN, et al. 1994). The attitudes of sighted persons, which includes the 
majority of practising clinicians, are thought to have a major influence on the 
successful adjustment of severely sight-impaired individuals to disability 
(Allen and Bellstedt 1996). The General Medical Council states that its 
standards and guidance about disability are informed by the social model, 
that is, ‘the problem of disability lies with society, not with the disabled 
person’, as opposed to the medical model where ‘the impairment is seen as 
the problem’ (GMC 2017). However, there is still a paucity of opportunity 
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within medical training to learn about the psycho-social aspects of disability, 
and in particular, the consequences of visual impairment. This may lead to 
deficiencies in provision of health-care and adequate support for patients 
with eye disease.  
The Stereotype Content Model (Fiske, et al. 2002) describes how universal 
dimensions of social cognition, namely, perceptions of others’ ‘warmth and 
competence’ can cause stereotyping (widely held but fixed and 
oversimplified images or ideas) of individuals and influence behaviour 
towards these ‘other’ individuals: 
‘People perceived as warm and competent elicit uniformly positive emotions 
and behavior, whereas those perceived as lacking warmth and competence 
elicit uniform negativity. People classified as high on one dimension and low 
on the other elicit predictable, ambivalent affective and behavioral reactions. 
These universal dimensions explain both interpersonal and intergroup social 
cognition.’  
(Fiske, et al. 2007) 
Thus, patients with visual impairment might be perceived by clinicians as 
‘well-intentioned and warm but incompetent’, particularly if they are in the 
younger or older age groups: 
‘Groups seen as well-intentioned and warm, but incompetent, include older 
people and younger people in Canada and elsewhere, and in places where 
they are salient, also people with disabilities. They evoke pity and sympathy, 
as well as active help and protection, but also passive neglect and 
demeaning. Pity itself is a top-down, paternalistic response, and this mix of 
active help and passive harm reflects it. These ambivalent responses would 
seem a chilling description of institutionalizing people to ensure their physical 
care but isolating them from the rest of society.’ 
(Fiske 2012) 
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Furthermore, research on ‘stereotype threat’ which refers to ‘the risk of 
confirming, as self-characteristic, a negative stereotype about one's group’ 
(Steele and Aronson 1995), suggests that members of a stigmatised group, 
such older people with a disability, are more likely to act in stereotypical 
ways when their ‘identity’ is made salient (St Claire 2009). Therefore, 
unconscious bias generated through negative stereotypes of individuals with 
visual impairment could be an important influence on clinicians’ behaviour 
towards these groups, which has relevance to the quality of the doctor-
patient relationship and the provision of patient-centred care.  This problem 
could be addressed through ‘interventions aimed at increasing the relative 
salience to doctors of the human worth of individuals’, which have been 
shown to assist in increasing unconditional respect towards individuals under 
clinical care (Clucas and Claire 2017). 
 
1.6 Aetiology of uveitis 
The various forms of uveitis represent a common manifestation of multiple 
underlying causes of ocular inflammation: 
• Inflammatory/ Idiopathic (when evaluation has failed to find an 
underlying cause for inflammation) 
• Infectious (including opportunistic infection caused by 
immunosuppression) 
• Infiltrative (invasive neoplastic processes) 
• Trauma 
• Iatrogenic 
• Inherited (secondary to metabolic or dystrophic disease) 
• Ischaemic 
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Infectious agents include bacteria, viruses, fungi and protozoa and examples 
of infectious pathogens well known to cause uveitis include: 
• Toxoplasma 
• Tuberculosis 
• Toxocara 
• Herpes viruses – Simplex, Zoster and Cytomegalovirus (CMV) 
• Candida 
• Bartonella 
Newer pathogens being implicated in the aetiology of infectious uveitis, 
include the Zika (Furtado, et al. 2016)  and Ebola (Shantha, et al. 2016) 
viruses. However, during the past century, the aetiology of inflammation has 
swung from infective to non-infectious inflammation and in the majority of 
cases of uveitis, the aetiology of inflammation is non-infectious and 
idiopathic.  The inflammatory process can be apparently localized to the eye 
or be part of a systemic inflammatory disease. 
Important examples of systemic non-infectious inflammatory disease 
associations with uveitis include: 
• Sarcoidosis 
• Multiple sclerosis 
• Vogt-Koyanagi-Harada Syndrome 
• Behcet syndrome 
• Spondylarthroses with and without HLA B27+ antigen 
In addition, there are two specific childhood systemic disease associations 
with uveitis: 
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• Juvenile idiopathic arthritis 
• Juvenile HLA B27+ arthritis 
The aetiology of sight-threatening retinitis may be described, as follows: 
‘Retinitis has inflammatory and infectious causes, which are either parasites, 
bacteria, viruses, fungi. The most common cause of infectious retinitis is 
related to Toxoplasma gondii which is an obligate intracellular protozoan 
parasite. Ocular toxoplasmosis may be congenital due to transplacental 
transmission of tachyzoites or acquired following consumption of raw or 
undercooked meat containing cysts or by ingestion of fruits, vegetables, or 
water contaminated by cat faeces rich in oocysts. Other parasites which can 
cause retinitis include toxocariasis, onchocerciasis, and diffuse unilateral 
subacute neuroretinitis can be caused by several different parasites. 
Cytomegalovirus (CMV) retinitis is seen predominantly in 
immunocompromised patients and especially those with acquired 
immunodeficiency syndrome (AIDS). It may also occur following organ 
transplantation in patients receiving systemic immunosuppression or 
following chemotherapy for malignant disease. Following primary CMV 
infection, which is usually asymptomatic in immunocompetent people, the 
virus remains latent and only reactivates when the immune system is 
suppressed. Acute retinal necrosis (ARN) is caused by herpes simplex or 
varicella zoster virus (VZV) infections. In immunocompetent patients, these 
viruses result in a progressive peripheral necrotizing retinitis. In 
immunocompromised patients, infections can cause a rapidly progressive 
disease, progressive outer retinal necrosis (PORN), which can involve the 
posterior pole and has a very poor visual prognosis. Noninfectious retinitis 
can be related to systemic diseases such as Behçet disease and sarcoidosis’ 
(Gilbert, et al. 2016a), reproduced with permission. 
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1.7 The ‘white dot syndromes’ 
The ‘white dot syndromes’ are a heterogeneous subgroup of posterior 
uveitides, so called because they clinically manifest as multiple whitish-
yellow inflammatory lesions at the level of the outer retina, retinal pigment 
epithelium and choroid. To date, no specific underlying cause (infectious, 
autoimmune or otherwise) has been identified for these inflammatory 
chorioretinal disorders and they are, therefore, defined by their clinical 
presentation and idiopathic aetiology. These white dot syndromes typically 
affect relatively young patients, who are often ‘healthy’ in the sense that they 
do not have any known or identifiable chronic systemic inflammatory 
disease.  
Multifocal choroiditis and punctate inner choroidopathy are specific idiopathic 
non-infectious uveitic diseases within the ‘white dot syndromes’ category.  
Along with other white dot syndromes, they are considered part of the 
‘AZOOR complex’, which Gass and others (Gass 1993; Gass, et al. 2002; 
Gass and Wilkinson 1972; Jampol and Wiredu 1995; Mrejen, et al. 2014; 
Taira, et al. 2006) have speculated are aetiologically and pathogenically 
related. MFC was initially described in patients who had ‘punched-out’ fundal 
lesions similar to presumed ocular histoplasmosis syndrome (POHS), a form 
of multifocal choroidal inflammation in Histoplasma-endemic areas of the 
United States (Nozik and Dorsch 1973). POHS tends to affect men and 
women equally, is not significantly associated with myopia, presents a little 
later in life, and is rarely associated with clinically evident recurrent episodes 
of choroiditis (Dreyer and Gass 1984; Gass and Wilkinson 1972). The 
original phenotypic description of MFC was later expanded to include a 
variant, MFC with panuveitis, which included recurrent episodes of anterior 
chamber and vitreous inflammation associated with active chorioretinal 
lesions, ranging from 50µm to 350µm in diameter (Dreyer and Gass 1984; 
Morgan and Schatz 1986; Nozik and Dorsch 1973). Around the same time, 
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PIC was first described in a series of 10 young, myopic women (aged 21 to 
37 years), whose multifocal choroidal lesions, ranging from 100µm to 300µm 
in diameter, evolved into atrophic scars, also similar in appearance to POHS, 
although 7 out of the 10 women who underwent skin testing for 
histoplasmosis were negative (Watzke, et al. 1984). Since no anterior 
chamber or vitreous inflammation was clinically detected in these young 
women, the term PIC was used to highlight the lack of evident intraocular 
inflammation associated with the choroidal lesions. Many clinicians believe 
that the ‘AZOOR complex’ diseases, and especially, MFC and PIC, represent 
a spectrum of the same disease and that there is no clinical utility in 
differentiating between them (Essex, et al. 2010; Essex, et al. 2013; Fung, et 
al. 2014; Morgan and Schatz 1986; Spaide, et al. 2013) 
 
1.8 Overview of the Immune System 
 
1.8.1 Innate and adaptive immunity 
Immune responses are typically classified as innate or acquired, which 
represent non-specific or specific responses, respectively, to foreign 
macromolecules (antigens). Innate immunity is characterised by physical 
barriers, fixed receptors based on pathogen molecular patterns, limited 
immunological memory and the fact that it does not require immunisation 
(priming) (Rich 2013). Acquired immunity is characterised by clonally 
variable receptors based on gene rearrangement, development of 
immunological memory, B-cell and/or T-cell activation, cytotoxic T-cells and 
antibody production (Rich 2013). Common features of both systems include: 
cytokines and chemokines, the complement cascade, phagocytic cells, NK 
cells and ‘natural’ autoantibodies (Rich 2013) 
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1.8.2 Cells of the immune system 
Pluripotent stem cells in the bone marrow give rise to immune cells from 
myeloid and lymphoid lineages (Figure 3): 
• Myeloid lineage: 
o Granulocytes, erythrocytes, monocytes-dendritic cells and 
megakaryocytes 
 
• Lymphoid lineage: 
o B-lymphocytes, T-lymphocytes and NK cells 
 
 
Figure 3: Origins of myeloid and lymphoid cells lineages of the immune system 
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1.8.3 Tissues of the immune system 
The tissues of the lymphoid immune system (Figure 4) consist of ‘central’ 
locations of primary lymphoid organs, where immune cell production and 
differentiation occur, and ‘peripheral’ secondary lymphoid organs where 
immune cells encounter and respond to antigens. B-cells and T-cells develop 
in the bone marrow and thymus respectively (Lewis 2013). The cells of the 
immune system come into contact with foreign antigen primarily at the 
mucosal surfaces and the skin, where they first interact with antigen-
presenting cells (APC) (Lewis 2013). Immune reactions subsequently occur 
in the secondary lymph organs, which include the spleen, lymph nodes, 
tonsils and Peyer’s patches of the bowel (Figure 4) (Lewis 2013).  
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Figure 4: Central and peripheral locations of the lymphoid system (courtesy of Dr V. 
Calder, UCL MSc in Biology of Vision Immunology Module lecture slides) 
 
1.8.4 Inflammation and the immune system 
The immune system primarily evolved to protect the host against infectious 
pathogens and other ‘invasive’ processes. The purpose of inflammation is to 
localize and remove the presumed cause of damage, that is, the invading 
pathogen. Specialized immune cells and proteins exist in the bloodstream to 
mediate this inflammatory response.  Host infection by pathogens, which 
include bacteria, fungi, viruses or parasites, activates the immune system 
and the inflammatory response. Bacteria products, especially endotoxin or 
LPS, have an ‘adjuvant’ effect on the innate immune response, which 
effectively activates an acute inflammatory response. Acute inflammation 
lasts for a short period during which immune cells, such as leukocytes, 
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accumulate at the site and remove the pathogen.  Following this, a resolution 
phase should occur, during which there is repair of the surrounding tissue 
(Serhan, et al. 2007). Chronic inflammation, on the other hand, ‘refers to a 
prolonged inflammatory response that involves a progressive change in the 
type of cells present at a site of inflammation. It is characterised by the 
simultaneous destruction and repair of tissue from the inflammatory process. 
It can follow an acute form of inflammation or be a prolonged low-grade form’ 
(Nature 2018).  Infection is a putative predisposing factor to some forms of 
chronic inflammation. The exact mechanisms by which infection might 
progress to chronic non-infectious inflammatory disease are not fully 
understood, but various mechanisms have been proposed (Fairweather, et 
al. 2001), which include: 
1. Molecular ‘antigen’ mimicry 
2. Epitope spreading  
3. Bystander activation 
4. Processing and presentation of cryptic antigens  
A general trend has been observed in the evolution of human infectious 
disease, which has implications for the prevalence of chronic inflammatory 
disease: 
‘The growing success of experimental treatment of auto-immune conditions 
with live helminths is giving weight to the controversial ‘hygiene hypothesis’, 
which posits that hosts exposed to too few infections become prone to 
immune-mediated diseases…It may indeed prove true that some non-zero 
burden of both germs and worms is optimal for human health.’ (Restif and 
Graham 2015) 
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1.8.5 Lymphocytes 
Lymphocytes represent about 20-30% of the leukocytes in circulation and 
are a central cell type of the adaptive immune system (Lewis 2013). The 
three types of lymphocyte exist: T-lymphocytes (T-cells), B-lymphocytes (B-
cells) and NK cells, which circulate in the peripheral blood, constituting 
approximately 80, 10 and 10% of the total lymphocyte population 
respectively (Lewis 2013). 
 
1.8.5.1 T-cell development and natural Treg 
T-cells develop in the thymus, a primary lymphoid organ, consisting of three 
major regions: the cortex, the medulla, and the corticomedullary region. T-
cells arise from CD34+ lymphoid progenitor cells in the bone marrow. These 
‘double negative’ progenitor cells, lacking expression of CD4 and CD8 
surface antigen, migrate in waves to the thymus during embryogenesis and 
enter the thymus at the corticomedullary junction (Swainson 2013)(Figure 5). 
Subsequent to migration, the immature T-cells, termed thymocytes, are 
mainly located in the cortex of thymus. Transcription of relevant genes and 
commitment of thymocytes to the T cell lineage is mediated by a Notch1 
signal. In order to reach the mature T-cell stage, successful rearrangement 
of the pair of genes encoding a heterodimeric T-cell receptor (TCR) (αβ or 
γδ) must occur, cells must survive thymic selection and undergo lineage 
commitment (Swainson 2013). As thymocytes mature, they migrate to the 
thymic medulla in a chemokine-dependent manner (Swainson 2013).  
Notch1 signaling is critical for driving developing thymocytes through the first 
β-selection point (Swainson 2013). Positive selection results in the survival of 
thymocytes which have a surface TCR that interacts with self-peptides 
complexed with Major Histocompatibility Complex (MHC) antigens 
(Swainson 2013) (Figure 5). Negative selection results in the deletion of 
thymocytes with high affinity TCRs to self-antigen, so called ‘central 
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tolerance’, which prevents the development of autoreactive T-cells 
(Swainson 2013) (Figure 5).  It is thought that only 3% of thymocytes survive 
the thymic selection process. Lineage choice results from interaction of 
thymocytes with MHC Class I and II- presented antigens. The αβ thymocytes 
undergo maturation and development stages, in which both CD4 and CD8 
are expressed (double positive thymocytes), which further differentiate to 
cells expressing CD4 (‘helper’ T-cells) or CD8 (‘cytotoxic’ T-cells) but not 
both (Lewis 2013). Thymus-derived CD4+FoxP3+ ‘natural’ regulatory T-cells 
(nTreg) regulate tolerance in the periphery, so called ‘peripheral tolerance’, 
by controlling self-reactive T-cells that escaped deletion in the thymus during 
the negative selection process (Swainson 2013) (Figure 5). 
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Figure 5: T-lymphocytes: central development, peripheral activation and interaction 
with APC and B-cells (Gregersen and Behrens 2006) 
 
1.8.5.2 Autoimmunity and T-cell subsets 
Human autoimmune disease is thought to occur secondary to imbalances 
between effector and regulatory immune responses, where the fundamental 
underlying mechanism is defective elimination and/or control of self-reactive 
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lymphocytes (Rosenblum, et al. 2015). Autoimmunity typically develops 
through stages of initiation and propagation, and often shows phases of 
resolution (indicated by clinical remissions) and exacerbations (indicated by 
symptomatic flares) (Rosenblum, et al. 2015). It is, therefore, useful to 
examine the development of autoimmunity through these three phases: 
initiation, propagation and resolution (Figure 6), which are preceded by a 
susceptibility phase (Cottrell 2013). Mechanisms underlying susceptibility to 
autoimmune disease include: 
• Incomplete induction of tolerance in the thymus to peripherally 
expressed auto-antigens 
• Impaired clearance and tolerance induction by apoptotic cells 
• Defective production of Treg 
• Altered immune signalling thresholds 
(Cottrell 2013) 
 
Figure 6: Phases of human autoimmunity (Rosenblum, et al. 2015). ‘Teff’ are T-effector 
cells and ‘T-reg’ are T-regulatory cells. 
 
Autoreactive effector CD4+ T cells have been associated with the 
pathogenesis of autoimmune disorders (Damsker, et al. 2010). T-helper 
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(Th)1 and Th17 subsets, characterised by expression of T-bet (Tbx21) and 
retinoic-acid related orphan receptor (ROR) γ-t (Rorc) transcription factors 
and secretion of the ‘signature’ pro-inflammatory cytokines, interferon (IFN)-γ 
and IL-17, respectively, are thought to be causal agents in the pathogenesis 
of autoimmunity (Caspi 2008; Damsker, et al. 2010) (Figure 7). Th17 effector 
cells may be induced in parallel to Th1, and, like Th1, polarized Th17 cells 
have the capacity to cause inflammation and autoimmune disease (Damsker, 
et al. 2010). The Th2 subset, characterised by the transcription factor, 
GATA-3, and production of cytokines IL-4, IL-5, and IL-13, was first 
described at the same time as the Th1 subset (Mosmann and Coffman 
1989), and before the Th17 subset was discovered (Figure 7). Although both 
Th1 and Th2 have important roles in host defence (with Th2 being 
particularly important in allergic responses and the clearance of extracellular 
pathogens), only the Th1 subset has been widely implicated in autoimmunity 
(Damsker, et al. 2010; Mosmann and Coffman 1989). Phenotypically 
categorised CD4+CD25+FoxP3+ T-regulatory (Treg) exist as a naturally 
occurring mechanism to suppress autoreactive T-cells through production of 
cytokines such as IL-10 and transforming growth factor β (TGF-β), in addition 
to other mechanisms (Agarwal and Caspi 2004; Caspi 2008; Caspi 2011; 
Caspi 2014; Zheng, et al. 2004) (Figure 7).  
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Figure 7: Antigen-activated naive CD4+ T cells adopt T-helper (Th) and T-regulatory 
(Treg) phenotypes as directed by cytokine cues and transcriptional factors. 
Professional illustration by Kenneth X. Probst. (Teshima 2011) 
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Therefore, it is thought that some forms of autoimmune disease may occur 
as a result of imbalances between pro-inflammatory Th1 and Th17 effectors 
and anti-inflammatory Treg (Figure 8). 
 
Figure 8: In immune tolerance there is a balance between T-effectors and Tregs, 
whereas in autoimmunity, there is an imbalance, which could be due to inadequate 
numbers of Treg, defects in Treg function or phenotype or reduced susceptibility of T-
effectors to Treg-mediated suppression (Chavele and Ehrenstein 2011). 
 
When discussing chronic inflammation, immunologists make a distinction 
between ‘autoinflammatory’ and ’autoimmune’ disease, which refers to the 
specific effectors of tissue damage in each case. In autoinflammation, the 
innate immune system directly causes tissue inflammation, whereas in 
autoimmunity the innate immune system activates the adaptive immune 
system, which then mediates the inflammatory process (Figure 9) (Doria, et 
al. 2012). 
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Figure 9:  Schematic pathway of pathogenesis of autoimmune and autoinflammatory 
diseases – adapted from “Autoinflammation and autoimmunity: bridging the divide” 
(Doria, et al. 2012). 
 
Animal models suggest that the inflammation in non-infectious uveitis is 
mediated by the adaptive immune system and, specifically, the Th1 and 
Th17 subsets of T-cells (Caspi 2010; Caspi 2011; Caspi 2014; Damsker, et 
al. 2010). Although the specific ‘self-antigens’ activating the immune system 
in the human forms of uveitis have not yet been determined, the immune-
mediated chronic inflammation in human uveitis is thought to be of 
autoimmune aetiology. 
 
1.8.5.3 Epigenetic regulation of T-cells 
The word ‘epigenetic’ means ‘around changes in genetic sequence’ and the 
term ‘has evolved to include any process that alters gene activity without 
changing the DNA sequence, and leads to modifications that can be 
transmitted to daughter cells (although experiments show that some 
epigenetic changes can be reversed)’ (Weinhold 2006). 
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Figure 10: The eukaryotic nuclear genome. Chromatin has highly complex structure 
with several levels of organization. The simplest level is the double-helical structure 
of DNA. From Pray, L. (2008) Eukaryotic genome complexity. Nature Education 
1(1):96. 
 
The eukaryotic nuclear genome is linear, conforming to the Watson-Crick 
double-helix structural model, and embedded in nucleosomes, which are 
complex DNA-protein structures which pack together to form chromosomes 
(Pray, 2008) (Figure 10). Processes such as transcription and replication 
require free access to the DNA template (Bhat, et al. 2017). Chromatin is 
substantially modulated by epigenetic modifications, notably DNA and 
histone modifications (Bhat, et al. 2017).  Nucleosomes, which consist of 
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DNA and a heterodimer of histones (H1, H2, H3 and H4), can act as a barrier 
to DNA-binding proteins (Bhat, et al. 2017). Nucleosome remodelling 
involves changes in DNA–protein interactions by disrupting, disassembling or 
moving nucleosomes and thus allowing DNA to get accessible for further 
processes (Bhat, et al. 2017). Consequently, chromatin accessibility and 
nucleosome remodelling are highly important for gene expression. 
Epigenetic mechanisms are associated with gene expression and ultimately 
protein expression (Bhat, et al. 2017). Types of epigenetic processes include 
methylation, acetylation, phosphorylation, ubiquitylation, and sumolyation 
(Weinhold 2006). However, the most studied epigenetic process is DNA 
methylation, which is the addition or removal of a methyl group (CH3), 
predominantly where cytosine bases occur consecutively (Weinhold 2006). 
Within the immune system, epigenetic control is a well-established means of 
gene regulation. Epigenetic mechanisms are essential during 
haematopoiesis to establish a specific transcription profile for each gene, 
which in turn may influence the cell phenotype. Furthermore, in response to 
certain environmental stimuli, such as viral infection, fully differentiated cells 
have the capacity to modify their gene expression to adapt to new conditions. 
Differentiation of naïve CD4+ cells into T-cell subsets such as effector 
Th1/Th17 or induced Tregs (iTregs) may depend on epigenetic regulation in 
response to changing environmental conditions, in addition to determination 
by cell fate programmes (Murphy and Stockinger 2010; Wilson, et al. 2009). 
This suggests that inflammatory environments may induce T-cell plasticity, in 
which phenotypically unstable peripherally induced CD4+CD25+FoxP3+ Treg 
subsets  (iTreg or pTreg) may co-exist with the more stable naturally 
occurring CD4+CD25+FoxP3+ Tregs (nTregs).  
The addition of a methyl group (-CH3) to DNA is a common epigenetic 
mechanism that cells use to switch genes ‘off’ and extensive methylation of 
cytosine in DNA is known to correlate with reduced gene transcription. 
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Furthermore, it has been observed that epigenetic mechanisms play a crucial 
role in controlling the expression of FoxP3 locus. Studies have revealed that 
both nTregs and pTreg cells possess a specific DNA hypomethylation 
pattern, the Treg-specific demethylated region (TSDR), within the FOXP3 
gene, which is associated with enhancement and stabilization of FoxP3 
expression (Floess, et al. 2007; Huehn, et al. 2009; Polansky, et al. 2008; 
Zheng, et al. 2010). DNA methylation, in general, is thought to play an 
essential role in T-cell function and failure to maintain DNA methylation 
patterns in mature T-cells has been implicated in the development of 
autoimmune disease (Richardson 2003). 
 
1.9 Ocular immune privilege 
Immune privilege was first described by Sir Peter Medawar, who observed 
that skin homografts survived for prolonged periods when grafted into the 
anterior chamber of the eye (or brain) (Medawar 1956). He attributed this 
phenomenon to the absence of vascular supply, which was in keeping with 
the historical observation that human cornea, an avascular tissue, could be 
grafted without rejection (Zirm 1989). Medawar was awarded a Nobel Prize 
for these discoveries (Medawar 1991).  
Ocular immune privilege has been subsequently studied in more detail and is 
described as: 
 ‘A complex phenomenon that involves multiple components, starting with 
sequestration behind an efficient blood–retina barrier, through active local 
inhibition by soluble and surface-bound molecules that actively inhibit 
activation and function of adaptive and innate immune cells, and culminating 
in systemic regulation via induction of T regulatory cells.’ (Stein-Streilein and 
Streilein 2002). 
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Key features of the eye pertinent to maintainance of immune privilege may 
be summarised as follows (Streilein 1995; Streilein and Cousins 1990): 
• the anatomical integrity of the blood-ocular barrier 
• the (virtual) absence of lymphatics 
• an afferent drainage pathway that is almost exclusively via the blood 
vasculature 
• an immunosuppressive intraocular microenvironment, including 
immunomodulatory cytokines, for example, TGF-β in the aqueous 
humour, and anterior chamber-associated immune deviation (ACAID) 
Immune privilege is thought to have evolved to protect the eye from 
infectious and inflammatory threats, which could have potential deleterious 
effects on vision. Conversely, it may also leave the eye vulnerable to 
autoimmune attack by T-cells that have been primed by chance encounter 
with a self or with mimic antigens in the systemic circulation (Caspi 2008). 
 
1.10 Pathophysiology of non-infectious uveitis  
Much of our knowledge of the pathogenesis of human uveitis has derived 
from animal models. Experimental autoimmune uveitis (EAU) can be induced 
by immunising animals, most commonly, rodents, with a retinal antigen (Ag), 
such as interphotoreceptor retinoid binding protein (IRBP) or retinal soluble 
Ag (S-Ag) (Agarwal and Caspi 2004; Agarwal, et al. 2012) (Figure 11).  
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Figure 11: Murine retinal histology sections showing cross-sections of: (a) normal 
murine retina and (b) inflamed retina in murine model of EAU (courtesy of Dr Virginia 
Calder). 
 
These retinal Ags are involved in the visual cycle and are typically unique to 
the eye, therefore serving as targets for the immune system in EAU. The 
blood-retinal barrier can be an effective barrier to small molecules but it is not 
a very effective barrier to cells. For example, circulating IFN-γ producing Th1 
cells and monocytes, which have been activated systemically, are able to 
cross the blood vessels and penetrate the barrier in the context of 
inflammation (Xu, et al. 2005; Xu, et al. 2004). When previously ‘unknown’ 
retinal Ag are exposed to the immune system, a break in immune tolerance 
may occur and then an inflammatory response ensues. 
Inflammation in EAU is mediated by Th1 and Th17 T-cell subsets and may 
be suppressed by Treg (Agarwal and Caspi 2004; Caspi 2008; Caspi 2011; 
Caspi 2014; Damsker, et al. 2010; Zheng, et al. 2004). A study in rats found 
that during resolution of the first acute attack of EAU, the number of ocular 
Tregs increased (Ke, et al. 2008). Interestingly, the suppressor function of 
Tregs was weaker in those rats who went on to develop recurrent EAU (Ke, 
et al. 2008). In mouse models of EAU, a significantly increased frequency 
and immunoregulatory action of CD4+CD25+ Treg cells has been associated 
with the development and regression of EAU, suggesting that CD4+CD25+ 
Treg cells are induced during EAU and may be involved in its regression 
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(Sun, et al. 2010). This is further supported by murine EAU evidence 
demonstrating that retina-specific functionally suppressive FoxP3+ Tregs 
accumulated in inflamed eyes and persisted for several months after disease 
remission (Silver, et al. 2015). Depletion of Tregs at the peak of uveitis 
delayed resolution and, following resolution, (when mice displayed a  low 
grade chronic inflammation), Treg depletion precipitated disease relapse 
(Silver, et al. 2015). 
 
1.11 Clinical presentation and features of human uveitis 
To make a diagnosis of uveitis, examination of the anterior and posterior 
chambers of the eye with slit lamp biomicroscopy or indirect ophthalmoscopy 
is required, in order to identify the characteristic signs of intraocular and 
chorioretinal inflammation. Figure 12 shows a normal view of a retinal 
fundus. 
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Figure 12: Clinical retinal photography image showing the normal appearance of the 
retina with the following structures: (a) optic disc, (b) macular area of the retina 
(responsible for central vision) and (c) retinal blood vessels (superior arcade). 
 
1.11.1 Anterior uveitis 
Anterior uveitis occurs when the anterior part of the uvea, the iris, is 
inflamed. On examining the eye, the cornea may be clear or keratic 
precipitates (KPs), inflammatory deposits from the inflamed iris, may be 
present on the posterior corneal surface, if inflammation is severe. The 
anterior chamber is often of normal depth but ‘cells’, ‘fibrin’ and ‘flare’, which 
occur secondary to exudative protein from the inflamed iris, may be seen in 
the slit light beam of the slit lamp. If a number of inflammatory cells have 
infiltrated the aqueous humour, these may settle and form a ‘hypopyon’ in 
the anterior chamber. Synaechia may occur in anterior uveitis, where the iris 
forms inflammatory adhesions to either the cornea (anterior synaechia) or 
lens (posterior synaechia). ‘Posterior synaechia’ may appear as a fixed 
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irregular-shaped pupil (Figure 13), which can become permanent if the pupil 
is not dilated with a mydriatic eyedrop. The intraocular pressure may also 
become elevated, leading to secondary glaucoma. 
 
 
Figure 13: Posterior synechiae, where the iris has become adherent to the crystalline 
lens posterior to it, as a result of inflammation in the anterior chamber of the eye 
(photo courtesy of Professor Sue Lightman) 
 
1.11.2 Intermediate uveitis 
Intermediate uveitis occurs when the main site of ocular inflammation is the 
pars plana and/ or the vitreous gel which fills the posterior chamber of the 
eye. The inflamed vitreous may appear hazy, due to the infiltration of 
inflammatory cells from adjacent structures, which is called ‘vitritis’ (Figure 
14). Inflammation of the pars plana portion of the ciliary body is known as 
‘pars planitis’. Whilst there may be associated inflammatory macular 
oedema, there should be no chorioretinitis. The fundal view, however, may 
be obscured by the vitritis. 
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Figure 14: Severe vitritis obscuring the view of the retina (fundus) (courtesy of 
Professor Sue Lightman) 
 
1.11.3 Posterior uveitis 
Posterior uveitis occurs when the choroid (posterior uvea) is inflamed, in 
which case the retina and retinal vessels overlying the choroid may be 
affected leading to a chorioretinitis, neuroretinitis or vasculitis. Sight-
threatening retinitis may manifest as either focal or diffuse areas of pale-
white retina  accompanied by retinal hemorrhages, vascular sheathing, 
retinal ischemia and retinal necrosis (Figure 15) (Gilbert, et al. 2016a). Non-
infectious retinitis in Behçet disease, for example, can be isolated or 
multifocal and is ischaemic in type, usually occurring with significant vitritis.  
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Figure 15: Retinal image of an HIV patient with CMV retinitis with extensive 
involvement of the posterior pole and widespread retinal haemorrhages at the brush 
border, reproduced with permission (Gilbert, et al. 2016a) 
 
Following an episode of chorioretinal inflammation, chorioretinal atrophy or 
scarring may occur (Figures 16-17). If this affects the macular area of the 
retinal, it is likely to have a significant effect on the patient’s central vision. If 
the uveitis is inactive at the time of examination, the presenting signs of 
uveitis may be scarring or post-inflammatory fibrotic changes, rather than the 
inflammation itself.  
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Figure 16: Multiple pale chorioretinal lesions in various phases of evolution (from 
active inflammatory lesions with indistinct edges to inactive scars with discrete 
borders and exposure of the underlying black retinal pigment epithelium and/or 
white/pale sclera). 
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Figure 17: Inactive chorioretinal scars (with discrete borders and exposure of the 
underlying black retinal pigment epithelium and/or white/pale sclera). 
 
1.11.4 Panuveitis 
In panuveitis, the inflammation is not confined to a single anatomic location 
of the eye, and any, or all, of the above clinical signs may occur. 
 
 1.12 Diagnosis and differential diagnosis of uveitis 
Ocular inflammation is a nonspecific sign related to many conditions and 
therefore a detailed history and clinical examination are important in guiding 
the diagnostic work-up, particularly with regard to the exclusion of infectious 
aetiologies (Gilbert, et al. 2016a). Retinal imaging tests, such as fluorescein 
angiography, may be helpful in identifying the extent of retinal involvement 
and, depending on the clinical presentation, blood tests, may be warranted. 
In many cases, the clinical appearance of the fundus and patient history can 
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direct diagnostic investigations. Table 4 lists the recommended systemic 
investigations in cases of retinitis. 
Table 4: Recommended systemic investigations in suspected cases of uveitis 
(Gilbert, et al. 2016a) 
 
 
 
If viral aetiology or a masquerade syndrome is suspected, a vitreous biopsy 
should be obtained in order to perform polymerase chain reaction (PCR) 
testing (for the presence of viral DNA) and/or cytology and immunology tests 
(for suspected haematological malignancy).  
 
1.13 Pharmacotherapy of uveitis 
Chronic relapsing remitting non-infectious uveitis is challenging to manage 
and severe cases require treatment with high dose oral immunosuppressive 
drugs. Corticosteroids and other immune-modulating treatments do not cure 
uveitis but, rather, suppress immune system activity. Control of inflammation 
is the most critical step in the management of uveitis and the prevention of 
vision loss, which can result from the cumulative damage to ocular structures 
(Sangwan 2010). The term ‘disease activity’ refers to the ongoing immune 
response, which can usually be reversed with immunosuppression, whereas 
Aetiology Systemic investigations in 
retinitis 
Sarcoidosis Serum angiotensin-converting 
enzyme (ACE), chest X-ray 
Syphilis Speciﬁc treponemal (FTA-ABS) 
and nonspeciﬁc treponemal 
antibody (VDRL) 
Toxoplasmosis Toxoplasma serology 
Cat scratch 
disease 
Bartonella serology 
HIV infection HIV serology 
Behçet disease HLA-B51 
Birdshot 
chorioretinopathy 
HLA-A29 
Tuberculosis Interferon-γ release assay 
(QuantiFERON Gold, Mantoux, 
or T-spot tests), chest X-ray 
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‘damage’ refers to the irreversible effects of inflammation on tissue (Barry, et 
al. 2014). In the clinical setting, after a diagnosis of uveitis has been made, 
patients are followed up regularly to determine disease activity, ocular 
complications, and side effects of treatment.  The clinical follow-up schedule 
is individualised according to the aetiology of the uveitis and its activity, the 
threat to vision, and type of treatment required (McCluskey, et al. 2000). 
Disease activity is routinely clinically assessed by examination (using slit-
lamp biomicroscopy) and clinical ocular imaging methods, such as optical 
coherence tomography (OCT).  A long-term ‘stepladder approach’ is used, 
involving initiation of the lowest appropriately aggressive therapy for the 
specific disease process and severity, and advancement up the ladder to 
other modalities as needed, because of subjective intolerance or failure to 
control inflammation (Foster, et al. 2016a). Initiating treatment with 
immunosuppressants aims to suppress pathogenic immune system over-
activity rather than ‘cure’ the underlying disease. This can lead to a durable 
drug-free ‘remission’ of uveitic disease, which is the overall treatment aim. 
 
1.13.1 Corticosteroids 
The mainstay immunosuppressant treatment for uveitis is the glucocorticoid 
subgroup of corticosteroids, sometimes with additional immunosuppressive 
drug therapy. Medical therapy should include topical, regional and systemic 
corticosteroids, as well as topical cycloplegics and mydriatics for 
symptomatic relief and prevention of synaechiae formation, when 
appropriate.  
Glucocorticoids are produced endogenously in response to 
adrenocorticotropic hormone (ACTH)-induced conversion of cholesterol to 
pregnolone in the adrenal cortex (Castiblanco and Foster 2014). They 
regulate gluconeogenesis and inhibit the inflammatory response through 
broad and non-selective inhibition of the immune system, notably by 
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inhibiting phospholipase A2 and thereby affecting the conversion of 
phospholipid to arachidonic acid (Castiblanco and Foster 2014). The end 
result is inhibition of prostaglandin production through the cyclooxygenase 
pathway and inhibition of production of leukotrienes through the 
lipooxygenase pathway (Castiblanco and Foster 2014). The following effects 
on immune cells have been observed: 
• Inhibition of leukocyte trafficking 
• Interference of functions of leukocytes, fibroblast and endothelial cells 
• Suppression of the production of humoral factors, such as, cytokines, 
involved in the inflammatory process 
Topical corticosteroids eyedrops are primarily used to treat anterior uveitis. 
The frequency of installation depends on the severity of inflammation and the 
agents vary in their formulation and potency (Table 5).  
  
 
 
71 
 
 
 
 
Table 5: Topical corticosteroid eyedrop formulations (Foster, et al. 2016a) 
 
 
 
Periocular or intraocular steroid (local) therapy may be given when patients 
are unresponsive or poorly complaint to systemic treatment or for patients in 
whom systemic therapy is contraindicated, for example pregnant women. 
Local therapy may also be a preferable choice for some patients, as it avoids 
the systemic side effects of oral therapy. The eye is an ideal organ for local 
therapy due to the fact that the intraocular space can be directly accessed, 
for example, through intravitreal steroid injections or implants, achieving high 
drug concentrations on target (Sharief, et al. 2018). The ocular side effects of 
corticosteroids include raised intraocular pressure, glaucoma and cataracts. 
Raised intraocular pressure may prove particularly problematic if there is an 
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existing clinical history of raised intraocular pressure associated with steroid 
use.  
The Multicentre Uveitis Steroid Treatment (MUST) trial was a multicentre 
clinical trial to compare local and systemic treatment for non-infectious 
uveitis, which examined the effect of systemic immunosuppression treatment 
on long-term control with long-acting local therapy in the form of a surgically 
inserted fluocinolone acetonide implant (Retisert; Bausch & Lomb, 
Bridgewater, NJ) (Kempen, et al. 2011). The interventional trial ran for 24 
months, with 255 patients (479 eyes with uveitis) randomised to either 
systemic immunosuppression or the long-acting intraocular Retisert implant, 
and followed up for an additional 5 years as part of an observational study. 
The primary results demonstrated that at 24 months, the implant resulted in 
comparable visual improvement to systemic immunosuppression with greater 
inflammatory control and macular oedema resolving in two thirds of eyes 
from both groups (Kempen, et al. 2011). Overall control of inflammation was 
superior in the implant group at every time point assessed, although most 
eyes in the systemic therapy arm also showed substantial improvement, 
achieving complete control or low levels of inflammation (Kempen, et al. 
2015).  Eyes receiving the implants had a greater likelihood of ocular side 
effects developing, with 90% of phakic eyes requiring cataract surgery and 
45% undergoing surgery to control raised intraocular pressure (IOP) (Sharief, 
et al. 2018).  
In the following cases of non-infectious uveitis, systemic immunosuppressive 
therapy might be considered (Jabs, et al. 2000):  
• Where there is poor response to local treatment or 
contraindications to local treatment e.g. raised IOP 
• Frequent relapse or recurrence of inflammation  
• Bilateral cases of inflammation 
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Furthermore, in all cases of uveitis of suspected infectious aetiology, 
antimicrobial treatment must be given along with the corticosteroid treatment, 
and local steroid injections should not be used (Gilbert et al., 2016).  
High loading doses of corticosteroids are often the best option for rapid 
control of inflammation in the case of a uveitic relapse and the clinical 
response should be carefully monitored through examination and imaging of 
the eye. The initial loading dose of oral prednisone typically is 1 mg per kg 
per day, for example, 60 to 80 mg per day in an adult (Jabs, et al. 2000). If 
uveitis clinically responds to high dose prednisolone, with reduction in the 
clinical signs of inflammation, the medication dose is tapered (by 1 to 10mg 
per week depending on the initial dose) until the lowest dose that maintains 
the vision, without adverse drug effects, is determined (Table 6).  
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Table 6: Suggested guidelines for the use of prednisone for chronic ocular inflammation (Jabs, et al. 2000) 
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In addition to the risk of infection associated with immunosuppression, given 
systemically, these drugs together have significant side effects which include 
hypertension, diabetes, liver dysfunction, osteoporosis and potential 
malignancy (Figure 18).   
 
Figure 18: Side effects of systemic corticosteroids (Gilbert, et al. 2017). 
 
Prescription of gastroprotective prophylaxis, such as a proton pump inhibitor 
drug, should be considered for patients on high dose or long-term treatment 
(Table 6). Bone density should be regularly monitored with Dual Energy X-
ray Bone Scan (DEXA) due to the risk of osteopenia and/ or osteoporosis, in 
addition to prescription of oral bone protection supplements, such as calcium 
and vitamin D tablets, or bisphosphonates in higher risk patients (Foster, et 
al. 2016a) (Table 6).  
Endocrine (Cushing's Syndrome)
Neuropsychiatric (depression, anxiety, hallucinations and sleep disturbance)
Gastrointestinal (gastritis)
Musculoskeletal (myopathy, osteoporosis and pathological fractures)
Cardiovascular (hypertension and hyperlipidaemia)
Metabolic (Type 2 diabetes mellitus)
Dermatological & Immunological (acne, hirsutism and increased susceptibility to 
infections) 
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A previous study showed that approximately half of the patients (525 out of 
1076 patients) attending a specialist uveitis service at Moorfield’s Eye 
Hospital, London UK required systemic steroids to control their ocular 
inflammation  (Tomkins-Netzer, et al. 2014). Around 60% of cases required a 
corticosteroid dose of more than 40 mg per day, and around 25% of patients 
required one or more second line agents to control their inflammation 
(Tomkins-Netzer, et al. 2014). 
On tapering high dose corticosteroid medication, it is not uncommon for 
relapses of ocular inflammation to occur. Such patients might require 
maintenance corticosteroid treatment or addition of a ‘steroid sparing agent’, 
that is, an immunosuppressive drug to reduce the corticosteroid dose and 
associated side effects. The Fundamentals Of Care for UveitiS (FOCUS) 
initiative recommended that non-corticosteroid systemic immunomodulatory 
therapy (NCSIT) be introduced to control persistent or severe inflammation 
or to prevent ocular structural complications that present a risk to visual 
function (Dick, et al.). Other indications for introducing NCSIT included 
contraindications or intolerance to other therapies or a need for 
corticosteroid-sparing effect to maintain disease remission. There are several 
categories of NCSIT, which include agents such as mycophenolate, 
methotrexate, azathioprine or cyclosporine, all of which act by targeting one 
or more aspects of the immune response (Table 7). 
 
 
77 
 
 
 
 
Table 7: Immunosuppressive drugs for ocular inflammation (Jabs, et al. 2000) 
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Unfortunately, some patients may have to progress through various drug 
combinations over time, due the various side or adverse effects of the drugs 
that they experience. It is worth noting that if patients respond inadequately 
to NCSIT, there are a number of factors to consider before changing clinical 
management (these are summarised in Table 8).  
 
 
Table 8: Management of patients with an inadequate response to noncorticosteroid 
systemic immunomodulatory therapy (Dick, et al.) 
 
 
  
 
1.13.2 Antimetabolites 
Antimetabolites are a class of compounds, exemplified by methotrexate and 
azathioprine, that inhibit nucleic acid synthesis and cell proliferation (Table 7) 
(Tomkins-Netzer, et al. 2012). Methotrexate is an analogue of folic acid, 
which inhibits purine and pyridine synthesis, therefore suppressing cellular 
inflammation. Its actions depend on the inhibition of dihydrofolate reductase, 
therefore, it is prescribed in combination with folic or folinic acid. It reduces 
cellular and humoral immune responses by affecting proliferation, inducing T-
cell apoptosis, altering B-cell response, inhibiting cytokine production and 
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also with antiangiogenic properties (Castiblanco and Foster 2014). 
Azathioprine is an imidazolyl derivative of 6-mercaptopurine. In its original 
form, it is a prodrug, which is metabolized in the liver to the active form, 6-
mercaptopurine, that is then converted to thioinosine 5-phosphate, that 
serves as a purine analogue that interferes with RNA and DNA synthesis 
(Castiblanco and Foster 2014). It has been shown to inhibit T-lymphocyte 
function by interfering with targeting of circulating T cells, decreasing the 
development of monocyte precursors and suppressing type IV 
hypersensitivity reaction, in addition to interfering with the participation of 
natural killer (NK) cells in the antibody-dependent cytotoxic reactions 
(Castiblanco and Foster 2014) 
The Systemic Immunosuppressive Therapy for Eyes (SITE) study was a 
recent, large survey of the use of NCSIT in uveitis, which provided valuable 
information about many of these immunosuppressive agents (Jabs 2017).  In 
the SITE study, 639 eyes were treated with methotrexate and, at 12 months, 
66% achieved corticosteroid-sparing control and 58% were able to reduce 
their steroid treatment to under 10mg (Tomkins-Netzer, et al. 2012). 
However, many patients required a full six months of therapy before the full 
steroid-sparing effect was seen. 16% of patients in this study discontinued 
methotrexate treatment due to side effects, the most common being 
gastrointestinal upset, bone marrow suppression or elevated liver enzymes 
(Tomkins-Netzer, et al. 2012).     
Mycophenolate mofetil is a selective purine synthesis inhibitor which is used 
to treat organ transplant rejection, in addition to autoimmune diseases.  By 
inhibiting the de novo purine pathway, it selectively inhibits B and T 
lymphocytes, and is widely used at a dose of 500-1500mg twice a day (Table 
7). It may achieve inflammation control faster than methotrexate or 
azathioprine, and it is also generally effective and well tolerated.  The SITE 
study showed that systemic corticosteroid use was reduced to 10 mg/day or 
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less in 41% and 55% of patients respectively (Tomkins-Netzer, et al. 2012).  
20% of patients discontinued the drug, with the most frequent side effects 
being gastrointestinal disturbance and bone marrow suppression  (Tomkins-
Netzer, et al. 2012). Comparative studies support the use of mycophenolate 
mofetil and methotrexate for control of inflammation and maintenance of 
vision, with, thus far, no evidence of superiority of one drug over the other 
(Dick, et al. ; Jabs 2017) . 
 
1.13.3 Alkylating agents 
Alkylating agents, specifically, cyclophosphamide and chlorambucil, are  
potent immunomodulatory agents (Table 7). Their mechanism of action is via 
alkylation of nucleotide bases, thereby inhibiting DNA synthesis and, thus, 
suppressing the cell replication rate.  They appear to be the most effective 
conventional immunosuppressive agents for inducing remission of uveitis 
(Jabs 2017). In the SITE study, cyclophosphamide was shown to be effective 
in achieving inflammation control in over 75% of uveitis patients at 12 months 
(Tomkins-Netzer, et al. 2012). Chlorambucil was reported to be useful in 
treating Behçet’s uveitis and Vogt-Koyanagi-Harada syndrome (Tomkins-
Netzer, et al. 2012).  However, alkylating agents are also the most toxic of 
conventional immunosuppressants and are associated with myelosupression 
and the development of malignancies (Castiblanco and Foster 2014). 
Cyclophosphamide is furthermore associated with high risk of sterile 
hemorrhagic cystitis and bladder carcinoma (Foster, et al. 2016a). Therefore, 
their use is restricted to a small number of cases of severe treatment-
refractory uveitis and weekly blood test monitoring is warranted to monitor 
drug toxicity and severe bone marrow suppression. 
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1.13.4 T-cell inhibitors 
Uveitis is considered a T-cell mediated disease and thus T-cell inhibitors, 
such as, cyclosporine, tacrolimus and sirolimus have entered common usage 
as steroid-sparing agents (Table 7). These agents affect the signal 
transduction of T lymphocytes, resulting in a reduction in T-cell activity and 
resultant suppression of inflammation. Cyclosporine is a calcineurin inhibitor 
and cytostatic agent and its primary effect is to inhibit T cell activation and 
recruitment.  Because of its rapid onset of action, cyclosporine is usually the 
treatment of choice for sight-threatening and progressive uveitis. However, 
the long-term use of cyclosporine is limited by a range of side effects, 
including neurological side effects, hirstutism, hyperglycaemia, 
hepatotoxicity, nephrotoxicity and hypertension. In the SITE study, over 50% 
of patients treated with cyclosporine showed inflammation control at 12 
months (Tomkins-Netzer, et al. 2012).  Tacrolimus is also thought to be 
efficacious in uveitis with a similar side-effect profile to cyclosporine, 
although the incidence of hypertension, hyperlipidemia, hirsutism and 
gingival hyperplasia are purportedly lower (Jabs 2017; Tomkins-Netzer, et al. 
2012).   
1.13.5 Biologic anti-inflammatory agents 
When antimetabolite therapy is not effective or well tolerated, or when 
disease is more advanced or severe, biologic response modifiers, also 
known as ‘biologics’, are the next medication in the ‘stepladder’ approach to 
medical therapy of ocular inflammation (Foster, et al. 2016b). These consist 
of biological molecules, typically antibodies, developed to target and alter 
certain areas or deactivate specific cytokines within the immune response. 
The biological agents most widely used for treating uveitis are tumour 
necrosis factor alpha (TNF-α) inhibitors, specifically infliximab and 
adalimumab. These monoclonal antibodies both have specificity for TNF-α, 
but whereas infliximab is a chimeric molecule containing non-human rodent 
 
 
82 
 
 
 
 
antigens, adalimumab is fully humanised. Infliximab has been found to be 
effective in treating Behçet’s uveitis patients, reducing the number of uveitis 
attacks compared with cyclosporine and other conventional agents 
(Tomkins-Netzer, et al. 2012).  Adalimumab is also recommended for the 
treatment of nonanterior non-infectious uveitis in adults (Dick, et al.). 
Previous RCT studies have shown that adalimumab significantly lowered 
uveitic flare and loss of vision and that, in severe forms of adult sight-
threatening non-infectious uveitis, it is  superior to placebo in improving 
vision and reducing flares (Dick, et al.). Furthermore, adalimumab is given by 
subcutaneous injection rather than intravenous infusion, making it more 
convenient for the patient and cheaper to administer.  Both drugs are 
associated with reactivation of latent tuberculosis infection and unmasking of 
multiple sclerosis (associated with intermediate uveitis), so careful pre-
treatment screening, including patient history and QuantiFERON blood tests 
are recommended (Tomkins-Netzer, et al. 2012).  Additionally, infliximab 
may require additional immunosuppression, with methotrexate for example, 
to reduce the risk of developing antibodies to the murine fragment of the 
antibody, unlike the fully-humanised adalimumab (Tomkins-Netzer, et al. 
2012).   
Interferon α-2a (IFNα2a) is an immunomodulatory cytokine which has also 
been studied in the treatment of refractory uveitis, and is thought to be 
capable of inducing disease remission through the activation of regulatory T-
cells, leading to the potential for its immunosuppressive effects for 6 to 12 
months after the drug is discontinued (Lightman, et al. 2015).  The most 
common side effects, reported in almost all patients, are flu-like symptoms, 
which may be quite debilitating, and more severe side-effects include 
leucopenia, thrombocytopenia and central nervous system effects 
(psychosis, depression) (Tomkins-Netzer, et al. 2012).  
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1.14 Clinical course of uveitis and prognosis 
Uveitis often responds well to high dose immunosuppressive treatment, 
however, some patients may relapse on tapered withdrawal of 
immunosuppression and a further proportion go on to develop chronic 
disease (Gupta and Murray, 2006). For the majority of patients with acute 
anterior uveitis, that shows a good clinical response to intensive topical 
corticosteroid treatment, the risk of irreversible sight threatening 
complications is low and the visual prognosis is good. However, those with 
chronic anterior uveitis, posterior uveitis, and panuveitis have a worse visual 
prognosis (Gutteridge and Hall, 2007).  
Chronic uveitis can be defined as active uveitis that persists longer than 
three months (McCluskey, et al. 2000).  In the UK, sarcoidosis is the 
commonest disease that presents as chronic uveitis in adults (McCluskey, et 
al. 2000). As with many chronic inflammatory diseases, non-infectious uveitis 
may follow a relapsing and remitting disease course.  
The prognosis of sight-threatening retinitis, ‘depends on the aetiology, the 
visual acuity at the time treatment is started, the degree of involvement of the 
macula and the optic disk, and the development of subsequent 
complications, such as retinal detachment. In cases of noninfectious retinitis, 
prompt treatment and long-term immunosuppressive control of the disease 
result in a stable long-term visual outcome, with most patients maintaining 
the vision at presentation. Causes of vision loss include macular scaring and 
atrophy, chronic cystoid macular oedema, epiretinal membranes, and 
macular ischemia. In cases of ARN, the extensive retinal necrosis can lead 
to the development of retinal detachment, posterior pole involvement, and 
vitreous haemorrhages, all of which result in a poor long-term visual 
outcome. In CMV retinitis, treatment is effective in arresting the progression 
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of retinitis and minimizing the complications related to that. Anti-retroviral 
therapy is required to control CMV replication in the long term and prevent 
further recurrence. However, patients may develop significant visual 
impairment secondary to large areas of retinal involvement, recurrent 
disease, epiretinal membranes, cystoid macular oedema, cataract, or retinal 
detachment. In toxoplasmosis, the visual prognosis depends on the location 
of the retinal involvement. Posterior pole involvement in the form of macular 
scars, optic nerve involvement, or vascular occlusion can lead to severe 
vision loss.’ (Gilbert, et al. 2016a), reproduced with permission. 
 
1.15 Improving management of non-infectious uveitis 
Non-infectious uveitis is a clinically heterogenous disease and it has been 
suggested that ‘many of the constraints in generating evidence for the 
efficacy of treatments have been due to the heterogeneity and spectrum of 
disorders of uveitis, their relatively low prevalence, and the lack of robust 
outcome measures’ (Lee and Dick 2012). As in the case of autoimmune 
disease, critical to improving diagnosis, monitoring and treatment of the 
disease, is application of some of the principles of personalised or stratified 
medicine, that is,  the precise clinical, molecular/genetic and immunological 
phenotyping of patients at various disease stages of non-infectious uveitis 
(Figure 19) (Cottrell 2013; Lonergan, et al. 2017). Understanding the 
mechanisms of disease amplification, propagation and regulation will enable 
the development of effective targeted therapies (Cottrell 2013).  
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Figure 19 ‘Schematic of the differences between traditional and stratified approaches 
to patient treatment. Treatment failure can result from either a lack of response or 
unacceptable adverse effects’ (Lonergan, et al. 2017) 
 
Currently, the inability to precisely define the potentially separate clinical 
entities which are currently labelled as ‘uveitis’ severely limits the application 
of individualised or stratified therapies. However, the need to develop better 
biomarkers and surrogate endpoints of disease activity for uveitis, in line with 
the United States Food and Drug Administration (FDA)/ National Institutes of 
Health (NIH) criteria (Figure 20), has been recognised (Denniston, et al. 
2017). Clinical outcome measures can also be developed to incorporate the 
impact of an eye condition on a patient’s life, so-called, patient-reported 
outcome measures (Denniston, et al. 2014). 
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Figure 20 Summary of FDA/NIH Guidance on biomarkers and surrogate endpoints 
 
1.16 Patient and public involvement in uveitis research 
Priority Setting Partnerships (PSPs) enable clinicians, patients and carers to 
identify and prioritise uncertainties about the effects of treatments that could 
be answered by research, through a collaborative approach (JLA 2017a). 
The James Lind Priority Setting Partnership (PSP) on Sight Loss and Vision 
was led by a Steering Group headed by representatives from Fight for Sight, 
the College of Optometrists, the UK Vision Strategy, and the NIHR 
Biomedical Research Centre at Moorfields Eye Hospital (JLA 2017c; Rowe, 
et al. 2014).  The consultation also included representatives of 
patient/service user groups and healthcare professionals from 
ophthalmology, optometry, orthoptics, ophthalmic nursing and social care 
(JLA 2017c): 
‘2,220 people responded to the survey, generating 4,461 
questions.  With questions across different eye diseases and conditions, it 
was decided that 12 final priority setting workshops would take place during 
April and May 2013.  17% of survey respondents identified themselves as 
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healthcare professionals and over 60% of the respondents were people with 
sight loss or an eye condition.’  (Figure 21) (JLA 2017c) 
The final workshop of a Priority Setting Partnership (PSP) enables patients, 
carers and clinicians to agree on the order of priority of a shortlist of 
unanswered questions, which is used to create a list of the Top 10 priorities 
for future research (JLA 2017d). A Top 10 priorities list was created for 
ocular inflammatory diseases (Figure 22), which included infectious and non-
infectious uveitis, in addition to other inflammatory diseases such as scleritis 
and thyroid eye disease. 
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Figure 21: Flow chart showing the steps of the process from stage 1 when 
establishing the Priority Setting Partnership (PSP) through to stage 5 at the final 
prioritisation (PICO, Population, Intervention, Comparison, Outcome) (Rowe et al., 
2014) 
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Figure 22: Top 10 priorities list for ocular inflammatory diseases (JLA, 2017b; Rowe et 
al., 2014) 
 
 
 
1.17 Definitions and models of health and disease 
The World Health Organization (WHO) defines health as ‘a state of complete 
physical, mental and social well-being’ and ‘not merely the absence of 
disease’ (WHO 1946). Researchers from the Louis Bolk Institute in the 
1. What are the most effective treatments for ocular and orbital 
inflammatory diseases? 
2. What causes thyroid eye disease? 
3. Can the severity of ocular and orbital inflammatory disease in an 
individual be predicted? 
4. Is it possible to prevent further occurrences of retinal damage 
caused by toxoplasmosis? 
5. What causes birdshot retinopathy? 
6. Why does disease burn out in patients with ocular and orbital 
inflammatory diseases? 
7. Can early detection methods be developed for ocular and orbital 
inflammatory diseases? 
8. What medications best prevent the development of eye disease in 
Behcets? 
9. What causes scleritis? 
10. Can diet or lifestyle changes prevent uveitis from developing? 
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Netherlands felt that this definition was inadequate because it represents 
health as a static rather than a dynamic state. They observed that this was 
particularly relevant for individuals with long term health conditions and 
disability, as it renders them ‘unhealthy’ despite efforts to cope and live with 
their condition: 
‘The WHO definition becomes counterproductive as it declares people with 
chronic diseases and disabilities definitively ill. It minimises the role of the 
human capacity to cope autonomously with life’s ever changing physical, 
emotional, and social challenges and to function with fulfilment and a feeling 
of wellbeing with a chronic disease or disability.’ (Huber, et al. 2011) 
The researchers developed a new definition of health ‘as the ability to adapt 
and self-manage, in light of the physical, emotional and social challenges of 
life’ (Huber, et al. 2016). The medical perspective of health has typically had 
a ‘negative’ disease-focus rather than a ‘positive’ health focus. Conventional 
medical treatment is based on a scientific process involving observation, 
description and differentiation, which moves from recognising and treating 
symptoms to identifying disease aetiologies and developing specific 
treatments (Clare 1980, 2001). This viewpoint has been criticized as 
mechanistic and reductionist, with illness understood in terms of causation 
and remediation, in contrast to holistic and social models. In his landmark 
paper on ‘The Biopsychosocial Model’, Engel observed that: 
“The dominant model of disease today is biomedical, and it leaves no room 
within its framework for the social, psychological, and behavioral dimensions 
of illness…We are now faced with the necessity and the challenge to 
broaden the approach to disease to include the psychosocial without 
sacrificing the enormous advantages of the biomedical approach” 
(Engel 1977) 
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Positive wellbeing can be defined as ‘optimal psychological experience and 
functioning’, which has an important relationship with health (Steptoe 2011). 
Studies suggest that when individuals engage in health promoting actions, 
their sense of well-being, satisfaction, and performance are greater and their 
incidence of symptoms and problems associated with disease and infirmity 
are lower because of a better ability to adapt and self-manage in the face of 
challenges (Becker, et al. 2009; Becker, et al. 2015). The concept of ‘positive 
health’, which takes into account an individual’s psycho-social wellbeing, in 
addition to their physical health and body functioning, may be addressed 
through community engagement. The National Institute for Health and Care 
Excellence (NICE) has noted that, ‘Community engagement is a highly 
complex area with several important purposes. These include empowering 
people within communities to gain more control over their lives and to play a 
part in decisions that affect their health and wellbeing’. One of the difficulties, 
however, in evaluating the contribution of positive wellbeing to health is that it 
occurs with a range of other psycho-social characteristics that may have 
intrinsically positive influences on health (Steptoe 2011).   
There is a role for individual social cognitions (the cognitive model), for 
example, self-efficacy, in determining health and wellbeing (Bandura 2000; 
Steptoe 2011) . Self-efficacy may be defined by one's belief in one's ability to 
succeed in specific situations or accomplish a task, which can play a major 
role in how one approaches health goals and challenges (Bandura 1977).  
 
1.18 Designing interventions to change health behaviours  
Health-related behaviours can contribute to major causes of mortality and 
morbidity. In the early 1950s, the focus of public health service was on 
understanding the factors which might motivate asymptomatic individuals to 
take up free or low cost tests of early disease detection (Rosenstock 1974). 
At that time, theories to explain health behaviours were being developed by 
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social psychologists, who did not have in depth knowledge of prevalent 
diseases or the health system. The Health Belief Model, the earliest Social 
Cognition Model (SCM), was designed to have a phenomenological 
orientation and to be adapted, in consultation with other social psychologists, 
for application to different health problems, if required (Rosenstock 1974). 
Notably, SCMs do not specifically mention individuals’ past experiences 
(Rosenstock 1974). Whilst SCMs help to identify target cognitions, which is 
particularly useful for preventative health behaviours, they do not describe 
how to change them, with the possible exception of ‘self-efficacy’ (Steptoe 
2011).  
The SCMs assume a rational cognitive approach to health behaviour, with 
intention being a strong predictor. Studies, however, indicate existence of an 
‘intention-behaviour’ gap, suggesting that intention formation does not 
always follow through to action (Armitage and Conner 2001; Webb and 
Sheeran 2006). It is known that past behaviour might influence future 
behaviour (Ouellette 1998) but this is not accounted for within the models. 
Therefore, SCMs are less suitable for predicting behaviours which have a 
habitual or addictive component, where habit strength will moderate the 
intention behaviour relationship (Triandis, 1977) and motivation is viewed as 
part of a complex system, subject to instability and fluctuation (West 2006). 
Furthermore, SCMs fail to incorporate wider information about physical 
environment, biological processes, past behaviour and the system in which 
the individual exists.  
A methodological approach which classifies behaviour change interventions 
(Abraham and Michie 2008) and uses models to understand individual 
behavior in the context of a wider system (Michie, et al. 2011) is likely to be 
more useful in informing behaviour change interventions, in comparison to 
using individual social cognitions, alone. A simple model, such as the COM-B 
model of behaviour in context (Michie, et al. 2011) is potentially amenable to 
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use by health-care researcher without a specialist psychology background, 
and might assist in the generation of evidence to explain behaviour in varied 
healthcare settings. Behaviour change taxonomy (Abraham and Michie 
2008) might also help to identify which models are suitable for targeting 
specific types of health cognition and/or behaviour, to promote change.  
 
1.19 Aims of the project 
The original plan of investigation for the research, as proposed by my 
supervisors and submitted with PhD registration, was to investigate whether 
peripheral blood levels of T-regulatory and B-regulatory cells in patients with 
non-infectious uveitis are induced by treatment with immunosuppressive 
and/or immunomodulating drugs when patients go into clinical remission. 
This line of investigation was informed by previous research by the group in 
a subset of patients with ocular Behcets disease (chronic non-infectious 
uveitis associated with systemic Behcets disease) showing that: 
1) The risk of severe sight loss is significantly reduced in patients with 
uveitis associated with Behcets’ Disease given biological anti-
inflammatory drugs, such as anti-tumour necrosis factor (-TNF) agents 
(Taylor, et al. 2011) 
2) In ocular Beҫhets Disease, Treg levels are increased by 3 months 
treatment with pegylated Interferon-α (pegIFNα), and the increased 
levels of Tregs are still detectable at 12 months, 6 months after 
cessation of therapy (Lightman, et al. 2014) 
These clinician-developed research aims were reviewed in the context of the 
James Lind PSP for research on ocular inflammatory disease and found to 
have relevance to the following questions: 
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1. What are the most effective treatments for ocular and orbital 
inflammatory diseases? 
2. Can the severity of ocular and orbital inflammatory disease in an 
individual be predicted? 
3. Why does disease burn out in patients with ocular and orbital 
inflammatory diseases? 
4. Can early detection methods be developed for ocular and orbital 
inflammatory diseases? 
With regard to Question 1 (what are the most effective treatments for ocular 
and orbital inflammatory diseases?), it is known that high dose ‘blockbuster’ 
systemic immunosuppression is the most effective available treatment, in 
terms of suppressing ocular inflammation (and thereby preventing severe 
sight loss) for many patients with sight-threatening uveitis. Systemic 
immunosuppression also has multiple side effects, which we know are 
undesirable to patients, and have long-term implications for health. With 
regard to Questions 2 to 4, the challenges in predicting the severity and 
prognosis of non-infectious uveitis could be in part attributed to limitations in 
phenotyping uveitis. Improvements in disease phenotyping and identification 
of disease biomarkers could help to predict prognosis and/or stratify 
management.   
Subsequently, the aims of the lab-based PhD research were changed by the 
supervisory team to focus on Treg only (rather than both Treg and Breg) and 
an additional clinical research project with a focus on clinical phenotyping of 
non-infectious uveitis was added by the primary supervisor. Furthermore, a 
public engagement project with a focus on sight-threatening retinal disease 
and behavioural science was carried out alongside the clinical and lab-based 
research, to support the patient-centred aims of the PhD. 
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Therefore, the revised aims of research and this PhD thesis were to 
individualise management of patients with non-infectious uveitis by 
investigating:  
1. Potential differences in clinical phenotypes of multifocal choroiditis 
(MFC) and punctate inner choroidopathy (PIC) (two subtypes of non-
infectious uveitis with similar clinical characteristics) at presentation 
and whether these are stable over time. 
2. Immunophenotyping of peripheral blood of patients with sight-
threatening non-infectious uveitis in sustained drug-induced clinical 
remission to investigate whether there are associations between 
levels of Treg, Th1, Th17, their related cytokines and the methylation 
levels of their epigenetic loci. 
3. Patient perspectives of sight-threatening retinal disease, with a view to 
identifying and targeting individual health behaviours for a pilot 
intervention. 
The research undertaken to achieve these in the following chapters, is as 
follows: 
1.19.1 Summary of Chapter 2 
The aim of this clinical study was to determine whether two subtypes of non-
infectious uveitis with similar clinical characteristics: multifocal choroiditis 
(MFC) and punctate inner choroidopathy (PIC) are distinct diseases or the 
same. This is important because of a growing clinical trend towards grouping 
MFC and PIC together as a single disease (Spaide, et al. 2013),  which could 
have detrimental implications for clinical phenotyping and management. 
This chapter has been submitted for publication as an original research 
paper and is currently undergoing revisions (Gilbert, Niederer et al, under 
review). A concurrent research paper, with a focus on PIC, has been 
published (Niederer, et al. 2017). 
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1.19.2 Summary of Chapters 3 & 4 
The aim of these laboratory studies were to improve the phenotyping of 
uveitis to allow more individualised patient management, with a focus on 
immunophenotypic analysis of patients in clinical remission, using different 
approaches:  Flow cytometric analysis of Treg, Th1 and Th17 levels and 
functional studies of Treg; and evaluation of serum cytokine levels of Treg, 
Th1 and/ or Th17 related cytokines and methylation changes at epigenetic 
loci related to these T-cell lineages; and statistical modelling of results. 
These chapters have been presented at ARVO Congress 2016, the German 
Ophthalmological Congress (DOG) 2016 and published as an original 
research paper (Gilbert, et al. 2018; Gilbert, et al. 2016b) 
 
1.19.3 Summary of Chapter 5 
The aim of this public engagement and qualitative analysis work was to 
engage with patients who have sight-threatening non-infectious retinal 
disease (which does not have curative treatment) and identify suitable 
interventional approach(es) which could serve to increase sense of agency 
and/or self-efficacy of affected individuals, in order to potentially change the 
course of their disease and/or its consequences. 
Sections of this chapter have been published as a short report of a pilot 
medical education intervention [Gilbert, Rose] (Rose, et al. 2018) and have 
been provisionally accepted as a social science review article (Gilbert, 
Rawlings et al, in press). 
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1.19.4 Summary of Chapter 6 
This is a general summary discussion of the results from the previous 
chapters, including of summary of conclusions from and limitations to the 
research, with suggestions for future work. 
 
 
 
 
98 
 
 
 
 
Chapter 2 Multifocal Choroiditis and Punctate Inner 
Choroidopathy: An Epidemiological Survey of 
Phenotypical Differences 
 
2.1 Introduction  
 
2.1.1 Background summary 
Non-infectious uveitis is a clinically heterogeneous disease. The aim of this 
study was to improve the phenotyping of uveitis to allow more individualised 
patient management, with a focus on clinical phenotyping of idiopathic 
multifocal choroiditis (MFC) and punctate inner choroidopathy (PIC).  
2.1.2 Study aim 
To determine whether two subtypes of non-infectious uveitis with similar 
clinical characteristics: multifocal choroiditis (MFC) and punctate inner 
choroidopathy (PIC) are distinct diseases or, in fact, the same disease.  
2.1.3 Objectives 
1. Review of the literature to date to determine the clinical consensus for 
categorizing patients as MFC or PIC  
2. Identify eligible cases with clinical diagnoses of MFC or PIC by a 
search of electronic hospital records. 
3. Classify study eyes as MFC or PIC based on objective clinical criteria 
identified from the literature review. 
4. Investigate the clinical trajectory of patients in each category, MFC or 
PIC, over 5 years with respect to the development of peripheral 
lesions. 
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5. Analyse and compare clinical and imaging features of MFC and PIC 
for phenotypic differences 
6. Determine if cases identified as MFC or PIC, using above 
standardised definition, did have a distinct clinical trajectory justifying 
their categorization as clinically distinct diseases.  
 
2.1.4 Rationale for study 
The study was devised in response to a contemporaneously published paper 
(Spaide, et al. 2013), which investigated the clinical phenotyping and 
definitions of multifocal choroiditis (MFC) and punctate inner choroidopathy 
(PIC), two subtypes of non-infectious uveitis with similar clinical 
characteristics. MFC and PIC are thought to be the most closely related of 
the white dot syndromes due to their similarity in clinical presentation with 
symptoms of field defects and photopsias, scar appearance and peripapillary 
location, tendency towards bilateral ocular involvement and frequency of 
development of choroidal neovascular membranes (CNV) (Gerstenblith, et 
al. 2007; Kaiser and Gragoudas 1996; Khorram, et al. 1991).  They share the 
same haplotype associations with interleukin-10 and tumour necrosis factor 
loci (Atan, et al. 2011). However, there are no definitive tests or standardised 
classifications for MFC and PIC and, as a result, diagnoses are subject to 
clinical bias.   
The authors of the aforementioned study obtained data from newer imaging 
modalities such as enhanced depth imaging OCT scans in order to try to re-
define MFC and PIC in a retrospective, consecutive, observational case 
series of 38 eyes of 22 patients (Spaide, et al. 2013). They found that the 
principle sites of disease involvement in eyes with these diagnoses were the 
subretinal pigment epithelium and outer retinal spaces (Spaide, et al. 2013). 
In this small group of patients with MFC or PIC, they found no difference in 
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the demographics and clinical characteristics, such as visual acuity, age, sex 
and degree of myopic refractive error, and concluded that there seemed to 
be ‘limited clinical utility in trying to differentiate them’ (Spaide, et al. 2013). 
This was an interesting conclusion because MFC and PIC have been 
historically considered different diseases, with the term ‘PIC’ often being 
used to describe eyes with smaller lesions clustered at the posterior pole in 
young, myopic women (Atan, et al. 2011; Brown, et al. 1996; De Meyer, et al. 
1999; Kedhar, et al. 2007). The findings of Spaide et al coincided with a 
developing clinical trend towards grouping MFC and PIC together as a single 
disease, with much discussion in the literature on this topic (Ahnood, et al. 
2017; Essex, et al. 2010; Essex, et al. 2013; Kedhar, et al. 2007; Morgan and 
Schatz 1986; Spaide, et al. 2013).  
The epidemiological data on PIC and MFC have been limited due to the low 
incidence of these diseases. Grouping these two diseases together as a 
single entity, if they are in fact different diseases, could have detrimental 
consequences for patient management. Therefore, the aim of this study was 
to provide clinical epidemiological data to assist in disease phenotyping and 
the determination of whether MFC and PIC should be regarded as different 
diseases. It has been previously observed that imaging modalities did not 
differentiate between MCP and PIC, but it was also conceded that this might 
be due to the disease definitions used in the study (Spaide, et al. 2013). 
Therefore, in this study, a comparison of demographic and clinical 
characteristics was undertaken for a large cohort of patients who were 
observed over a 5-year period and classified as MFC or PIC, according to 
chorio-retinal lesion location and associated inflammation. A standardised 
approach was used to minimise subjective clinical diagnostic bias.   
2.1.5 Non-invasive clinical imaging of the eye 
Colour images of the ocular fundus (the part of the posterior segment of the 
eye, which is opposite to, and viewed through, the pupil) may assist with 
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diagnosis and documentation of abnormalities observed in the retina and 
posterior choroid on clinical examination, such as retinitis and/or choroiditis 
(Foster and Vitale 2002). Ultra-widefield images, such as those captured by 
the Optos fundus camera (Optos, Dunfermline, Scotland, UK) are being 
increasingly used in the clinical management of uveitis. These images, which 
can capture up to 200-degrees of the ocular fundus in a single photograph, 
reveal a wider and more peripheral view of the fundus than the standard 30- 
to 50-degree fundus images. 
Fundus autofluorescence (AF) imaging is based on the principle that 
increased (hyper) or decreased (hypo) autofluorescence emitted from ocular 
fluorophores, such as lipofuscin, in the retinal pigment epithelium, may 
indicate retinal pathology.  AF imaging has value in that it may detect retinal 
abnormalities beyond those detected on clinical funduscopic examination. 
Optical coherence tomography (OCT) imaging is analogous to ultrasound B-
scan imaging, except that it uses light waves rather than sound waves to 
obtain images of retinal structures of a higher longitudinal resolution. OCT is 
based on the principle of white light or low coherence interferometry, that is, 
that light reflected or scattered off the subject under investigation interferes 
with light from a reference arm (Figure 23): 
• The light originates from a light source and is split into two arms by 
the beam splitter.  
• The light incident on the tissue undergoes partial backscattering, due 
to the presence of discrete, as well as a continuum of, reflection sites 
at different depths within the ocular tissue.  
• The two beams will interfere if the path length difference of the two 
arms in the interferometer is within the coherence length of the optical 
signal, 
• At the output of the interferometer the backscattered light from the 
tissue is then recombined with the light from the reference arm.  
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• The interference signal recorded at the detection end is then used to 
extract axial structural information of the tissue, which can be 
represented as an A-scan. 
• The beam incident on the tissue is scanned laterally and a series of A-
scans are collected and then used to obtain the cross-sectional image 
of the tissue. 
• The coherence gating allows the detection system to discriminate 
between reflections from closely spaced reflectors, thus enabling high 
resolution imaging. 
 
  
 
Figure 23: Principles of Optical Coherence Tomography (OCT) 
 
 
Spectral-domain OCT (SD-OCT), also known as Fourier-domain OCT (FD-
OCT), is a subtype of OCT imaging where the reference mirror is fixed and 
the interference pattern is detected spectrally and converted to spatial 
information by the Fourier transformation (Figure 23). This allows greater 
tissue resolving power, higher scan density, and faster data acquisition than 
previous versions of the technology, allowing better visualisation of retinal 
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layers (Figure 24). Enhanced depth imaging (EDI) OCT (Figure 25) allows 
enhanced visualisation of choroid and sclera, in addition to the retinal layers. 
This is achieved by displacing the zero delay point, the point of maximal OCT 
signal sensitivity, closer to the choroid rather than the inner retinal layers 
(Baltmr, et al. 2014). This technique facilitates quantitative measurement of 
choroidal thickness with high reliability and reproducibility (Baltmr, et al. 
2014). 
 
 
 
 
Figure 24: SD-OCT showing normal retinal layers: NFL:Nerve fiber layer. GCL: 
Ganglion cell layer. IPL: Inner plexiform layer. INL: Inner nuclear layer. OL: Outer 
plexiform layer. ONL: Outer nuclear layer. ELM: External limiting membrane. PIS: 
Photoreceptors inner segments. POS: Photoreceptors outer segments. RPE: Retinal 
pigment epithelium 
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Figure 25: Enhanced depth optical coherence tomographic B-scan using a Heidelberg 
Spectralis OCT (Heidelberg Engineering, Germany). (a) Near-infrared fundus image, 
(b) corresponding EDI-OCT demonstrating normal retinal and choroidal anatomy at 
the macula. Note that both retinal and choroidal layers can be clearly identified on the 
same scan. (Baltmr, et al. 2014) 
 
 
2.2 Methods 
 
2.2.1 Ethical approvals 
The study adhered to the tenets of the Declaration of Helsinki and was 
approved by the local institutional review boards (National Health Service 
Research Ethics Committee Approval, R&D reference: 16039, in the UK and 
The Institutional Review Board of Rabin Medical Center in Israel).   
 
2.2.2 Literature search  
A literature search was conducted on MEDLINE by combining searches for 
the terms ‘multifocal choroiditis’ with (OR) ‘punctate inner choroidopathy’ in 
any part of the publication text (Figure 26). 
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Figure 26: PRISMA diagram of literature search conducted using MEDLINE by 
combining searches for the terms ‘multifocal choroiditis’ with (OR) ‘punctate inner 
choroidopathy’ in any part of the publication text and subsequent article inclusion. 
 
2.2.3 Review of literature and determination of clinical consensus 
regarding disease definitions 
MFC was initially described in patients who had ‘punched-out’ fundal lesions 
similar to presumed ocular histoplasmosis syndrome (POHS), a form of 
multifocal choroidal inflammation in Histoplasma-endemic areas of the 
United States (Nozik and Dorsch 1973). POHS tends to affect men and 
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women equally, is not significantly associated with myopia, presents a little 
later in life, and is rarely associated with clinically evident recurrent episodes 
of choroiditis (Dreyer and Gass 1984; Gass and Wilkinson 1972). The 
original phenotypic description of MFC was later expanded to include a 
variant, MFC with panuveitis, which included recurrent episodes of anterior 
chamber and vitreous inflammation associated with active chorioretinal 
lesions, ranging from 50µm to 350µm in diameter (Dreyer and Gass 1984; 
Morgan and Schatz 1986; Nozik and Dorsch 1973). It was later found that 
MFC lesions might range in size from 500µm to 1000µm and, therefore, 
characterised by chorioretinal lesions that were larger than initially described 
(Kedhar, et al. 2007). Around the same time that MFC was originally 
reported, PIC was first described in a series of 10 young, myopic women 
(aged 21 to 37 years), whose multifocal choroidal lesions, ranging from 
100µm to 300µm in diameter, evolved into atrophic scars, also similar in 
appearance to POHS, although 7 out of the 10 women who underwent skin 
testing for histoplasmosis were negative (Watzke, et al. 1984). Since no 
anterior chamber or vitreous inflammation was clinically detected in these 
young women, the term PIC was used to highlight the lack of evident 
intraocular inflammation associated with the choroidal lesions.  
A review of the literature to date suggests that authors of at least 11 previous 
publications have agreed that MFC and PIC are idiopathic white dot 
syndromes which might be clinically differentiated on the basis of their 
distinctive ‘fundus pattern’ (Eldem and Sener 1991), that is, morphology of 
chorioretinal lesions, which in the case of PIC, are focal, predominantly in the 
posterior pole area of the retina, whereas they extend to the periphery of the 
retina in MFC (Amer and Lois 2011; Brown and Folk 1998; De Meyer, et al. 
1999; Gerstenblith, et al. 2007; Hirooka, et al. 2014; Hirooka, et al. 2006; 
Kedhar, et al. 2007; Raven, et al. 2017; Scheider 1993; Shakoor and Vitale 
2012; Zarranz-Ventura, et al. 2014). There is also a consensus amongst 
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authors of 12 previous publications that, in cases diagnosed as PIC, there 
should be no history or other evidence of intraocular inflammation, in the 
form of anterior or vitreous cells (Ahnood, et al. 2017; Amer and Lois 2011; 
Atan, et al. 2011; Brown and Folk 1998; Brown, et al. 1996; De Meyer, et al. 
1999; Essex, et al. 2010; Flaxel, et al. 1998; Kedhar, et al. 2007; Reddy, et 
al. 1996; Shimada, et al. 2008; Spaide, et al. 2013). Evidence to strengthen 
this clinical consensus was provided by a study, which categorised cases of 
MFC and PIC by morphology only, and found that cases diagnosed as PIC 
lacked inflammation (Kedhar, et al. 2007). It has been frequently noted that 
PIC has a demographic predilection for young, myopic women (Brown, et al. 
1996; Flaxel, et al. 1998; Hirooka, et al. 2014; Raven, et al. 2017) and 
observed that patients presenting with focal chorioretinal lesions around the 
posterior pole area, diagnosed as PIC, are young females (Amer and Lois 
2011; Chen and Hwang 2014; Eldem and Sener 1991; Gerstenblith, et al. 
2007; Reddy, et al. 1996; Saito, et al. 2007; Wachtlin, et al. 2003). This 
predilection of PIC for young females was confirmed by a survey of 77 
subjects with PIC (Gerstenblith, et al. 2007) and a larger group of 136 
subjects, which included ‘atypical’ PIC with larger POHS-like lesions (Essex, 
et al. 2010). A few studies have also differentiated between MFC and PIC on 
the basis of lesion size, with being PIC diagnosed by the presence of ‘small’ 
yellowish white lesions, measuring 100- to 300-μm in diameter (Leung, et al. 
2014) and MFC diagnosed by the presence of lesions larger than 300μm 
(Shimada, et al. 2008). Authors who have prospectively followed cases 
which they have differentiated as MFC and PIC, based on clinical features, 
have noted that their clinical courses are different (Atan, et al. 2011; Kedhar, 
et al. 2007; Shen, et al. 2011). 
It is noted that there is no standardised classification criteria used to describe 
MFC and PIC and, therefore, where they have been differentiated, 
 
 
108 
 
 
 
 
inconsistent combinations of the above criteria have been used to define 
them.  
Based on the described review of literature, the greatest level of clinical 
consensus supports that PIC is characterised by posterior pole lesions 
without an associated intraocular inflammatory response, which differentiates 
it from cases of MFC, characterised by peripheral chorioretinal lesions, with 
or without an intraocular inflammatory response. There appeared to be a 
lesser degree of consensus regarding the size of the chorioretinal lesions 
which characterise MFC and PIC. Many authors agreed about the 
predilection of PIC for young women but this was not considered a definitive 
characteristic for diagnosis because PIC was observed to affect subjects 
outside this demographic.  
For the purposes of this study, it was determined that defining criteria for 
MFC or PIC would be based on a sequential classification approach, as 
follows: 
1. Disease morphology, determined by chorioretinal lesion distribution, 
that is, whether lesions predominantly involve the posterior pole, or 
extend to the peripheral retina. 
2. Presence of identifiable intraocular inflammation, in eyes with lesions 
predominantly in the posterior pole area. 
Therefore, if chorio-retinal lesions were confined to the posterior pole AND 
there was no inflammation, the diagnosis would be ‘PIC’; If there were 
peripheral chorio-retinal lesions OR intraocular inflammation, the diagnosis 
would be ‘MFC’. 
2.2.4 Study design, setting and participants 
This was a cross-sectional and longitudinal observational study. The setting 
was tertiary referral centres for clinical management of uveitis in the United 
Kingdom (UK)  and Israel. A total of 343 eyes of 185 study participants were 
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identified as having a diagnosis of MFC or PIC from clinically coded 
electronic hospital records. 
 
2.2.5 Subject selection 
Subjects were identified by searching electronic hospital databases for cases 
of uveitis containing the terms ‘multifocal choroiditis’ and ‘punctate inner 
choroidopathy’ in all subjects seen at two tertiary centres, Moorfields Eye 
Hospital, UK and Rabin Medical Centre, Israel between September 1992 and 
July 2017. The database search yielded a total number of 2399 subjects with 
uveitis and, of these, 396 (16.5%) cases contained the relevant search 
terms.  Subjects were then excluded if they had fewer than 5 years of follow-
up records or if there was evidence of underlying infective or a systemic 
inflammatory diagnosis including: a fundal appearance suspicious for POHS 
and/or a history of travel to Histoplasma-endemic regions; a history of travel 
to known viral, for example, Zika, endemic regions; positive blood serology 
for an underlying systemic condition, such as tuberculosis or sarcoidosis, 
which could mimic an idiopathic white dot syndrome;  or if there was any 
doubt, otherwise, as to the diagnosis. Following exclusion of cases, as 
described, a total of 185 eligible subjects were identified. 
 
2.2.6 Data collection  
All available paper casenotes, electronic records and clinical imaging, 
including wide field colour fundus photography, fundus autofluorescence 
(AF) imaging, spectral domain (SD) and enhanced depth (EDI) optical 
coherence tomography (OCT) imaging, were reviewed for the subjects 
included in the study, between March 2014 and July 2017. Clinical 
information, including: age; gender; best corrected visual acuity (BCVA) at 
baseline presentation and 5 years later; presence of myopia; refractive error 
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(spherical equivalent); presence of choroidal neovasularisation (both active 
and inactive); and whether treatment was received, was entered into an 
Excel (Microsoft Inc.) spreadsheet. BCVA was converted to logarithm of the 
minimum angle of resolution (LogMAR) units for analysis (Lange, et al. 
2009).  
 
2.2.7 Identification of peripheral retinal lesions 
Subjects’ contemporaneous clinical notes and imaging, including, wide field 
colour fundus and AF imaging, where available, were reviewed at baseline 
presentation and observed over a 5-year period to identify the presence of 
peripheral retinal lesions. A peripheral retinal lesion was defined as any 
lesion outside the standardized template for the combined Early Treatment 
Diabetic Retinopathy Study (ETDRS) 7 standard fields on the Optos 200 
degree widefield image (ResMax; Optos plc) (Figures 27-28) (Silva, et al. 
2015).  
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Figure 27: Image (adapted from Silva, Cavallerano et al) showing ultrawide (OPTOS) 
field view of the retina, with the standardized template for the combined ETDRS 7 
standard fields demarcated by the boundary highlighted in yellow. For the purposes 
of the current study, the entire fundal area outside the yellow boundary represented 
the peripheral retinal field. Chorioretinal lesions in the peripheral area represented 
‘peripheral retinal lesions’. 
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Figure 28: Further image for comparison of imaging areas within the Optos 200 
widefield and within the EDTRS 30 7-field (Silva, et al. 2012). 
 
2.2.8 Identification of ‘active’ disease and intraocular inflammation 
Current methods for clinical assessment of the inflammatory status of eyes 
with uveitis are predominantly based on clinical estimates of inflammatory 
signs according to standardized scales (Jabs, et al. 2005a; Nussenblatt, et 
al. 1985). For example, the ‘Nussenblatt scale’ for grading of vitreous haze is 
based on estimation of the clarity of the fundus when viewed with the indirect 
ophthalmoscope and a 20D lens in comparison to a set of reference 
photographs (Nussenblatt, et al. 1985). These scales have introduced some 
level of standardisation into clinical grading of inflammation but are, 
nevertheless, subjective systems. More recent objective methodologies of 
vitreous inflammation measurement, in eyes with uveitis, have compared the 
signal intensity of the vitreous compartment with that of the RPE on SD-OCT, 
to generate an optical density ratio with arbitrary units (Keane, et al. 2015a). 
These ‘VIT/RPE-relative intensity values’ have been shown to provide good 
objective measurements of vitreous inflammation, which do not appear to be 
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influenced by phakic status and previous vitrectomy surgery (Keane, et al. 
2015b; Zarranz-Ventura, et al. 2014). OCT-derived clinical parameters are 
considered ‘well-defined and reliable’ endpoints for research studies and 
currently being developed for use in clinical trials investigating the 
management of uveitis (Denniston, et al. 2017). These objective methods for 
clinical assessment of inflammation are likely to be valuable but they require 
further validation and were, therefore, not included in the methodology of the 
current study. 
In the current study, uveitic disease activity was determined by standard 
clinical methods used in a specialist hospital setting: clinical assessment of 
subject history; physical examination; retinal and choroidal imaging (including 
wide field imaging); and previous clinical documentation of disease activity. 
‘Active’ disease included new visual symptoms in combination with anterior 
chamber or vitreous chamber activity and/or new chorioretinal lesions, but 
excluded choroidal neovasularisation. ‘Inactive’ disease was the absence of 
disease activity, as described. Prior history of intraocular inflammation was 
determined by reviewing all previous clinical documentation and imaging for 
evidence of vitreous and/ or anterior chamber activity.  
 
2.2.9 Classification of eyes as ‘PIC’ or ‘MFC’, according to presence of 
peripheral lesions and intraocular inflammation 
Following clinical data collection and image analysis of all cases clinically 
coded as idiopathic MFC and PIC, eyes were classified as PIC or MFC only 
according to the location and distribution of their lesions and identifiable 
evidence of inflammation (as detailed above). An approach was used in 
which eyes with lesions at the level of the RPE or inner choroid, in the 
absence of any other evidence of intraocular inflammation, and the absence 
of peripheral lesions were designated as PIC (Figure 29A).  Following this, 
the remaining cases with peripheral multifocal lesions at the level of the RPE 
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or inner choroid, with or without evidence of anterior chamber or vitreous 
inflammation, were identified as MFC (Figure 29B). Observers were masked 
to the clinical diagnosis during image analysis to minimise bias.  
 
Figure 29: Colour images showing A: typical fundal appearance of ‘PIC’ B: typical 
fundal appearance of ‘MFC’ classified using the study criteria. 
 
 
 
 
2.2.10 Chorioretinal lesion size analysis from fundus AF images 
The size of chorioretinal lesions at the posterior pole retinal area (defined as 
the area within the retinal arcades) of each eye on was determined from 
fundus autofluorescence (AF) images. All AF images included a 
standardised scale in the bottom left hand corner of the image. Colour 
fundus images, on the other hand, did not include a standardised scale. 
Furthermore, lesions could be detected on AF images, which were not 
visualised on colour fundus image and lesions on AF images had clear 
boundaries, which constituted defined endpoints for measurement. An image 
analysis software package (ImageJ, National Institutes of Health, USA) was 
used to measure chorioretinal lesion size as follows: the horizontal diameter 
(X) of each lesion at the posterior pole was measured images taken during 
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an inactive phase of disease (Figure 30A). The measurement was 
transformed according to the standardised 500µm image scale, as follows: 
 
 
 
The horizontal diameter of every lesion in the posterior pole region of an eye 
was determined and these measurements were used to calculate mean 
posterior pole lesion size for this eye. Choroidal neovascular (CNV) lesions 
were excluded from measurement, as these were considered to represent a 
secondary complication of the disease, rather than a chorioretinal lesion 
characterising the primary disease. CNV lesions were identified and 
excluded from analysis on the basis of their AF imaging features, which 
included: their foveal location; their larger size in comparison to the typical 
chorioretinal lesions which characterised the primary disease; and their 
heterogenous features on AF imaging, including areas of hypo- and hyper-
autofluorescence (Figure 30B). 
 
Mean lesion diameter    x    500(µm) 
                      X   
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Figure 30: The horizontal diameter (X) of each lesion at the posterior pole was 
measured images taken during an inactive phase of disease (Figure A) and 
transformed according to the standardised 500µm image scale. CNV lesions were 
identified and excluded from analysis on the basis of their AF imaging features, which 
included: their foveal location; their larger size in comparison to the typical 
chorioretinal lesions which characterised the primary disease; and their 
heterogenous features on AF imaging, including areas of hypo- and hyper-
autofluorescence (Figure B). 
 
 
2.2.11 Qualitative analysis of anatomical disease features using SD-
OCT images 
Imaging was acquired by experienced technicians using SD-OCT technology 
(Spectralis, Heidelberg Engineering, Germany). This imaging device 
captures near infrared fundus photographs with a 55⸰ field of view. A 
standardized, qualitative analysis of retinal and choroidal morphology on SD-
OCT imaging was performed, as per previously described qualitative 
analyses of MFC and/or PIC (Spaide, et al. 2013; Zarranz-Ventura, et al. 
2014), evaluating for: 
• presence of infiltration into the outer retinal and/or subretinal space 
(Figures 31a and 33) 
• subretinal exudation (Figure 32) 
• loss of anatomical integrity of the retinal layers (Figure 31b) 
 
 
117 
 
 
 
 
• retinal pigment epithelium (RPE) elevation: homogenous (Figure 33) 
or heterogenous (Figure 34) 
• intraretinal spaces or cystoid macular oedema (Figure 35) 
 
Figure 31: SD-OCT image showing: a) infiltration into subretinal and outer 
retinal space and b) loss of anatomical integrity of the retinal layers (Spaide, 
et al. 2013) 
 
 
 
Figure 32: SD-OCT image showing subretinal exudation (Spaide, et al. 2013) 
 
 
 
Figure 33: SD-OCT image showing a hyperreflective dome-shaped 
homogenous elevation of the RPE (white arrow) and an adjacent infiltration 
into the subretinal space (triangular arrowheads) (Spaide, et al. 2013) 
 
 
 
a b 
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Figure 34: SD-OCT image showing a hyperreflective heterogenous elevation of the 
RPE  
 
 
 
Figure 35: SD-OCT image showing cystoid macular oedema in a uveitic eye (courtesy 
of Dr Lazha Sharief) 
 
2.2.12 Quantitative analysis of choroidal thickness using EDI-OCT 
images 
EDI scans were acquired on the SD-OCT machine by experienced 
technicians, using a custom EDI scanning protocol described in a previous 
study by another group at the same institution: ‘each EDI-OCT image set 
consisted of 7 OCT B-scans obtained in a 20⸰ x 5⸰ horizontal raster pattern 
centred around the fovea and each individual B-scan was generated from 50 
averaged scans’ (Zarranz-Ventura, et al. 2014). The aforementioned study 
performed a quantitative analysis of ‘PIC’ cases using custom software 
(OCTOR; Doheny Image Reading Center, Los Angeles, CA), which allowed 
manual delineation of any morphologic compartment of interest and then 
provided detailed quantitative analysis of this compartment’ (Zarranz-
Ventura, et al. 2014). The OCTOR software was not available for general 
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use, so was not used for the current study. It is of note that the automated 
method of choroidal thickness measurement, using OCTOR software, 
requires the boundaries for the neurosensory retina, RPE and choroid to be 
manually segmented (Zarranz-Ventura, et al. 2014) and is, therefore, still 
subject to introduction of human error at this level of analysis. The current 
study used the following methods to measure choroidal thickness, which are 
based on similar principles of quantitative analysis used in the study by 
Zarranz-Ventura, Sim et al, except that measurements were performed 
manually, using the caliper function of the SD-OCT software on the EDI-OCT 
scans.  
Determination of the boundaries for the neurosensory retina, RPE and 
choroid and estimation of the choroidal thickness within the central macular 
area were, additionally, informed by previously published methodology for 
manual evaluation of choroidal thickness in ocular inflammation (Baltmr, et 
al. 2014; Géhl, et al. 2014). Briefly, choroidal thickness was measured in the 
central subfield (CSF) of the standardised Early Treatment Diabetic 
Retinopathy Study (ETDRS) grid, a region with a diameter of 1.0 mm around 
the fovea, on the EDI-OCT scan. A central choroidal thickness measurement 
was taken (CSF) in addition to two nasal (N1 and N2) and two temporal (T1 
and T2) measurements at the ETDRS grid outer ring diameters of 3 and 6 
mm respectively. Choroidal thickness measurements were performed 
perpendicular to the RPE, using the outer border of the hyper-reflective line 
corresponding to the RPE/Bruch membrane complex as the inner boundary 
and outer border of the choroid stroma as the outer boundary (Figure 36).  
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Figure 36: Choroidal thickness was measured in the central subfield (CSF) of the 
standardised Early Treatment Diabetic Retinopathy Study (ETDRS) grid, a region with 
a diameter of 1.0 mm around the fovea, on the EDI-OCT scan. 
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This method of manual choroidal thickness measurement using EDI-OCT 
scans has been shown to be the most reproducible (Vuong, et al. 2016). The 
mean thickness of the choroid at the 3 mm and 6 mm rings (the mean of N1, 
N2, T1, T2 and CSF choroidal thickness measurements) was calculated and 
used for further statistical analysis. Image analysis was performed by a 
single experienced observer and independently reviewed by a further 
experienced observer.  
 
2.2.13 Main study outcome measure 
The main outcome measure used in this study was the difference in 
observed clinical and imaging characteristics between eyes classified as 
MFC or PIC, as above. 
 
2.2.14 Data analysis and statistics 
Study data was analysed with frequency and descriptive statistics using 
Instat software package version 3 (GraphPad Inc.) and SPSS software 
package version 22 (SPSS Inc, Chicago, IL, USA).  Cohen's kappa 
coefficient was used to calculate inter-rater agreement for qualitative 
measurements. Continuous data were plotted as frequency histograms and 
statistical tests for normality were performed. Data is presented in mean ± 
standard deviation for normally distributed data, and median ± interquartile 
range for skewed data. Categorical variables are presented as a percentage 
(%) of n. It is of note that, in this study, no discordant diagnoses of MFC and 
PIC were found in eyes from the same subject. Intraclass correlation 
coefficients (ICC) were calculated for paired eye data and high correlations 
between pairs of eyes were found for some variables. The dataset was not 
appropriate for generalised linear modelling with adjustment for correlation 
by a general estimating equation (GEE), so data was analysed using 
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univariate statistical tests: student T-test, Mann Whitney U test or Fisher’s 
exact test, as appropriate (Fan, et al. 2011). The assumptions for these tests 
include the assumption of independence, and so, in cases where subjects 
had both eyes included in the study and there were high correlations 
between pairs of variables, the right eye was included in the analysis (Fan, et 
al. 2011). P-values obtained from statistical tests were adjusted using the 
Benjamini-Hochberg correction for false discovery rate (FDR) in multiple 
analyses. All tests were two-tailed, and an adjusted P-value of < 0.05 was 
considered statistically significant. 
 
2.3 Results 
 
2.3.1 Demographics and clinical characteristics of the entire cohort 
The age range across the entire cohort of 185 subjects was 11 to 89 years 
with final (5-year) BCVA of 2.3 to -0.2 LogMAR (light perception to 20/12.5 
Snellen) (Figures 37-38). Eighty-two percent of eyes were from female 
subjects and 74% were myopic, with refractive errors across the whole group 
varying from +3.00 to -17.00D (spherical equivalent) (Figure 39). Fifty-eight 
percent had a previous history of choroidal neovascularisation. During the 5-
year period of observation, one eye from the cohort (0.3%), which had 
chorioretinal lesions confined to the posterior pole at baseline, was observed 
to develop peripheral lesions associated with anterior chamber inflammation.  
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No eyes developed peripheral lesions in the absence of inflammation over 
this period of observation. 
 
Figure 36: Frequency distribution of age (years) across the cohort 
 
 
Figure 37: Frequency distribution of right eye refractive error (spherical equivalent) 
across the cohort 
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Figure 38: Frequency distribution of baseline right eye visual acuity across the cohort 
 
2.3.2 Comparison of demographics and clinical characteristics 
Following classification as PIC or MFC, 169 eyes had MFC and 174 eyes 
had PIC. Figures 36-38 show the comparative frequencies of visual acuity, 
age and refractive error at baseline across the group following classification 
as MFC or PIC.  Table 9 summarises the demographic and clinical 
differences between MFC and PIC groups. 
There was no significant difference in the prevalence of bilateral disease in 
the subjects with PIC in comparison to subjects with MFC. The median 
BCVA at baseline presentation was logMAR 0.0 (20/30) in both the PIC and 
MFC groups (p= 0.235); and logMAR 0.2 (20/32) in the PIC and logMAR 0.0 
(20/30) in the MFC group at 5 years (p=0.235). However, eyes with PIC were 
from significantly younger subjects than eyes with MFC (33 years vs 40 
years, p=0.006); the proportion of eyes in females was significantly higher in 
the PIC group (93% vs 71%, p=0.001); a significantly higher proportion of 
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PIC eyes had CNV (73% vs 43%, p=0.001); and a significantly higher 
proportion of PIC eyes also had myopia (any myopic refractive error) (91% 
vs 59%, p=0.001), with a significantly higher degree of myopic refractive 
error (spherical equivalent)  (-7.50D vs -2.75D, p=0.001). 
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Table 9: Demographics and clinical characteristics of subjects with PIC and MFC 
 
 Punctate Inner 
Choroidopathy 
Multifocal 
Choroiditis 
Adjusted 
P-value 
       
Number of eyes 174 169   
Subjects with bilateral disease 
(%) 
80 (85) 78 (86) 0.255 
Baseline logMAR right VA 
(Snellen) 
0.0±0.5 
(20/20) 
0.0±0.5 (20/20) 0.235 
5 year logMAR right VA  
(Snellen) 
0.2±0.5 
(20/32) 
0.0±0.5 (20/20) 0.235 
Age (years) at baseline 33±15 40±21 0.006* 
Females (%) 162 (93) 120 (71) 0.001* 
CNV (%) 127 (73) 73 (43) 0.001* 
Myopia (%) 158 (91) 100 (59) 0.001* 
Median spherical equivalent (D) -7.50±0.5 -2.75±0.6 0.001* 
Received any treatment (%)  84 (48) 137 (81) 0.001* 
Systemic immunosuppression  
(% of treatment) 
 50  
(60) 
125  
(91) 
0.001* 
  Anti-VEGF injections 
(% of treatment) 
 64  
(76) 
 25  
(15) 
0.001* 
    
 
2.3.3 Comparison of treatment received  
Table 9 summarises the differences in treatment received by the two groups. 
The overall proportion of eyes receiving any treatment (laser 
photocoagulation, photodynamic therapy, surgical excision, intravitreal 
injections and/or oral immunosuppression) was significantly larger in the 
MFC group than the PIC group (81% vs 48%, p= 0.001), which included a 
significantly greater proportion of patients who received systemic 
immunosuppression (91% vs 60%, p=0.001). Indications for 
immunosuppressive treatment included intraocular inflammation, new 
chorioretinal lesions, recurrent secondary CNV, decreased BCVA and visual 
symptoms in combination with evidence of intra- or sub-retinal fluid or lesion 
progression on clinical imaging. Anti-VEGF injections were received by a 
higher proportion of eyes with PIC compared to MFC (76% vs 15% p=0.001).  
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2.3.4 Comparison of imaging features  
Spectralis imaging data was collected from 55 eyes in the active phase of 
disease, which included 25 eyes with PIC and 30 eyes with MFC; and from 
259 eyes in the inactive phase of disease, which included 128 eyes with PIC 
and 131 eyes with MFC (not all of the study eyes had Spectralis imaging). 
Table 10 summarises the findings from the fundus AF, SD-OCT and ED-
OCT analyses in active and inactive phases of disease, respectively. Inter-
rater agreement between measurements was high (Κ = 0.78). Qualitative 
analysis of anatomical features on OCT imaging did not demonstrate any 
significant differences in the presence of infiltration into the subretinal or 
outer retinal spaces, subretinal exudation, anatomical integrity of the retinal 
layers, retinal pigment epithelium (RPE) elevation, intraretinal spaces or 
cystoid macular oedema or alterations in the choroidal reflective pattern 
between eyes classified as MFC or PIC. Furthermore, there was no 
significant difference in the frequency of lesions in the perifoveal (within the 
EDTRS macular grid) area of eyes with PIC or MFC in the active and inactive 
phases of disease. Although there was no observed difference in frequency 
of ERMs between MFC and PIC in the active phase of disease, in the 
inactive phase of disease, a greater proportion of eyes in the MFC group had 
ERM (50% vs 12%, p=0.011). The median central choroidal thickness, during 
the active phase of disease was greater in eyes diagnosed with PIC (238µm) 
compared to eyes diagnosed with MFC (189µm), however this was not found 
to be statistically significant (p=0.690). There was no difference in the 
median central choroidal thickness, during the inactive phases of disease, 
between MFC and PIC (182µm vs 189µm, p=1.000).  The median diameter 
of lesions within the posterior pole area of the retina during the inactive 
phases of disease ranged from 100µm to 833µm in the PIC group and from 
101µm to 1140µm in the MFC group. The median lesion diameter in MFC 
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group (378µm) was not significantly greater (p=0.276) than that of the PIC 
group (296µm).  
 
Table 10: Multi-modal imaging features of eyes with PIC and MFC during active and 
inactive phases of disease 
 Punctate Inner 
Choroidopathy 
Multifocal 
Choroiditis 
Adjusted 
P-value 
      
Eyes imaged in active phase of disease  
 
25 30  
Subretinal and/or outer retinal infiltration (%) 21 (85) 23 (77) 0.702 
Subretinal exudation (%) 8 (31) 13 (44) 0.702 
Loss of anatomical integrity (%) 25 (100) 26 (86) 0.690 
RPE elevation by material (%) 21 (84) 21 (70) 0.690 
          Homogenous (%) 10 (48) 8 (37) 0.690 
          Heterogenous (%) 11 (52) 13 (63) 0.690 
Intraretinal spaces  
or cystoid macular oedema (%) 
10 (39) 
19 (63) 
0.690 
Epiretinal membrane (%) 4 (14) 
19 (63) 
0.121 
Median central choroidal thickness (µm) 238±107 
189±89 
0.690 
Perifoveal lesions (%) 20 (80) 19 (63) 0.690 
      
Eyes imaged in inactive phase of disease  128 131  
Median lesion size (µm) 296±103 378±200 0.276 
Subretinal and outer retinal infiltration (%) 82 (64) 92 (70) 1.000 
Subretinal exudation (%) 8 (6) 5 (4) 1.000 
Loss of anatomical integrity (%) 105 (82) 107 (82) 1.000 
RPE elevation by material (%) 105 (82) 86 (66) 0.759 
               Homogenous (%) 64 (61) 56 (65) 1.000 
               Heterogenous (%) 41 (39) 30 (35) 1.000 
Intraretinal spaces or cystoid macular 
oedema (%) 
23 (18) 
34 (26) 
1.000 
Epiretinal membrane (%) 15 (12) 66 (50)  0.011* 
Median central choroidal thickness (µm) 182±87 189±119 1.000 
Perifoveal lesions (%) 78 (61) 73 (56) 1.000 
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2.4 Discussion 
 
This study examining eyes with diagnoses of MFC or PIC represents the 
largest to date and provides some evidence that these diseases are 
phenotypically different, with PIC showing a predilection for younger, more 
highly myopic women and secondary CNV development.  Subjective clinical 
diagnostic bias was minimised in the methods by classifying eyes as having 
a diagnosis of PIC or MFC using a standardised approach, based on clinical 
consensus of disease characteristics (fundal distribution of lesions and 
presence of intraocular inflammation) in the literature to date. Eyes which 
may have been previously diagnosed with ‘atypical PIC’ (Essex, et al. 2010) 
were classified as having MFC. There were no discordant diagnoses 
between eyes. Eyes with chorioretinal lesions confined to the posterior pole 
were observed over 5 years for phenotypic stability and, in the absence of 
intraocular inflammation, none of these eyes developed peripheral lesions.  It 
was determined from our data that MFC and PIC differ significantly in 
demographic and clinical characteristics. Our findings contrast with those 
from Spaide et al, who compared MFC with panuveitis and PIC in a smaller 
retrospective case series of 38 eyes of 22 patients, using multi-modal 
imaging and a disease definition based on clinical evidence of inflammation 
only (and not lesion location), and did not observe any clinical differences 
(Spaide, et al. 2013).  However, similarly to Spaide et al, we found that 
lesions in both groups involved the outer retina and sub-RPE space.  
A higher proportion of eyes in our MFC group received treatment, of any 
kind, compared to the PIC group. The PIC group, however, received more 
anti-VEGF injections, due to the higher association of CNV. This did not 
result in any significant differences in the BCVA between the PIC and MFC 
groups five years after baseline presentation. These findings are partly 
supported by research concurrent to this study, which suggested that visual 
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loss is common in subjects with PIC, predominantly secondary to late 
development of CNV; and that treatment with oral corticosteroids may help to 
reduce the risk of CNV development, with anti-VEGF therapy for CNV being 
associated with better clinical outcomes (Niederer, et al. 2017). 
These data show that PIC was associated with a significantly higher 
proportion of eyes with myopia and a higher degree of myopic refractive error 
than MFC. It was originally suggested that the lesions in PIC were secondary 
to myopia, representing ‘a lacquer-crack’ type scar (Watzke, et al. 1984). 
However, PIC pathogenesis is now thought to be immune-mediated and SD-
OCT findings demonstrate that the breach in Bruch’s membrane occurs later 
in PIC lesion development, potentially as a consequence of inflammatory 
disruption (Channa, et al. 2012; Zhang, et al. 2013a). Furthermore, it has 
been shown that ocular inflammation, caused by Kawasaki Disease, 
independently increased the risk of myopia (in a population with a high 
prevalence of myopia) (Kung, et al. 2017). This might suggest that the 
myopia observed in PIC subjects could be a consequence of the 
inflammation rather than the predisposing cause for the observed lesions. 
Against this assertion, however, is the fact that the inflammation in Kawasaki 
disease occurs in childhood, and there is no substantial evidence, as yet, 
which demonstrates that chorio-retinal inflammation onset occurs during 
childhood, in subjects with PIC. In the current study, the youngest subject 
age at first presentation with PIC was 15 years and the median age of 
presentation, 33 years.  
Subjects with PIC have been reported to have personal and/or family history 
of autoimmune disease with a prevalence of 3-26% (Atan, et al. 2011; 
Gerstenblith, et al. 2007). It is well known that autoimmune disease is more 
common in women, which may be due to the effect of sex hormones, 
microchimerism, gene encoded by X or Y chromosomes, X chromosome 
inactivation and differing innate immune responses to environmental factors, 
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notably, infectious agents (Fairweather, et al. 2001; Fairweather, et al. 2012; 
Fairweather and Rose 2004).  
It could be argued that since PIC manifests with posterior pole lesions and a 
higher prevalence of secondary CNV, these patients are more likely to notice 
visual symptoms and present at an earlier age. However, our SD-OCT 
analysis did not reveal any significant difference in the prevalence of peri-
foveal lesions in the active and inactive phases of disease between eyes with 
MFC or PIC.  
Evidence of anterior chamber or vitreous inflammation, required for our 
classification of eyes as MFC or PIC, was determined from clinical 
examination and review of clinical documentation and imaging. Since AC and 
vitreous inflammation (if it occurs in MFC) is episodic, it is possible that this 
may not have been captured during a clinic visit. Nevertheless, the fact that 
the MFC group with inactive disease had a higher proportion of subjects with 
ERM than the PIC group suggests that there was a higher prevalence of 
previous intraocular inflammation in this group.  
It was observed that the mean choroidal thickness in active PIC was greater 
than in active MFC but this difference was not statistically significant, 
probably since fewer eyes were imaged during the active phase of disease 
compared to the inactive phase. A standardised manual caliper approach 
was used to measure central choroidal thickness in subjects with MFC and 
PIC. Due to the influence of myopia on chorioretinal thickness and its 
association with PIC, the effect of inflammatory activity on chorioretinal 
thickness was likely underestimated. A previous study has demonstrated 
that, in subjects with a diagnosis of PIC, choroidal thickness increased 
throughout the active phase in 30% of the 27 eyes in which lesions 
progressed (Zhang, et al. 2013a). Although not convincingly demonstrated in 
the current study, it is possible that inflammation in active PIC involves the 
choroid to a greater extent than the inflammation in MFC. Mean lesion size in 
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this study was based on AF images. Due to the clear delineation of lesion 
borders on AF images, a standardised image scale and a higher number of 
images available for analysis, this meant that the measurements taken had 
greater reliability and validity than measurements taken from colour fundus 
photos. However, given that areas of chorioretinal atrophy may enlarge over 
time in myopic eyes, retrospective clinical differentiation between these two 
diseases, based on lesion size, remains challenging. 
Studies to date comparing MFC and PIC have been limited by small sample 
size and lack of standardisation in disease definitions. Currently, many 
clinicians do not believe that there is any clinical utility in differentiating 
between MFC and PIC, which predisposes towards diagnostic bias and away 
from individualised disease management. Results based on ultrastructural 
electron microscopy (Pachydaki, et al. 2012) support the hypothesis that PIC 
is an inflammatory disease originating in the choroid which predominantly 
affects young myopic women.  In another study of 42 patients with PIC, the 
authors conclude, based on SD-OCT findings, that PIC is a chorioretinitis 
rather than an inner choroidopathy. They describe a 5 stage evolution 
process initially involving the inner choroid and progressing to disrupt the 
RPE and Bruch’s membrane, with the formation of a chorioretinal nodule 
being ‘the core event of PIC inflammation’ (Zhang, et al. 2013a) . Other 
studies have shown the value of AF imaging in monitoring progression of PIC 
(Hua, et al. 2014; Kramer and Priel 2014).  Although advances in multi-modal 
imaging have allowed us to analyse the posterior pole at a greater level of 
detail, this has not thus far facilitated more specific differentiation between 
these two syndromes. Detailed clinicopathological studies of these diseases 
are not often feasible but our group and others have previously 
demonstrated that clinical inflammation in MFC is associated with infiltration 
of B-lymphocytes, particularly in the CNV, which has not been observed in 
PIC (Dunlop, et al. 1998; Shimada, et al. 2008).  As yet, there is no further 
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evidence to support distinct pathophysiological processes in PIC and MFC, 
apart from the proposed differences in clinical phenotype. 
In summary, these data provide some evidence to support clinical 
differentiation between MFC and PIC on the basis of chorioretinal lesion 
location and associated inflammation.  It is demonstrated here that subjects 
with diagnoses of PIC or MFC, based on these criteria, had significantly 
different demographics and showed phenotypical stability over a 5-year 
period. These could represent important differences in disease 
pathophysiology and phenotype, which have relevance for individualised 
management. The phenotypical differences identified here between cases 
classified as PIC or MFC could be further investigated in conjunction with 
pathophysiological data and/or assessment of effects on retinal function in a 
future study. 
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Chapter 3 An Investigation into the Role of Treg in 
Clinical Remission of Sight-threatening Non-
infectious Uveitis: Materials and Methods  
 
3.1 Background to methods 
 
3.1.1 Study background and rationale 
Non-infectious uveitis is a clinically heterogeneous disease. The overall aim 
of the laboratory studies was to improve the phenotyping of uveitis through 
identification of immunological biomarkers, such as T-regulatory cells, 
associated with clinical remission, which could allow more individualised 
patient management by helping to predict which patients are at risk of 
inflammatory disease relapse. 
 
3.1.2 Study aims 
1. To investigate the association of immunological biomarkers 
(peripheral blood levels of Treg, Th1 and Th17, their related cytokines 
and methylation changes at epigenetic loci of their signature 
transcription factors) with sustained clinical remission of non-infectious 
uveitis, in patients who have previously received treatment with oral 
immunosuppression. 
 
2. To develop a clinically relevant statistical model for predicting clinical 
remission in non-infectious sight-threatening uveitis. 
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3.1.3 Hypothesis: 
Clinical remission of non-infectious uveitis in patients, who have previously 
received treatment with oral immunosuppression, is associated with an 
‘immunoregulatory’ signature, characterised by upregulation of 
phenotypically stable T-reg 
 
3.1.4 Objectives 
• To isolate peripheral blood mononuclear cells (PBMC) from patients 
from non-infectious uveitis in clinical remission for comparison of Treg, 
Th1 and Th17 population frequency in peripheral blood with those 
from patients with active uveitis and control subjects. 
• To compare the immunosuppressive function of Treg isolated from 
patients with non-infectious uveitis in clinical remission with those from 
patients with active uveitis and control subjects. 
• To isolate peripheral blood sera from study subjects for analysis of 
serum cytokine levels of IL-10, IL-22, IL-17A, IFNγ and TGFβ. 
• To isolate high quality DNA from PBMC from study subjects for CpG 
methylation site analysis of epigenetic loci, relevant to Treg, Th1 and 
Th17 lineages. 
• To compare serum cytokine levels and CpG methylation levels in 
samples from patients in clinical remission with those from patients 
with active uveitis and control subjects. 
• To analyse relationships between the serum cytokine levels and 
percentage (%) DNA methylation with previous immunosuppressive 
treatment duration, % frequency of Treg, TIGIT+ Treg, Th1 and Th17 
across the whole study population. 
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• To statistically model the relationship variables analysed above, in 
order to assist individualised clinical management of patients with 
sight-threatening non-infectious uveitis. 
3.1.5 Immunophenotyping clinical remission of sight-threatening non-
infectious uveitis  
Treatment paradigms of systemic autoimmune diseases, such as rheumatoid 
arthritis (RA) and inflammatory bowel disease, have evolved beyond partial 
symptom control, alone, towards the induction and maintenance of sustained 
biological remission. This is also known as a ‘treat to target’ strategy, with the 
goal of improving long-term disease outcomes (Colombel, Louis, Peyrin-
Biroulet, Sandborn, & Panaccione, 2012).  A working definition of sustained 
‘deep remission’, which includes long-term biological remission and symptom 
control with defined patient outcomes, including no disease progression, has 
been proposed for Crohn’s disease (Colombel et al., 2012; Zallot & Peyrin-
Biroulet, 2013). Clinical remission in uveitis, however, has not been defined 
or investigated as an immunologically distinct phase of disease. 
Understanding the immunological mechanisms underlying disease 
remission, in addition to the focus on inhibiting inflammation, could have 
significant implications for clinical phenotyping of uveitis and determining the 
best therapeutic approach to induce remission for each patient.  
 
3.1.6 Immunophenotyping ocular inflammation using peripheral blood 
samples 
This study was designed to detect peripheral blood biomarkers associated 
with ocular inflammation. All recruited patients had forms of sight-threatening 
non-infectious uveitis severe enough to require systemically administered 
immunosuppressive treatment, which is known to be effective in ocular 
treating inflammation. The response of the eye to immunosuppressive 
treatment, in contrast to other organs, such as the bowel, can be directly 
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visualised, without necessitating an invasive procedure. Biopsies of aqueous 
or vitreous humour are occasionally performed as part of routine clinical 
management of sight-threatening uveitis and are required in cases when 
clinical presentation and/or screening blood tests point towards an infective 
or neoplastic cause of inflammation.  
The supervisors of this research have previously analysed aqueous humour 
samples from the eyes of patients with uveitis (Ooi, Galatowicz, Towler, 
Lightman, & Calder, 2006). However, the procedure of direct intraocular 
sampling, itself, carries risks of introducing infection, triggering or 
exacerbating inflammation and causing retinal detachment to the eye being 
sampled. Even when it is deemed clinically necessary, sequential/ repeated 
intraocular sampling should be avoided.  In this study, all patients were 
screened for known common infective causes of uveitis and, therefore, 
additional intraocular sampling for immunophenotypic analysis was not 
undertaken as part of this study. 
The study methods for collection of peripheral blood samples excluded 
patients with known systemic diagnoses, for example, sarcoidosis or 
Behçet’s disease, and any other identifiable systemic inflammation. Patients 
with anterior uveitis were also excluded from recruitment, as this form of 
ocular inflammation is confined to the anterior segment of the eye, and 
therefore, tends not be sight-threatening and/or necessitate systemic 
immunosuppression.  
The blood components of immunological interest were collected from the 
plasma and leukocytes fractions of the samples. 
The typical composition of human blood is as follows: 
o 55% plasma 
o 45% cells 
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o 95% erythrocytes  
o 5% platelets 
o marginal – 1% leukocytes 
The typical composition of the leukocyte compartment is as follows: 
o granulocytes (polymorphonuclear leukocytes) 
▪ neutrophils 30-80% 
▪ basophils 0.4% 
▪ eosinophils 2.3% 
o agranulocytes (mononuclear leukocytes) 
▪ lymphocytes 30-40% 
▪ monocytes/ macrophages 2-12% 
▪ dendritic cells 0.2-1% 
Differential blood counts give relative percentages of each type of leukocyte 
within the blood sample. Approximate reference ranges for differential 
leukocyte counts in normal adults are as follows: 
• Neutrophils - 2.0–7.0×109/L (40–80%) 
• Lymphocytes - 1.0–3.0×109/L (20–40%) 
• Monocytes - 0.2–1.0×109/L (2–10%) 
• Eosinophils - 0.02–0.5×109/L (1–6%) 
• Basophils - 0.02–0.1×109/L (<1–2%) 
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3.1.7 Flow cytometric immunophenotyping of peripheral blood for T-
reg, Th1, Th17 and related cytokines  
 
3.1.7.1 Immunophenotyping by flow cytometry 
Flow cytometry has become a standard laboratory tool for identifying 
homogeneous subsets of cells within the complex immune system. 
Identification and enumeration of immune cell subsets is referred to as 
‘immunophenotyping’. This technology makes use of monoclonal antibody 
reagents (which recognise specific epitopes on immune cells), directly 
conjugated to a ‘fluorochrome’ dye. The dyes have characteristic 
photochemical properties which allow them to absorb and emit 
electromagnetic radiation of different wavelengths in the visible spectrum, 
based on the energy lost during the return of excited electrons to their 
ground state (Fleisher, 2013). The energy absorbed and emitted is 
associated with their illumination by a specific wavelength of light, where the 
emitted light has a longer wavelength (lower energy) than the wavelength of 
the excitation beam (Fleisher, 2013). 
Flow cytometry can be used to test for the presence and absence of cell 
surface antigens and the use of panels of monoclonal reagents can help 
address questions regarding cell differentiation (Fleisher, 2013). The clinical 
application of this technology has been facilitated by a series of 
developments in flow cytometry instruments (hardware), systems for data 
analysis (software) and fluorescent dye chemistry and the range of 
monoclonal antibody- dye conjugates now available.  
The older systems could only incorporate two- to four-color flow cytometric 
measurements, however it is now possible to simultaneously measure up to 
18 distinct fluorescence and two scattered light parameters on each cell. 
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Multicolour flow cytometry can, therefore, provide a comprehensive overview 
of immunophenotypic information, for each sample studied.  
Flow cytometric data is analysed by acquisition of cells on a flow cytometer, 
followed by a method known as cell ‘gating’, a process by which cell 
populations of interest are defined based on two non-fluorescent parameters 
(forward and side light scatter) in addition to mean fluorescent intensities 
(MFI) for the immune markers of interest. The information that flow cytometry 
provides about the immune cells populations within the samples can be very 
useful for diagnosing and/or managing disease in addition understanding 
disease pathogenesis.  
3.1.7.2 Considerations for immunophenotypic analysis of Treg, Th1 and 
Th17  
T-regulatory cells (Treg) were first identified as a circulating subset of CD4+ T 
cells expressing high levels of CD25 (the IL-2 receptor α-chain), which, by 
adoptive transfer, demonstrated the ability to protect the host from 
autoimmune pathology, such as multi-organ autoimmune diseases and/or 
rodent graft-versus-host disease (GVHD)-like wasting disease (Powrie and 
Mason 1990; Sakaguchi, et al. 1982; Smith, et al. 1991; Suri-Payer, et al. 
1998). IL-2, itself, has important, non-redundant effects on Treg maintenance 
and survival and CD25 is present on activated T cells and B cells, in addition, 
to some thymocytes and myeloid precursors in humans. Approximately 30% 
of human CD4+ T cells exhibit continuous low expression of CD25 and these 
levels increase during activation. Whereas CD4+CD25+ T-cells in mice were 
found to exhibit regulatory function, only the CD4+ T-cells expressing high 
levels of CD25 (CD25hi) demonstrated similar regulatory function in humans 
(Baecher-Allan, et al. 2001). 
The identification of the Forkhead family transcription factor, (Fox)P3, 
(Brunkow, et al. 2001; Chatila, et al. 2000) and its specific expression in 
CD4+CD25+ regulatory T cells (Fontenot, et al. 2003), led to FoxP3 
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expression becoming a defining characteristic of Treg. The FoxP3 gene 
contains a forkhead (FKH) domain at the C terminus, critical for nuclear 
localisation and DNA binding, an N terminus transcriptional repressor 
domain, in addition to C2H2 zinc finger and leucine zipper domains, which 
mediate DNA binding and dimerization (Figure 39) (Li, et al. 2006). The 
basal, T cell-specific promoter contains six NF-AT and AP-1 binding sites, 
which positively regulate the transactivation of the FoxP3 promoter after the 
TCR is triggered (Mantel, et al. 2006).  
 
Figure 39: Schematic diagram of the X Chromosome, (a) FoxP3 gene and (b) FoxP3 
protein, modified from NCBI Reference Sequence (RefSeq) (Marques, et al. 2015). (a) 
shows two isoforms of the gene, with a difference in exon 2. (b) shows the FoxP3 
protein with Forkhead (FKH) Forkhead family transcription factor domain at the C 
terminus, the Repressor domain at the N terminus; and in between lie the Leucine 
zipper (LZ) and Zinc finger (ZF) domains.  
 
FoxP3 is considered the Treg ‘master transcription factor’ because it is 
critically required for Treg-cell development and function and for suppressing 
autoimmunity  (Bennett, et al. 2001; Fontenot, et al. 2003; Hori, et al. 2003a; 
Hori, et al. 2003b). Deficiencies in FoxP3 were shown to cause 
lymphoproliferation and multiorgan autoimmunity in scurfy mutant mice and 
human IPEX patients, which could be rescued by transfer of Treg cells 
reproduced by inactivation of FoxP3 uniquely in T cells (Benoist and Mathis 
2012). The large majority of FoxP3-expressing Treg are found within the 
CD4+CD25+ T-cell population, which constitutes approximately 5-10% of total 
CD4+ T cells in humans. 
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Natural CD4+CD25+FoxP3+ Treg (nTreg) cells differentiate in the thymus, 
where they undergo selection determined by high-avidity interactions with 
APCs, following which they migrate to peripheral tissues (Figure 40). 
Adaptive CD4+CD25+FoxP3+ Treg (iTreg) cells, on the other hand, are 
thought to differentiate from naïve, activated effector or proliferating memory 
CD4+ T cells outside the thymus, in the ‘periphery’ (Akbar, et al. 2007) 
(Figure 40). The peripheral population of FoxP3+ Treg cells, therefore, 
consists of both nTreg and iTreg cells, which have a similar phenotype and 
function (Curotto de Lafaille and Lafaille 2009).  
 
Figure 40: ‘Natural Treg (nTreg) cells differentiate in the thymus and migrate to 
peripheral tissues. Adaptive FoxP3+ Treg (iTreg) cells differentiate in secondary 
lymphoid organs and tissues. The peripheral population of FoxP3+ Treg cells 
comprises both nTreg and iTreg cells.’ (Curotto de Lafaille and Lafaille 2009). 
 
It is known that activated human T-cells may transiently upregulate FOXP3 
and that these FoxP3+ T-cells are not effective at suppressing inflammation 
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(Allan, et al. 2007; Gavin, et al. 2006; Tran, et al. 2007; Wang, et al. 2007).  It 
appears that only in circumstances in which human cells express FoxP3 at 
high and constitutive levels do they acquire suppressor function (Allan et al. 
2008).  It is, therefore, of note that not all CD25+ cells are suppressive and 
not all FoxP3+ cells express CD25 (Fontenot et al. 2005).  It has been shown 
that inflammatory environments may induce T-cell plasticity (Murphy and 
Stockinger 2010). Furthermore, it is postulated that there may be a threshold 
of expression and/or activation of transcription factors by FoxP3+ Tregs, 
which allows them to act either as lineage-specific regulators or contributors 
to Th1 or Th17 effector responses (Povoleri, et al. 2013). This potential for 
plasticity presents challenges for the identification of phenotypically stable T-
reg lineages. 
FoxP3 expression is important, but not sufficient, for the establishment of the 
Treg lineage because the development of a Treg-specific genome-wide 
methylation pattern is also critical (Morikawa, et al. 2014; Ohkura, et al. 
2012). FoxP3 gene expression is controlled by four elements, containing 
conserved non-coding sequences (CNS), which are regulated by epigenetic 
modifications that determine chromatin structure and DNA methylation, 
altering the accessibility of the gene locus to transcription factors (Povoleri, 
et al. 2013) (Figure 41).  
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Figure 41: The FoxP3 epigenome and transcription factor binding sites. ‘Four distinct 
regions of the FoxP3 gene are susceptible to epigenetic modification. These are the 
FoxP3 promoter and three other conserved non-coding sequences (CNS): CNS1 – the 
TGF-β sensor/enhancer, CNS2 – Treg-cell-specific demethylation region (TSDR), and 
CNS3 – a FoxP3 pioneer element. Epigenetic modifications include histone 
acetylation/deacetylation and CpG methylation/demethylation and are shown at each 
locus’ (Povoleri, et al. 2013). 
 
The first site is in the FoxP3 promoter, a CNS site located 6 kb upstream of 
the translational start site of the FoxP3 gene. Activation occurs following 
TCR stimulation through binding of NFAT and AP1 (Mantel, et al. 2006). The 
FoxP3 promoter is thought to be is more accessible in Treg cells than Tconv 
(Baron, et al. 2007). Another CNS site, an evolutionarily conserved DNA 
hypomethylation pattern, the Treg-specific demethylated region (TSDR) is 
associated with enhancement and stabilization of FoxP3 expression (Floess, 
et al. 2007; Huehn, et al. 2009; Polansky, et al. 2008; Zheng, et al. 2010).  
The TSDR has been identified in both humans and mice and has been found 
to be fully demethylated in Treg cells and methylated in conventional T-cells 
(Tconv) (Baron, et al. 2007; Floess, et al. 2007; Polansky, et al. 2008). 
Activated Tconv cells and TGF-β-treated cells displayed no FoxP3 
demethylation, although they expressed FoxP3, whereas ex vivo expanded 
Treg, remained demethylated even after extensive in vitro stimulation and 
expansion (Baron, et al. 2007; Floess, et al. 2007; Polansky, et al. 2008). 
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DNA methylation status of FoxP3 has been also shown to correlate with 
suppressive activity of nTreg (Huehn, et al. 2009). In a genome wide 
methylation analysis of human naive nTreg and conventional naive CD4+ T 
cells, it was found that FOXP3 binding coincided with hypomethylation in the 
Treg genome (Zhang, et al. 2013b). The TDSR, in combination with CD25 
and FoxP3 expression, has, therefore, allowed identification of T-cells with a 
stable phenotype (Janson, et al. 2008). 
Different subtypes of Tregs have been described, some of which are 
identified by the expression of their signature cytokines, IL-10 and TGF-β 
(Shevach and Thornton 2014; Zhang, et al. 2014) (Table 11). Helios, an 
Ikaros transcription factor, was proposed as a marker of nTreg (Thornton, et 
al. 2010) but this view has been subsequently challenged by the 
demonstration that Helios is induced during T cell activation and proliferation 
and then down-regulated (Akimova, et al. 2011; Elkord 2016).  
 
Table 11: Some subtypes of regulatory T cell (Treg) and their actions (Zhang, et al. 
2014) 
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Cell surface markers for further characterising Treg have been described, 
which include glucocorticoid-induced tumour necrosis factor receptor (GITR), 
CTLA-4, Neuropilin-1, and PD-1, but there is no agreement amongst experts, 
as to which of these might constitute definitive Treg markers (Sakaguchi, et 
al. 2013). Furthermore, GITR and CTLA-4 are not exclusive to Treg and are 
also expressed by activated T cells.  
Although T cells express IL-7Rα (CD127), it was found that lower levels of 
CD127 (CD127lo) were expressed by Treg (Liu, et al. 2006). Therefore, 
CD127lo in combination with high CD25 expression, has been proposed as a 
Treg phenotypic marker (Klein, et al. 2010; Liu, et al. 2006). It was 
demonstrated that FoxP3 interacted with the CD127 promoter and that the 
CD127lo marker could be used to selectively enrich human Treg cells for in 
vitro functional studies, resulting  a purified CD4+CD25+CD127lo cells of 
which 85-95% were reported to express FoxP3+ (Liu, et al. 2006), However, 
CD127 may be also upregulated following T cell activation and higher levels 
than originally reported have been shown to be expressed by activated Treg 
(Simonetta, et al. 2010).   
Thus, there remains a lack of consensus regarding immunophenotypic cell 
surface markers for functionally suppressive Treg, and, particularly, markers 
that might be helpful in identifying these Treg subsets in human autoimmune 
disease.  
A recently discovered co-inhibitory molecule, T cell immunoreceptor with Ig 
and ITIM domains (TIGIT) has been proposed as a novel marker of Treg 
(Joller, et al. 2014). TIGIT is expressed by Tregs (Yu, et al. 2009) and 
suppresses a range of immune cells, including T-cells, dendritic cells and NK 
cells. Recent studies show that TIGIT ligation directly inhibits T cell 
proliferation and cytokine production in CD4+ T cells (Joller, et al. 2011).  
Furthermore, increased expression of TIGIT delineated Treg from activated 
effector T cells (Zhang, et al. 2013b). There is also evidence that 
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hypomethylation at the TIGIT locus is associated with FOXP3 binding and 
the nTreg phenotype (Zhang, et al. 2013b).  Treg cells expressing TIGIT 
were found to selectively inhibit Th1 and Th17, but not Th2 responses (Joller, 
et al. 2014). Since, it is known that the Th1 and Th17 subsets are pivotal to 
the pathogenesis of autoimmune disease, TIGIT may be a biomarker of 
stable, functionally suppressive Tregs in these diseases.   
A previous study, published by the supervisors of this PhD, characterised 
Treg in peripheral blood of subjects with ocular inflammatory disease, by flow 
cytometric immunophenotyping, using the previously described, well-
established Treg markers: CD4, CD25 and FoxP3 (Lightman et al., 2014). In 
the current study, flow cytometry methods are also used to 
immunophenotype subjects’ bloods for Treg, however, the cell surface 
marker, TIGIT, was additionally used as a surrogate marker for capacity of 
Treg to selectively suppress Th1 and Th17 (Jager & Kuchroo, 2010; Joller et 
al., 2011; Joller et al., 2014; Kurtulus et al., 2015). Immunophenotypic 
markers were also added to the flow cytometry panel to characterise Th1 
and Th17 populations, according to expression of their ‘signature’ 
transcription factors, T-bet and RORγt, respectively. However, whilst 
immunophenotypic studies may assess the presence or absence of cells or 
surface molecules, they do not evaluate the functional status of the cells. 
Relevant to this study was the assessment of Treg function, therefore, 
methods were included to assess the ability of CD127lo Treg to suppress 
proliferating T-cells. 
The cytokine milieu is an important part of this ‘microenvironment’, which has 
been shown to regulate the Treg/Th17 balance and influence cell plasticity; 
disruption of this balance may lead to the development of inflammatory 
disease (Leung, et al. 2010; Lochner, et al. 2008; Omenetti and Pizarro 
2015; Sefik, et al. 2015). In clinical trials of systemically-administered 
immunomodulating therapies, induction of disease remission in uveitis was 
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associated with modulation of cytokine production, in addition to systemic 
upregulation of Tregs (Calleja, et al. 2012; Lightman, et al. 2014). Levels of 
corticosteroids have been found to positively correlate with IL-
10+FoxP3+CD25+CD4+ T regulatory cells but not with CD4+IL-17+ Th17 cells 
in the ocular form of Behçet’s Disease (Zhang, et al. 2016). In some clinical 
studies, pharmacological effects on cytokines were demonstrated without a 
significant increase in the proportion of systemic FoxP3+ Tregs levels 
(Molins, et al. 2015). These studies suggest that the mechanism of disease 
remission in uveitis, may be mediated through cytokines.  
 
3.2 Methods 
    
3.2.1 Ethical approvals 
Research performed as part of this thesis adhered to the tenets of the 
Declaration of Helsinki and was carried out in accordance with the 
recommendations of the UK National Research Ethics Service (NRES) – 
London Harrow Committee and the Moorfields Eye Hospital National Health 
Service (NHS) Foundation Trust, Department of Research and Development 
(13/LO/1653; 16039). Written informed consent was obtained from recruited 
subjects. 
 
3.2.2 Design, setting and study subjects 
Design: Cross-sectional and prospective cohort observational study  
Setting: Tertiary referral centre for clinical management of uveitis in the UK 
Participants:  A total of 50 patients prospectively recruited from a specialist 
uveitis clinic in tertiary care centre for ophthalmology in London UK and 10 
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volunteers recruited from a higher education institution (university) in 
London, UK. 
 
3.2.3 Flow cytometry panel design, controls and standardisation 
A multicolour flow cytometry panel for immunophenotyping Treg, Th1 and 
Th17 was designed taking into account: the required cell surface markers 
with the available fluorochrome conjugates, the expected frequency of 
expression in the sample, the excitation/ emission spectrum, the relative 
brightness of the chosen fluorochrome conjugate (Table 12) and the 
available laser channels in the flow cytometer used to acquire the data 
(Table 13) [The panel included phenotypic markers for B-cells, as described 
in the original aim of PhD thesis. However, the B-cell data was not analysed 
as part of this thesis. 
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Table 12: Template for flow cytometry panel design (markers shaded in grey were not 
analysed as part of this thesis) 
Cell markers 
(cell type)  
Expected 
frequency of 
expression in 
PBMC 
 
Human 
fluorochrome
-conjugated 
antibodies 
Excitation 
laser 
detector 
channel 
(nm) 
Excitation/
Emission 
spectrum 
(nm) 
Relative 
brightness of 
fluorochrome 
CD3  30-70% VioBlue 405 400/455 1 
CD8 5-30% AlexaFluor700 633 633/719 5 
CD4 25-60% BUV395 355 348/395 5 
CD25 
 
2-40% 
depending on 
activation 
status 
BV711 
 
405 407/711 5 
FoxP3 0.05-15% 
 
AlexaFluor647 640 650/668 5 
TIGIT 
 
2-8% PE 
 
488  496/578 6 
RORγt 0-5% Alexa488 488 495/519 5 
T-bet 10-40% PerCp-Cy5.5 488 482/695 3 
CD19 10-40% BV605 405 405/603 6 
CD24 
 
Not known PE-Cy7 488 496/775 6 
CD38 Not known PE-Dazzle594 488 496/612 6 
Live/Dead 
fixable dye 
Variable 
(depending on 
cell type) 
Near Infra-red 
(IR) 
640 750/775 NA 
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      Table 13: BD LSRFortessa laser channels 
 
In order to ensure the validity of multicolour flow cytometry results, the 
following controls were incorporated into the flow cytometry methods: 
• Quality control 
o This included monitoring instrument set-up and performance 
(with calibration beads being run weekly on the instrument), 
optimising sample preparation, standardising reagents, sample 
controls and data interpretation (Fleisher 2013) 
• Positive-negative discrimination 
o This requires establishing criteria for the boundaries between 
stained (positive) cells and (unstained) negative cells. This may 
be achieved through the use of 1) isotype controls or 2) 
fluorescence-minus-one (FMO) controls. 
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• Compensation controls 
o Multi-colour fluorochromatic dyes emit fluorescent signals, 
which may overlap in their emission spectrum. Flow cytometry 
panels are designed to minimise this type of overlap. However, 
in cases where it cannot be avoided, signal overlap can be 
corrected by electronic subtraction of the overlap in a process 
known as ‘compensation’. 
Flow cytometry antibody concentrations for staining of stimulated and 
unstimulated cells were optimised by titration. 
 
3.2.4 Patient recruitment for experimental assays 
A total of 50 patients with a diagnosis of idiopathic non-infectious uveitis 
were consecutively recruited to the study from Moorfields Eye Hospital, 
London, UK between November 2014 and December 2016. Inclusion criteria 
for all patients were as follows: age 18 to 59 years; a current or previous 
diagnosis of noninfectious intermediate, posterior or pan-uveitis as per 
standardization of uveitis nomenclature (SUN) (Jabs et al., 2005); and the 
absence of known associated infectious disease or systemic inflammatory 
disease. Eligibility for recruitment was further determined by uveitic disease 
activity.  To meet the clinical criteria for disease ‘in clinical remission’, 
patients were required to have no signs of disease activity at the time of 
recruitment; have a previous diagnosis of active non-infectious chronic 
relapsing and remitting uveitis which was treated with oral corticosteroids +/- 
second line corticosteroid-sparing treatments prior to the period of clinical 
remission; and have discontinued all immunosuppressive treatment and 
remained quiescent for at least 6 months. To meet the criteria for ‘active’ 
disease, patients were required to have new onset of uveitic disease 
occurrence at the time of recruitment (a new diagnosis or reactivation of 
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existing disease), which was regardless of treatment status. Disease activity 
was determined by clinical symptoms, examination with slit lamp 
biomicroscopy and clinical imaging (optical coherence tomography, fundus 
autofluorescence and fluorescein angiography). Patients who met the study 
inclusion criteria and who were clinically assessed to have active disease 
(i.e. anterior chamber cells ≥0.5+, vitreous cells ≥0.5+, inflammatory cystoid 
macular oedema, optic disc oedema, active vasculitis, or new/ active chorio-
retinal lesions) were considered eligible as ‘active’ patients in the study. As 
controls, 10 age-matched subjects with no history of uveitis, systemic 
inflammatory disease or known infectious disease were enrolled onto the 
study. 
 
3.2.5 Specimen collection for experimental assays 
A 30ml sample of heparinized peripheral venous blood was obtained from all 
subjects using VACUETTE NH Sodium Heparin tubes and safety 
venupuncture equipment (Greiner BioOne, UK). All venous blood samples 
were obtained by a clinician experienced in phlebotomy (the thesis author) 
and stored at room temperature until processing for experimental assays 
and/ or crypreservation within a 4-hour period. For the active patient cohort, 
baseline (Time 0) blood samples were obtained before starting/ modifying 
the immunosuppressive treatment regime. Additional peripheral venous 
blood samples were prospectively obtained from four active patients at 2, 6 
and 12 months after starting/ changing treatment.  
 
3.2.6 PBMC isolation from peripheral blood samples 
When peripheral whole blood is sampled for human studies of the immune 
system, it should be processed to remove erythrocytes (red blood cells) prior 
to staining for flow cytometric analysis or other in vitro assays. Density 
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gradient centrifugation uses a solution of high molecular weight sucrose 
polymers, such as Histopaque-1077 (Sigma Aldrich, UK), which separates 
whole blood into two fractions above and below the density of 1.077g/ml. 
Peripheral blood mononuclear cells PBMC are the populations of immune 
cells that remain at the less dense, upper interface of the opaque layer, often 
referred to as the ‘buffy coat’. PBMC, including lymphocytes (T cells, B cells 
and NK cells), monocytes and dendritic cells are collected from this ‘buffy 
coat’ layer when the fractionation method is used. Erythrocytes and 
polymorphonuclear cells (PMNs), including granulocytes, such as neutrophils 
and eosinophils, are generally removed during this fractionation because 
they are denser than 1.077g/ml.  Trace levels of basophils, however, might 
be present in the less dense PBMC fraction because they may be less dense 
then 1.077g/ml.  
To optimize the yield of cells obtained from each blood sample, prior to 
processing samples from study subjects, the following tests were performed 
using volunteer peripheral blood and blood components, that is, non-clinical 
issue leukocyte blood cones for research use from NHS Blood and 
Transplant (Colindale, UK): 
• Comparison of Leucosep (Greiner Bio-one) tubes (containing high 
density polyethylene barrier) with universal tubes (no barrier) for 
efficiency of density gradient centrifugation and cell viability. 
• Optimization of time from venipuncture to PBMC isolation, using the 
following time points post blood sampling: 1 hour, 4 hours, 8 hours 
and 24 hours. 
• Optimization of peripheral blood dilutions (undiluted, 1:2, 1:3, 1:4) 
prior to PBMC isolation. 
• Optimization of ratio of Histopaque-1077 to blood volume (1:1, 1:2) 
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• Optimization of PBMC isolation protocol including centrifugation 
settings, spin-time and cell washes to create a stream-lined workflow 
from venipuncture to flow cytometric analysis. 
The following protocol was used to obtain PBMC from fresh heparinized 
blood (≤ 4 hours following venipuncture) by Histopaque-1077 (Sigma-Aldrich, 
Gillingham, UK) density gradient centrifugation (Figure 42): 
16ml of Histopaque-1077 solution was placed in a 50ml Leucosep tube 
(Greiner Bio-one, Germany) and centrifuged for 90 seconds at 1000 x g. This 
centrifugation step ensured that the majority of the Histopaque remained 
beneath the filters in the Leucosep tubes, thereby minimising contact with the 
blood samples. Venous blood samples were diluted 1:4 with RPMI 1640 
before being gently pipetted onto the filters within the prefilled Leucosep 
tubes, under aseptic conditions.  These tubes were then centrifuged for 15 
minutes at 800 x g.  Following centrifugation, PBMC were retrieved from the 
enriched cell fraction above the porous barrier (the barrier helped to avoid 
recontamination with pelleted erythrocytes and granulocytes) by means of a 
Pasteur pipette.  Retrieved PBMC were gently pipetted into 20mL of 
prewarmed (37⸰C) sterile-filtered media RPMI-1640 supplemented with 10% 
human AB Serum (Sigma-Aldrich) in a polyethylene tube with a conical base. 
The tube was then gently inverted to mix any remaining Histopaque-1077 
with the media, which helped to prevent it from forming a layer which would 
hinder isolated PBMC from being pelleted. The cell suspension was then 
centrifuged for 10 minutes at 300 x g. The pelleted cells were resuspended in 
supplemented RPMI-1640 and the centrifugation step was repeated at 5 
minutes at 300 x g. The isolated PBMC were counted (see ‘Cell counting’). 
10 x 106 PBMC from each sample were reserved for multi-colour flow 
cytometric analysis and the remaining PBMC were cryopreserved (see 
‘Cryopreservation of PBMC’)  
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3.2.7 Cryopreservation of PBMC 
PBMC were cryopreserved in human AB serum with 10% Hybri-Max Sterile-
filtered DMSO (Sigma-Aldrich) at -20⸰C for 1 hour prior to transfer to -70⸰C 
and then to liquid nitrogen for longer term storage, for subsequent DNA 
isolation and methylation analysis. 
 
  
 
 
  
 
Centrifuge            
800 x g    
15 minutes 
 
 
Histopaque-1077 
High-density 
polyethylene    
barrier 
Diluted anti-
coagulated 
whole blood 
Lymphocytes 
& other mono-
nuclear cells 
Erythrocytes & 
granulocytes 
Plasma 
Figure 42: Schematic figure of a density gradient centrifugation: Anticoagulated 
venous blood is layered onto Histopaque-1077.  During centrifugation, 
erythrocytes and granulocytes are aggregated by polysucrose and rapidly 
sediment; whereas, lymphocytes and other mononuclear cells remain at the 
plasma-Histopaque 1077 interface.  Erythrocyte contamination is negligible. 
Image and description adapted from Sigma Aldrich Histopaque-1077 product 
information, 2017, and D.Yang, 2009. 
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3.2.8 Optimisation of T- cell culture and stimulation conditions 
Cell culture conditions were tested and optimised, by comparing the 
following: 
• Cell medium (RPMI-1640 vs X-VIVO) for T-cell culture 
• T-cell stimulation techniques:  
o PMA/ ionomycin stimulation 
o soluble anti-CD3 (HIT3a) NA/LE and anti-CD28 NA/LE  
o plate-bound anti-CD3 (HIT3a) NA/LE and anti-CD28 NA/LE  
o Dynabeads (bead mounted anti-CD3 and anti-CD28) 
Following these tests, it was determined that experimental cell culture 
conditions requiring stimulated cells should use X-VIVO 15 medium with L-
glutamine, gentamicin, and phenol red (Lonza, Cambridge, UK) for 5 days, 
with the addition of 5µg/ml soluble anti-CD3 (HIT3a) NA/LE, 1µg/ml anti-
CD28 NA/LE (BD Biosciences) and 50IU IL-2 IS/ml (Miltenyi Biotec, Woking, 
UK) to the culture media, unless otherwise specified below.  
 
3.2.9 Cell counting  
Viable cell counts for all experiments, with the exception of high speed cell 
sorting, were determined using a haemocytometer with Trypan Blue dye 
(0.4%) exclusion, using cell counting methods described by Public Health 
England (PHE 2017).  
Prior to cell sorting experiments, which required a high degree of counting 
accuracy, viable cell counts were determined using the Vi-CELL cell counter 
(Beckman Coulter UK Ltd, High Wycombe) for cell viability analysis by 
Trypan Blue exclusion. 
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3.2.10 Antibodies used for immunophenotyping by flow cytometry 
For multi-colour immunophenotyping by flow cytometry, the following 
antibodies (Abs) were used: RORγt-Alexa Fluor 488, T-bet-PerCP-Cy5.5, 
CD3-Vioblue, CD25-Brilliant Violet 711, CD4-Brilliant Ultraviolet 395, FoxP3-
Alexa Fluor 647, TIGIT-PE and Near Infrared live/dead fixable cell stain. For 
live cell sorting, the following Abs were used: CD4-PerCP-Cy5.5, CD127-
Brilliant Violet 605, CD3-Brilliant Violet 785, CD25-PE-Dazzle594, CD14-
APC-Fire and SYTOX blue dead cell stain. Abs were provided by BioLegend 
(London, UK), BD Biosciences (Oxford, UK), eBiosciences (Hatfield, UK), 
Miltenyi Biotec and ThermoFisher Scientific (Dartford, UK). 
 
3.2.11 Treg and Th1/Th17 immunophenotyping by flow cytometry: 
staining protocol 
10 x 106 PBMC isolated from each subject sample by density gradient 
centrifugation were resuspended in 50 μL Flow Cytometry Staining Buffer 
(eBiosciences). The samples were then stained with directly conjugated Abs 
for cell surface molecules (CD3, CD4, CD25, TIGIT), as follows: 
The appropriate volume of each primary antibody (Ab) was resuspended in 
50 μL Flow Cytometry Staining Buffer and added to the 50 μL cell 
suspension, so that the final concentration of antibody was a 1:25 dilution 
and the final staining volume was 100 μL (i.e. 50 μL of cell sample + 50 μL of 
antibody mix) (the titration protocol, which determined the Ab concentration 
for staining, is included in the Appendix). The PBMC and Ab suspension was 
then gently vortexed to mix it. The PBMC were then protected from light and 
incubated for 40 minutes at 2-8°C to stain them for the required cell surface 
antigens. The stained cells were then washed by adding 1mL Flow 
Cytometry Staining Buffer and centrifuging at 350 x g for 5 minutes at room 
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temperature. This wash step was repeated. The supernatant was discarded 
prior to proceeding to the next stage of the staining protocol.  
To eliminate potential artefacts due to dead cell contamination, the cell 
suspensions were then stained with a 1:1000 dilution of Zombie NIR 
(BioLegend) Fixable Viability Dye, a fixable dead cell stain. This was to allow 
dead cells, which existed prior to fixation/ permeabilization process, to be 
excluded from the subsequent analysis. 
Following staining of dead cells, PBMC were prepared for evaluation of 
intracellular proteins, using a technique which allowed the simultaneous 
analysis of cell surface molecules and intracellular antigens, including 
nuclear transcription factors, such as FoxP3, at the single-cell level. The 
following protocol, which combines fixation and permeabilization into a single 
step, was adapted from FoxP3 transcription factor Fix/Perm kit 
manufacturers’ protocol  
Following the last wash of the dead cell staining protocol, the supernatant 
was discarded and the sample was pulse vortexed to completely dissociate 
the pellet. 1 mL of Fixation/Permeabilization working solution was added to 
each tube and the tube was pulse vortexed. The samples were protected 
from light and incubate for 30 minutes at room temperature. 2 mL of 1X 
Permeabilization Buffer was added to each tube. The samples were 
centrifuged at 300-400 x g for 5 minutes at room temperature, then the 
supernatant was discarded.  After decanting, the pellet was resuspended in 
the residual volume (approximately 100 μL) of 1X Permeabilization Buffer. 
Intracellular staining was performed using directed conjugated Abs 
recognizing transcription factors (FoxP3, RORγt, T-bet). Subject-specific 
fluorescence-minus-one (FMO) controls for CD25, TIGIT, FoxP3, RORγt and 
T-bet were included in each experiment. The samples were incubated with 
Abs for 30 minutes at room temperature, during which time they were 
protected from light. Following incubation, 2 mL of 1X Permeabilization 
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Buffer to each tube. Samples were centrifuged at 300-400 x g for 5 minutes 
at room temperature, then the supernatant was discarded (this step was 
repeated for a further wash). The stained cells were then resuspended in 
approximately 300μL Flow Cytometry Staining Buffer prior to acquiring 
samples on a flow cytometer. 
 
3.2.12 Comparison of multi-colour flow cytometry panel with a pre-
manufactured Treg isolation kit 
T-reg staining using titrated concentrations of the multi-colour panel Abs, 
designed for the study, was compared with staining using a Regulatory T 
Cell Staining Kit (CD4+CD25+FoxP3+) (eBiosciences, Thermofisher Scientific, 
UK), which had been pre-titrated and tested by the manufacturer 
(eBiosciences, UK) for staining and analysis of PBMC by flow cytomtetry. 
Staining was performed using the Treg kit manufacturers’ protocol 
(thermofisher.com, 2017), which specified the following Ab concentrations: 
• The PCH101 antibody and the Rat IgG2a K Isotype Control: 5 μL 
(0.25 μg) per test.  
• The OKT4 antibody: 5 μL (0.25 μg) per test.  
• The BC96 antibody: 5 μL (0.125 μg) per test.  
A test was defined as the amount (μg) of antibody that will stain a cell sample 
in a final volume of 100 μL.  
 
3.2.13 Treg and Th1/Th17 immunophenotyping by flow cytometry: data 
acquisition  
The peripheral blood levels of the following cell subsets were determined by 
flow cytometry: CD25+FoxP3+ Treg, CD25+FoxP3+TIGIT+ Treg, T-bet+ Th1, 
RORγt + Th17, T-bet+ RORγt + Th1/17, FoxP3+ T-bet+ Treg and FoxP3+ 
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RORγt + T-reg in the CD3+CD4+ subset. Flow cytometric data was acquired 
using a LSRFortessa (BD Biosciences, San Jose, California) and BD 
FACSDiva version 6.1.3 software with a total of 50,000 events being 
recorded for each sample through a live, single cell CD3+CD4+ gate 
(workflow and gating strategy shown in Figures 43 & 44, respectively). Viable 
cells were identified by low uptake of the fixable dead cell stain. Single-
stained OneComp and UltraComp beads (eBiosciences) were used to 
generate compensation matrices. FMO controls were used to identify gating 
boundaries where cell populations were ill-defined. Analysis of flow 
cytometry data was performed using FlowJo version 10 software (TreeStar 
Inc., Ashland, OR, USA).  
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Figure 43: Flow cytometry work-flow for immunophenotyping 
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Figure 44: Treg gating strategy illustrating that viable cells were identified by (1) low 
uptake of the fixable dead cell stain, followed by (2) identification of single cells, 
based on area (A) and height (H) of both forward scatter (FSC) and side scatter (SSC) 
profiles, then (3) lymphocyte phenotype based on their FSC-A against SSC-A profile 
and then finally (4) positive expression of CD3, CD4, FoxP3(high), CD25(high) +/- 
TIGIT markers. 
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3.2.14 Cell sorting for T-cell proliferation assays 
Freshly isolated PBMCs from subject samples in each group were stained 
with CD3, CD4, CD25, CD127 and CD14 cell surface antibodies. 
CD3+CD4+CD25+CD127lo, CD3+CD4+CD25- and CD14+ populations 
representing Treg, putative T-effectors and monocyte subsets, respectively, 
were isolated directly from the stained PBMC by means of high speed Influx 
flow cytometric cell-sorting (BD Biosciences, San Jose, California) (process 
overview with gating strategy shown in Figures 45).  
CD3+CD4+CD25- T-cells were washed and resuspended at 10 x 106/ ml in 
sterile PBS (Sigma Aldrich) containing 1 μL of 1 mM Violet Proliferation Dye 
(VPD) 450 stock solution (BD Biosciences) for each 1 mL of cell suspension 
for a final VPD450 concentration of 1 μM, according to the manufacturer’s 
instructions. The cells were stained by incubating the dye-cell suspension in 
a 37ºC water bath for 10 minutes. The reaction was quenched by adding 9× 
the original volume of PBS to the cells, followed by centrifugation, discarding 
the supernatant, and resuspending the cells in 10 mL of RPMI 1640 medium 
with 10% FBS before washing again. 
 
3.2.15 T-cell proliferation assay protocol to determine Treg function 
The in vitro capacity of the Treg to suppress the proliferation of VPD450-
labelled CD3+CD4+CD25- responding T-cells (Tresp) was assessed. 
The following tests were performed to optimise the assay: 
• Comparison of T-cell culture in 6 well, 24 well, 48 well and 96-well 
plates (1 x 106 per well density)  
• Comparison of stimulation techniques  
• Comparison of VPD450 with CFSE proliferation dye 
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VPD450-labelled CD3+CD4+CD25-  Tresp were co-cultured with sorted 
CD14+ monocytes (MC) at 1:1 ratio and sorted CD3+CD4+CD25hiCD127lo T-
regs were co-cultured with Tresp and MC at a 1:3:3 ratio. Cell culture 
conditions were as previously described.  
 
 
Figure 45: Process overview of cell sorting for T-cell proliferation assays using Treg 
sort gating strategy. Cell subsets were identified by expression of the following 
markers: Treg CD3+CD4+CD25hiCD127lo; Tresp CD3+CD4+CD25- and MC CD14+ 
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Data was acquired by flow cytometry and analysed using the cell tracking 
function of Modfit LT modelling software (Verity Software House, Maine, 
USA) to generate a statistic termed proliferation index (PI) (Figure 46). Dead 
cells were gated out using SYTOX Blue dead cell stain (ThermoFisher 
Scientific, UK) at the time of data acquisition. Percentage (%) suppression 
was determined for each subject sample, as per previously described 
methods, with adaptation for small numbers of isolated T-cells (Nguyen and 
Ehrenstein 2016; Ward, et al. 2014). 
 
 
Figure 46: Modelling of in vitro T-cell proliferation using Modfit LT modelling software 
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3.2.16 Optimisation of cell culture conditions and T-cell cell culture for 
cytokine assays 
Cell culture conditions were tested and optimised, by comparing the 
following: 
• Cell medium (RPMI-1640 vs X-VIVO) for T-cell culture 
• T-cell stimulation techniques:  
o PMA/ ionomycin stimulation 
o soluble anti-CD3 (HIT3a) NA/LE and anti-CD28 NA/LE  
o plate-bound anti-CD3 (HIT3a) NA/LE and anti-CD28 NA/LE  
o Dynabeads (bead mounted anti-CD3 and anti-CD28) 
For experimental cell culture conditions requiring stimulated cells, freshly 
isolated PBMC were cultured in X-VIVO 15 medium with L-glutamine, 
gentamicin, and phenol red (Lonza, Cambridge, UK) for 5 days, with the 
addition of 5µg/ml soluble anti-CD3 (HIT3a) NA/LE, 1µg/ml anti-CD28 NA/LE 
(BD Biosciences) and 50IU IL-2 IS/ml (Miltenyi Biotec, Woking, UK) to the 
culture media, unless otherwise specified.  
Percentage (%) suppression = 
 
 (Tresp + MC) － (Tresp + MC+ Treg)    × 100  
                (Tresp + MC) 
 
where Tresp is CD4+CD25- ‘responding T-cells’, MC is CD14+ 
‘macrophages’ and Treg is CD4+CD25+CD127lo ‘T-regulatory cells’. 
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3.2.17 Cytokine analysis 
Whole blood samples were centrifuged following collection to obtain serum 
supernatant samples, which were stored in 1.5ml aliquots at -70⸰C for 
subsequent multiplex cytokine analysis. Cryopreserved subject serum 
cytokine samples were thawed and immediately analysed for cytokines 
levels of TGF-β, IL-10, IFNγ, IL-17A and IL-22. 
Acidified serum aliquots subject samples were analysed for TGF-β by the 
quantitative sandwich enzyme immunoassay technique (ELISA) (R&D 
Systems), according to the manufacturer’s instructions. The principles of the 
ELISA assay were as follows: 
• Prior to analysis for TGF-β levels by ELISA, samples were prepared 
and acidified using a Sample Activation Kit according to the 
manufacturer’s instructions (R&D Systems). 
• A monoclonal antibody specific for TGF-β1 was pre-coated onto a 
microplate. 
• Standards, controls and samples were pipetted into the wells and any 
TGF-β1 present was bound by the immobilised antibody. 
• After washing away unbound substances, an enzyme-linked 
polyclonal antibody specific for TGF-β1 was added to the wells to 
sandwich the TGF-β1 immobilised during the previous step. 
• Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution was added to the wells, after which a colour 
developed in proportion to the amount of the TGF-β1 bound in the 
initial step. 
• The colour development was stopped and the intensity of the colour 
was measured. 
• The samples were read using the optical density OD) setting of the 
Modulus II Microplate Multimode Reader (Promega Corporation). 
The remaining samples from the above subjects were analysed by multiplex 
bead arrays (R&D Systems) using a MAGPIX Luminex system (Luminex, 
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Texas, USA), according the manufacturer’s instructions. The Luminex assay 
was similar in principle to the ELISA assay, except it used colour-coded 
beads pre-coated with antibody, which were detected by a proprietary 
system, rather than a colorimetry system. The advantage of the Luminex 
system was that it allowed multiple cytokines to be simultaneously detected 
in the same sample. For this experiment, the assay protocol did not require 
the samples to be pre-acidified. The principle steps of the Luminex assay 
were, as follows: 
• Colour-coded beads, pre-coated with analyte-specific capture 
antibody for IL-10, IFNγ, IL-17A and IL-22 were added to the samples. 
These analyte-specific antibodies captured the analytes of interest.  
 
• Biotinylated detection antibodies specific to the above analytes were 
added to form an antibody-antigen sandwich. 
 
 
• Phycoerythrin (PE)-conjugated Streptavidin was added. 
 
• The beads were detected on the MAGPIX Luminex system (Luminex) 
analyser. This was a dual-laser flow-based detection instrument 
where one laser classified the bead and determined the analyte that 
was being detected and second laser determined the magnitude of 
the PE-derived signal, which was in direct proportion to the amount of 
bound analyte.  
 
• The data were analysed using xPONENT software (Luminex). 
 
Standard curves were plotted using the data obtained from the above assays 
(included in the Appendix). Minimum levels of detection based on these 
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standard curves for each array were:  TGF-β (7.4pg/mL), IL-10 (7.30pg/mL), 
IFNγ (17.30pg/mL), IL-17A (2.65pg/mL) and IL-22 (6.10pg/mL). 
For intracellular cytokine staining, freshly isolated PBMC from a patient with 
active disease (Patient 1) at 2 months and 6 months after baseline were 
stimulated with Dynabeads Human T-Activator CD3/CD28 (ThermoFisher 
Scientific) for 24 hours or a cell stimulation cocktail (containing PMA and 
ionomycin) 1:500 for 6 hours as a positive control, with the addition of protein 
transport inhibitor (containing Brefeldin A) to the culture medium for the last 4 
hours. Staining and flow cytometric analyses were as in Chapter 3, with the 
following modifications: directly conjugated Abs for cell surface molecules 
(CD3 and CD4); fixation and permeabilization with an intracellular cytokine 
fixation/ permeabilization kit (BD Biosciences); and directly conjugated Abs 
recognizing intracellular cytokines (IL-10, IFNγ and IL-17A). Subject-specific 
fluorescence-minus-one (FMO) controls for IL-10, IFNγ and IL-17A were 
included in each experiment.  
 
3.2.18 Thawing of cryopreserved PBMCs 
RPMI 1640 medium with the addition of 10% human AB serum was brought 
to 37°C in a water bath until use.  Cryopreserved PBMCs required for further 
experiments were identified from storage in liquid nitrogen tank, removed 
and placed in a 37°C water bath to facilitate rapid thawing. As the freezing 
medium liquified, prewarmed RPMI medium was added to the cryotubes 
under aseptic conditions and cells were gently resuspended in new tubes in 
a 20ml volume of prewarmed media.  The cell suspension was then 
centrifuged for 10 minutes at 350 x g.  The supernatants were decanted and 
cells were resuspended in media and re-washed to remove any remaining 
DMSO, before being using for further experiments. 
 
 
 
171 
 
 
 
 
3.2.19 Genomic DNA extraction 
Genomic DNA extraction was performed directly on samples of thawed 
cryopreserved PBMC from each subject group using the DNeasy Blood and 
Tissue Kit (Qiagen, Manchester, UK).  The genomic DNA extraction protocol 
was optimised for DNA yield and quality using leukocyte cone blood (NHS 
Blood and Tissue Bank, Colindale). The protocol was initially performed on 
cone blood-derived PBMC sorted into Treg and non-Treg T-cells, using the 
BD Influx high speed cell sorter, as described in Chapter 3.  Unfortunately, 
cell losses occurred during the culturing of thawed cells and subsequent cell 
sorting, which meant that the samples did not yield the required DNA 
quantity (600ng-750ng) and quality (280/260) for bisulphite Amplicon 
Sequencing using an NGS approach on the Illumina sequencing platform. 
Therefore, the decision was made perform DNA extraction on unsorted 
subject PBMC samples. The following DNA extraction protocol was used, 
adapted from the manufacturer’s instructions for extracting genomic DNA 
from cells:  
A maximum of 5 x 106 PBMC were centrifuged for 5 min at 300 x g (190 
rpm). Pelleted cells were resuspended in 200 μl PBS. 20 μl proteinase K 
were added to the cell suspension. 200 μl Buffer AL was added and mixed 
thoroughly with the cell suspension by vortexing. Samples were incubated at 
at 56°C for 10 min. Following thism 200 μl ethanol (96–100%) was added 
and the suspension was mixed thoroughly by vortexing. The resulting 
mixture was pipetted into a DNeasy Mini spin column placed in a 2 ml 
collection tube. This was centrifuged at ≥ 6000 x g (8000 rpm) for 1 min. The 
flow-through in the collection tube was discarded. The spin column was 
placed in a new 2 ml collection tube and 500 μl of Buffer AW1 was added. 
This was centrifuged for 1 min at ≥6000 x g. The flow-through in the 
collection tube was discarded. The spin column was placed in a new 2 ml 
collection tube and 500 μl Buffer AW2 was added. This was centrifuged for 3 
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min at 20,000 x g (14,000 rpm). The flow-through in the collection tube was 
discarded. The spin column was transferred to a new 1.5 ml microcentrifuge 
tube.  DNA was eluted by adding 200 μl Buffer AE to the centre of the spin 
column membrane.  The sample was incubated for 1 min at room 
temperature (15–25°C). Following incubation, the sample was centrifuged for 
1 min at ≥6000 x g to maximise the DNA yield. The spin column was 
discarded and the extracted DNA was resuspended in the microcentrifuge 
tube and stored at -70⸰C until methylation analysis. 
 
3.2.20 DNA methylation analysis 
DNA samples were transferred to Barts Genome Centre (London, UK) on 
ice, where they were analysed at five DNA sites of cytosine (CpG) 
methylation (FOXP3 TSDR, FOXP3 Promoter, TBX21, RORC2 and TIGIT) 
with bisulphite Amplicon Sequencing, using an NGS approach on the 
Illumina sequencing platform (Fluidigm, California, USA). A summary flow 
chart and bisulphite Amplicon target sites are shown in Figures 47 and 48, 
respectively. Further information on the primers used for the assays is 
included in the Appendix. 
  
 
 
173 
 
 
 
 
 
     Figure 47: Flow diagram showing overview of DNA methylation analysis 
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Figure 48: Bisulphite Amplicon epigenetic target sites for FOXP3 TSDR, FOXP3 
Promoter, TBX21, RORC2 and TIGIT loci. 
 
3.2.21.1 Sample Quality 
Prior to DNA bisulphite treatment, the integrity of the DNA was assessed 
using the Agilent 2100 Bioanalyser Tapestation (Agilent Technologies, 
Waldbronn, Germany) and the DNA concentration was measured using 
Qubit Fluorometric Quantification (Thermo Fisher Scientific). 
 
3.2.21.2 Bisulfite conversion of DNA 
500ng of normalised DNA was bisulphite converted using the EZ DNA 
Methylation kit (Cambridge BioSciences, Cambridge). The incubation 
conditions recommended by the manufacturers guide [95˚C for 30 sec.,50˚C 
for 60 min] x 16 cycles, 4˚C hold were used for the conversion reaction. The 
yield of bisulphite converted DNA was estimated using the RNA-40 setting 
on the NanoDrop 8000 Spectrophotometer V2.0 (ThermoScientific, USA). 
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3.2.21.3 Targeted re-sequencing of methylation sites 
Primers for the target sites were designed using Pyromark Assay Design 2.0 
software (Qiagen) and synthesised with Fluidigm Universal CS1 and CS2 
tags (Fluidigm, San Francisco, US) to allow for the construction of DNA 
libraries using Fluidigm proprietary indexes. Primer design was based on 
primers used in previously published research (Bending, et al. 2014; Zhang, 
et al. 2013b) . In the case of the TSDR and Promoter regions of FOXP3, the 
primers were altered slightly so that the Amplicon size would be as close to 
300bp as possible. Primer sequences were checked prior to synthesis for the 
assay by performing a BLAST sequence search.  
 
MyTaq™ HS DNA Polymerase (Bioline, USA) was used to optimise the 
assays and amplify the DNAs. The PCR products were checked for 
amplification on an Agilent 2100 Bioanalyser D1K Tape (Agilent 
Technologies, Waldbronn, Germany) after which unique Fluidigm Barcodes 
were added to the PCR product (Table 2) under the following PCR cycling 
conditions: 95°C for 10 minutes; [95°C for 15 seconds, 60°C for 30 seconds, 
72°C for 1 minute] cycle 14 times; 4°C hold. 
To check that the barcodes had been successfully incorporated onto the 
PCR products, the barcoded PCR product was run on a Agilent D1K tape. If 
the barcodes had attached then a shift of ~60bp was observed between the 
PCR product and the barcoded products. 
Equal volumes of barcoded products were pooled and primer dimer was 
removed using Agencourt Ampure XP beads (Beckman Coulter Life 
Sciences) at a volume of 1:1. The pool was quantified using High Sensitivity 
Qubit Reagents (Qiagen) and the library size was measured using the 
Agilent 2100 High Sensitivity D1K (Agilent Technologies, Waldbronn, 
Germany) to calculate the molarity of the library before sequencing. 
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150bp Paired-end sequencing was performed using the Miseq Illumina 
sequencer (Illumina, Inc) to a total of 400,000 reads passing filter per 
sample. 
 
3.2.21.4 Analysis of variants 
Bismark (Krueger & Andrews, 2011) was used to align bisulphite-treated 
reads to a human reference genome and calculate the cytosine methylation 
calls at the target sites. Biostatistical analysis generated beta (%) 
methylation values as a ratio of methylated to unmethylated DNA for each 
CpG site of interest. 
 
3.2.21 Statistical analysis 
Statistical analysis of final datasets was performed with SPSS version 24 
(IBM Software) and GraphPad Prism version 7 (GraphPad Software). Data 
were plotted as histograms to assess normality and descriptive statistics 
were calculated.  Differences between groups were determined by the 
Kruskal-Wallis test with post-hoc Bonferroni correction for multiple 
comparisons. Bivariate correlations between immunological variables were 
calculated using Spearman’s test. Relationships between selected variables, 
which had clinically relevant associations, were modelled using multiple 
linear regression and logistic regression, using ‘stepwise’ and ‘enter’’ variable 
entry, respectively. Where possible, variables with a non-normal distribution 
were transformed to a normal distribution, using a log transformation, to 
include in the multiple regression model.  All significance tests were 2-tailed. 
P values < 0.05 were considered significant. Results are expressed as 
frequency n (%) or median (IQR), unless otherwise stated. 
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Chapter 4: An Investigation into the Role of Treg in 
Clinical Remission of Sight-threatening Non-
infectious Uveitis: Results  
 
4.1 Subject characteristics 
A total of 50 uveitis patients and 10 control subjects were recruited to the 
study (Table 14). Of the 50 patients recruited, 37 were in clinical remission 
and 13 had active disease at the time of recruitment. 22 (59%) of the patients 
in the clinical remission group received previous therapy with corticosteroids 
only, the remaining patients received additional second-line 
immunosuppressive treatment (Table 15).  
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Table 14: Subject demographics and clinical characteristics 
 
 
Characteristics 
Control 
n=10 
Active 
n=13 
Quiescent 
n=37 
 
Median age in years (IQR) 
    30 
  (29-33) 
41  
(27-46) 
47 
 (35-55) 
 
Female sex - no. (%) 
 
6 (60) 6 (46) 19 (51) 
Weight at baseline (kg) - 75 
(67-89) 
73  
(63-79) 
Race or ethnic group -no. (%)    
        White/ European 6 (60) 6 (46) 26 (70) 
        Asian/Middle Eastern 4 (40) 3 (23) 10 (27) 
        Black/Afro-Carribean 
 
0 (0) 4 (31) 1 (3) 
Uveitis SUN classification    
        Intermediate - 6 (46) 16 (43) 
        Posterior -  1  (8) 6 (16) 
        Panuveitis 
 
- 6 (46) 15 (41) 
Bilateral disease - no.  (%) 
 
- 10 (77) 30 (81) 
Median visual acuity (logMAR) - 0.2  
(0.1-0.4) 
0.2  
(0.1-0.5) 
 
Visually significant cataract (%) - 2 (15) 9 (24) 
Previous cataract surgery 
 
- 2 (15) 15 (41) 
Median disease duration since diagnosis – months (IQR) - 33 
(7-119) 
147 
(50-249) 
 
Median time since last flare – months (IQR) - 0 48  
(14-114) 
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Table 15: Oral immunosuppression use by study subjects 
 
 
Characteristics 
Control 
n=10 
Active 
n=13 
Quiescent 
n=37 
 
On oral immunosuppressive treatment at baseline- no. (%) 
 
- 
 
 
6 (46) 
 
0 (0) 
Previous oral immunosuppression received- no. (%)  10 (77) 37 (100) 
      Prednisolone only  4 (40) 22 (59) 
      Additional second line immunosuppression  6 (60) 15 (41) 
              Mycophenolate mofetil - 3 (23) 5 (14) 
              Ciclosporin - 0 (0) 7 (20) 
              Azathioprine - 1 (8) 2 (5) 
              Methotrexate - 0 (0) 1 (3) 
              Biologicals 
 
- 0 (0) 1 (3) 
Median duration of previous oral immunosuppression  
- months (IQR) 
- 6  
(4-12) 
24  
(7-72) 
 
Of the active patients, who had intermediate uveitis, posterior uveitis or 
panuveitis, 11 (85%) had cells and/or haze in the vitreous, 7 (54%) had cells 
in anterior chamber, 6 (46%) had macular oedema, 3 (23%) had optic disc 
oedema, two (15%) had vasculitis and one (8%) had chorio-retinal lesions at 
baseline. Six (46%) of these patients with active disease were on systemic 
immunosuppression at the time of recruitment. A subgroup analysis 
comparing the active patients on therapy and active patients not on therapy 
at baseline did not reveal any differences between the groups. Four of the 13 
active patients underwent additional immunophenotyping at 2, 6 and 12 
months after starting or changing treatment.  
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4.2 Immunological results 
The immunological biomarker levels and comparison across the three 
subject groups (active, remission and controls) with summary P-values are 
shown in Table 16, with the post-hoc pairwise comparisons and adjusted P-
values shown in Table 17. 
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Table 16: Three-way comparison of differences in immunological markers between 
groups (important results highlighted in yellow) 
 
Immunological Marker Subject Cohort 
 
3-way 
Comparison 
 
 Control Active Remission Summary P-
value 
T-cell subsets (%) and 
cell ratios in the 
CD3+CD4+ compartment 
    
    CD25+FoxP3+ (Treg) 5.6 (5.3-6.7) 4.4 (3.6-6.0) 7.1 (5.8-8.3) 0.000*** 
    CD25+FoxP3+ TIGIT+ 
    (TIGIT+ Treg) 
4.2 (3.3-4.4) 2.5 (2.1-4.3) 5.0 (4.2-5.9) 0.000*** 
    TIGIT+Treg to 
TIGIT+FoxP3- (non-Treg) 
0.6 (0.5-0.7) 0.4 (0.2-0.6) 0.6 (0.5-0.8) 0.049* 
    Tbet+ (Th1) 57 (41-66) 59 (49-72) 49 (43-56) 0.025* 
    RORγt+ (Th17) 2.4 (1.2-4.5) 1.5 (0.8-4.4) 1.7 (1.2-3.2) 0.564 
    Treg to Th1 0.7 (0.6-0.8) 0.4 (0.3-0.6) 0.7 (0.5-0.9) 0.000*** 
    Treg to Th17 0.4 (0.2-0.4) 2.0 (0.8-3.5) 2.8 (1.5-4.3) 0.001** 
    Tbet+FoxP3+  0.7 (0.5-0.8) 0.7 (0.5-1.2) 1.1 (1.0-1.6) 0.000*** 
    RORγt+ FoxP3+  0.6 (0.5-0.9) 0.5 (0.1-0.7) 0.6 (0.3-1.1) 0.363 
    RORγt+ Tbet+  1.5 (0.6-2.5) 1.0 (0.4-2.0) 1.5 (0.9-2.3) 0.183 
 
Serum cytokine levels 
(pg/mL) 
    
     IL-10 24 (23-25) 12 (10-12) 21.5 (20-23) 0.000*** 
     TGF-β 57 (39-85) 62 (49-97) 161 (122-285) 0.001** 
     IFN-γ 208(197-214) 409(405-419) 298 (296-300) 0.000*** 
     IL-17 14 (13-14) 15 (14-16) 13 (12-13) 0.003** 
     IL-22 19 (17-20) 21 (20-22) 18 (17-19) 0.002** 
 
CpG site methylation 
levels (%) 
    
     FOXP3 Promoter 69 (52-75) 72 (66-77) 53 (46-68) 0.037* 
     FOXP3 TSDR 69 (61-71) 76 (68-83) 63 (59-67) 0.005** 
     TIGIT 54 (47-55)                   59 (57-64) 48 (46-53) 0.004** 
     TBX21/ TBET 0.7 (0.6-0.8) 0.4 (0.3-0.5) 0.7 (0.5-0.8) 0.122 
     RORC2/ RORγT   55 (52-61) 46 (44-51) 55 (51-58) 0.006* 
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Table 17: Pairwise comparison of differences in immunological markers between 
groups 
 
 
Immunological Markers  
Summary  
P-value 
(Kruskall-
Wallis) 
Adjusted P-values 
(Post-hoc Pairwise  
Comparison Between  
Remission, Active  
and Control Subjects) 
 
  Remission  
v. 
Active 
Remission 
  v. 
Control 
Active 
v. 
Control 
T-cell subsets (%) and ratios in 
the 
CD3+CD4+ compartment 
    
    Treg (CD25+FoxP3+)     0.000*** ↑0.000*** 0.118         0.267 
    TIGIT+Treg     0.000*** ↑0.000*** 0.661         0.126 
    TIGIT+Treg: TIGIT+FoxP3-     0.049* ↑0.049* 1.000         0.219 
    Th1 (Tbet+)     0.025*    ↓0.024*     0.755         0.858 
    Th17 (RORγt+)     0.564 - - - 
    Treg: Th1     0.001**    ↑0.001** 1.000    ↓ 0.013* 
    Treg: Th17     0.000***        0.828 ↑0.000***    ↑ 0.014* 
    Tbet+Treg     0.000***    ↑0.005** ↑0.000***         0.859 
    RORγt+Treg     0.363 - - - 
    Th1/17 (RORγt+ Tbet+ ) 
 
    0.183 - - - 
Serum cytokine levels 
(pg/mL) 
    
     IL-10     0.000***   ↑ 0.011* 0.082    ↓ 0.000*** 
     TGF-β     0.001**   ↑ 0.007** ↑0.004**         1.000 
      IFN-γ     0.000***   ↓ 0.015* 0.130    ↑ 0.000*** 
      IL-17     0.003**   ↓ 0.002** 0.460         0.408 
      IL-22 
 
    0.002**   ↓ 0.001** 0.693         0.210 
CpG site methylation levels 
(%) 
    
      FOXP3 Promoter     0.037*   ↓ 0.036* 0.405         1.000 
      FOXP3 TSDR     0.005**   ↓ 0.003**     0.709         0.177 
      TIGIT  0.004**   ↓ 0.003**     0.850         0.120 
      TBX21/ TBET     0.122 - - - 
      RORC2/ RORγT     0.006*   ↑ 0.016*     1.000    ↓ 0.014* 
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4.2.1 Clinical remission of uveitis is associated with higher levels of 
Treg polarised toward T-bet and TIGIT compared to active disease 
To determine whether there was a difference in peripheral blood Treg levels 
between control, active and quiescent subjects in disease remission, their 
PBMC were analyzed by flow cytometry for levels of CD25+FoxP3+ Treg, 
FoxP3+TIGIT+ Treg, FoxP3-TIGIT+ T-cells and FoxP3+T-bet+ Treg in the 
CD3+CD4+ lymphocyte subset (Figures 49 and 51). Highly statistically 
significant differences were found between the active and remission groups 
in the levels of Treg (4.4±1.2 vs 7.1±1.3, P=0.0002) and TIGIT+ Treg 
(2.5±1.3 vs 5.0±0.9, P=0.0002)  and T-bet+ Treg (0.7±0.4 vs 1.1±0.3, 
P=0.000) (Figures 50 and 55; Tables 16-17). The levels of 
CD4+FoxP3+TIGIT+ Treg and CD4+FOXP3-TIGIT+ T-cells in each subject 
sample were analysed as the ratio of CD4+FoxP3+TIGIT+ Treg to 
CD4+FOXP3-TIGIT+. The ratio of CD4+FoxP3+TIGIT+ Treg to CD4+FOXP3-
TIGIT+ T-cells was significantly higher in the remission group compared to 
the active group (0.6±0.2 vs 0.4±0.1, P=0.049) (Figure 52; Tables 16-17). 
CD25+FoxP3+ Treg, FoxP3+TIGIT+ Treg and FoxP3+T-bet+ Treg were also 
observed to increase as disease resolved in patients with active uveitis 
(Figure 56). There were no statistically significant differences between Treg 
levels in control and active uveitis patient groups (Tables 16-17).    
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Figure 49: Flow cytometry plots showing example % levels of CD25+FoxP3+ Treg (left 
column) and FoxP3+TIGIT+ Treg (right column) in the three subject groups 
 
 
Figure 50: Dot plots showing comparative % levels of CD25+FoxP3+ Treg (left) and 
FoxP3+TIGIT+ Treg (right) in the three subject groups 
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Figure 51: Flow cytometry plots showing example % levels of CD4+FoxP3+TIGIT+ Treg 
and CD4+FOXP3-TIGIT+ T-cells in the three groups (analysed as the ratio of 
CD4+FoxP3+TIGIT+ Treg to CD4+FOXP3-TIGIT+). 
 
 
Figure 52: Dot plots showing comparative ratios of CD4+FoxP3+TIGIT+ Treg to 
CD4+FOXP3-TIGIT+ T-cells in the three subject groups 
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Figure 53: Flow cytometry plots showing example % levels of T-bet+ Treg in the three 
subject groups 
 
 
Figure 54: Flow cytometry plots showing example % levels of FoxP3+RORγt+ Treg in 
the three subject groups 
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Figure 55: Dot plots showing comparative % levels of FoxP3+T-bet+Treg (left) and 
FoxP3+ RORγt+Treg (right) in the three subject groups 
 
 
Figure 56: % levels of CD25+FoxP3+ Treg (top left ), FoxP3+TIGIT+ Treg (top right), 
FoxP3+T-bet+ Treg (bottom left) and FoxP3+RORγt+ Treg (bottom right) in patients with 
active disease over 12 months after starting/ changing oral immunosuppression 
treatment. 
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4.2.2 FoxP3+RORγt+ Treg are not associated with clinical remission but 
may have a role in clinical resolution of non-infectious uveitis 
Peripheral blood levels were analyzed for CD3+CD4+ FoxP3+RORγt+ T-reg 
(Figure 54). Although the remission and control groups had higher median 
levels of FoxP3+RORγt+ T-reg compared to the active group, these 
differences did not reach statistical significance (P=0.363) (Figure 55; Tables 
16-17). However, an overall increase in FoxP3+ RORγt+ Treg levels was 
observed over 12 months in all four patients with active disease at baseline 
(Figure 56). 
 
4.2.3 Clinical remission of uveitis is associated with overall lower levels 
of Th1 transcription factors and a higher ratio of Treg to Th1 compared 
to active disease 
To determine whether there was a difference in Th1 (T-bet transcription 
factor expression) levels and ratios of Treg to Th1 between control, active 
and quiescent subjects in disease remission, their PBMC were analysed by 
flow cytometry for levels of CD25+FoxP3+ Treg and T-bet+ T-cells in the 
CD3+CD4+ lymphocyte subset (Figures 50 and 52). Significantly lower levels 
of T-bet transcription factor levels (48.5±6.8 vs. 58.6±11.7, P=0.024) and 
higher ratios of Treg:Th1 (0.7±0.2 vs. 0.4±0.1, P=0.001) were found in 
remission patients compared to active patients (Figure 59; Tables 16-17). 
Active patients also had significant lower ratios of Treg:Th1 compared to 
control subjects (0.4±0.1 vs. 0.7±0.1, P=0.013) (Tables 16-17). Disease 
resolution in active patients over the course of 12 months appeared to be 
associated with an increase in levels of Treg and decrease in levels of Th1.  
                  
 
 
189 
 
 
 
 
4.2.4 Clinical remission of uveitis is not associated with overall lower 
levels of Th17 transcription factors or a higher ratio of Treg to Th17 
compared to active disease 
To determine whether there was a difference in Th17 (RORγt + transcription 
factor expression) levels and Treg:Th17 ratios between control, active and 
quiescent subjects in disease remission, their PBMC were analysed by flow 
cytometry for levels of CD25+FoxP3+ Treg and RORγt + T-cells  in the 
CD3+CD4+ lymphocyte subset (Figure 57). No significant difference was 
found in Th17 levels between the three groups (P=0.564), although it was 
noted that both active (2.0±1.3) and remission (2 .8±1.4) patients had 
significantly higher Treg:Th17 ratios in comparison to control subjects 
(0.4±0.3, P= 0.014; P=0.0003 respectively) (Figure 58; Tables 16-17). 
Increased Th17 levels in three out of four patients with active disease were 
noted as the disease clinically resolved over 12 months (Figure 59) . 
 
Figure 57: Flow cytometry plots showing example % levels of Th17 CD4+RORγt+ T-
cells (above) and Th1 CD4+T-bet+ T-cells (below) in the 3 groups 
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Figure 58: Comparative % levels of Th17 CD4+RORγt+ T-cells (above left), ratio 
of Treg to Th17 (below left), % levels of Th1 CD4+T-bet+ T-cells (above right) 
and ratio of Treg to Th1 (below right) in the 3 groups. 
 
 
 
Figure 59: % levels of Th17 CD4+RORγt+ T-cells (left) and Th1 CD4+T-bet+ T-cells (right) 
in patients with active disease over 12 months after starting/ changing oral 
immunosuppression treatment. 
 
4.2.5 Clinical remission of uveitis is not associated with decreased 
levels of ‘double positive’ effector RORγt+ Tbet+ T-cells 
Peripheral blood levels were analyzed for ‘double positive’ RORγt+Tbet+ T-
cells in the CD3+CD4+ subset (Figure 60). There was no significant 
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difference in levels of RORγt+ Tbet+ T-cells between the three groups 
(P=0.183) (Figure 61; Tables 16-17). 
 
Figure 60: Flow cytometry plots showing example % ‘double positive’ effector 
CD4+RORγt+ Tbet+ T-cells in the three subject groups 
 
 
Figure 61: Dot plots showing % ‘double positive’ effector CD4+RORγt+ Tbet+ T-cells in 
the three subject groups 
  
4.2.6 Clinical remission of uveitis is associated with Treg which 
demonstrate a high capacity to suppress proliferating T-effectors 
Cell-sorted populations of Treg, putative T-effectors and macrophages were 
set up in in vitro culture and the T-cell proliferation index was modelled by 
Modfit software, which was used to calculate % suppression by Treg, as 
described above. Treg from active uveitis without treatment failed to 
suppress proliferation of T-cells in vitro (Figure 62). In contrast, Treg from 
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active uveitis treated with oral immunosuppression, Treg from control 
subjects and Treg from uveitis in clinical remission all showed in vitro 
functional suppression, with the highest suppressive capacity demonstrated 
by Treg from uveitis in clinical remission (Figure 62). Data is shown from the 
following subjects: Patients 1 and 50 (in active disease group), Patient 49 (in 
clinical remission group) and Volunteer 2 (in control group). Patient 50 had 
active disease and had not yet started oral immunosuppression, whereas 
Patient 1 had a diagnosis of active disease at baseline and had received 6 
months of oral immunosuppression. 
 
 
Figure 62: Summary of T-cell and Treg co-culture assay proliferation data showing % 
suppression capacity of Treg from each subject group. 
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Figure 63: Serum cytokine levels (pg/mL) in the three subject groups: A. IL-10 B. TGF-
β C. IFN-γ D. IL-17A and E. IL-22 
 
Figure 64: Intracellular cytokine levels  (IL-10, IL-17A and IFN-γ) in a patient with 
active uveitis at 2 months and 12 months after changing oral immunosuppressive 
treatment. 
 
4.2.7 Clinical remission of uveitis is associated with higher serum 
levels of TGF-β and IL-10 and lower serum levels of IFNγ, IL-17A and IL-
22 compared to active disease 
Cytokine levels of IL-10, TGF-β, IFNγ, IL-17A and IL-22 were assayed in 
serum from 10 remission patients, 8 active patients and 5 control subjects 
from the above groups. IL-10 levels were significantly higher in serum from 
B 
C D E 
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remission patients compared to active patients (21.5±2.4 vs 11.6±1.5, 
P=0.011), and lower in active patients compared to controls (11.6±1.5 vs 
24.2±2.3, P=0.000) (Figure 63; Tables 16-17). TGF-β levels were higher in 
remission patients than in active (161.1±81.4 vs 62.7±24.0, P=0.007) and 
control (161.1±1.5 vs 56.9±24.0, P=0.004) subjects (Figure 63; Tables 16-
17). Clinical remission was also associated with significantly lower serum 
levels of IFNγ (P=0.015), IL-17A (P=0.002) and IL-22 (P=0.001) compared to 
patients with active disease (Figure 63). Increased intracellular IL-10 and IL-
17A and decreased intracellular IFNγ levels were found in CD4+ T-cells from 
active uveitis, 6 months after starting treatment, when the disease had 
clinically resolved (Figure 64).
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Figure 65: DNA methylation levels at A. FoxP3 TSDR B. FoxP3 Promoter C. TIGIT D. RORC2 and E.TBX21  
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Figure 66: Change in DNA methylation levels at A. FoxP3 TSDR B. FoxP3 Promoter C. TIGIT D. RORC2 and E.TBX21 in patients with active 
treatment over a 12 month period after starting/ changing oral immunosuppression. 
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4.2.8 Lower levels of methylation at key epigenetic CpG sites 
determining Treg function in PBMC were associated with clinical 
remission but were not observed with consistency in clinical resolution 
of uveitis 
To determine whether there was a difference in methylation at epigenetic 
CpG sites associated with Treg function (FoxP3 and TIGIT), bisulphite 
Amplicon Sequencing using an NGS approach was performed using 
cryopreserved PBMC from 8 active patients, 8 control subjects and 12 
remission patients. The sample consisted of 17 female subjects (61%) and 
11 male subjects (39%). Cryopreserved served samples, at 12 months 
following treatment, were also obtained from 4 of the 8 active patients. 
Following biostatistical analysis of the epigenetic percentage (%) methylation 
data, a single CpG site demonstrating a high level of differential methylation 
between samples was selected for statistical comparison between the three 
groups at that site, as follows: FoxP3 TSDR (49117116), FoxP3 Promotor 
(49121204) and TIGIT (114012658). The median CpG site % methylation 
levels of the FoxP3 TSDR (48±3.6 vs 59±7.4, P=0.003) (Figure 65A), FoxP3 
Promotor (53±11 vs 72±5.3, P=0.036) (Figure 65B) and TIGIT (48±3.3 vs 
59±3.3, P=0.003) (Figure 65C; Tables 16-17). CpG sites were significantly 
lower in patients in clinical remission compared to active patients. When 
comparing % CpG site methylation within individual patients with active 
disease at 0 months and resolved disease at 12 months, a decrease in 
methylation at the FoxP3 Promotor was observed over time whereas the 
methylation of FoxP3 TSDR and TIGIT appeared more stable (Figure 66A, B 
& C).  
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4.2.9 Higher levels of methylation at RORC CpG sites, but not TBX21 
CpG sites were associated with clinical remission, and increased levels 
RORC methylation may be a biomarker of disease response to 
treatment 
To determine whether there was a difference in methylation at epigenetic 
CpG sites associated with the T-effector transcription expression levels 
(RORγt and T-bet) assessed by flow cytometry in this study, bisulphite 
Amplicon Sequencing using an NGS approach was performed using 
cryopreserved PBMC as previously described. Following biostatistical 
analysis of the epigenetic percentage (%) methylation data, a single CpG site 
demonstrating a high level of differential methylation between samples was 
selected for statistical comparison between the three groups at that site, as 
follows: RORC2/ RORγT (151798858) and TBX21/ T-BET (45810951). The 
median CpG site % methylation level of RORC2 was higher in patients in 
clinical remission (55±3.3 vs 46±3.4, P=0.016) and in control subjects 
compared to active (55±4.3 vs 46±3.4, P=0.014) patients (Figure 65D; 
Tables 16-17). Within the active patient cohort, higher RORC % CpG 
methylation levels were observed at 12 months compared to 0 months after 
starting/ changing immunosuppressive treatment (Figure 66D). TBX21 CpG 
sites had overall low levels of methylation compared to the other T-cell-
associated epigenetic methylation sites and no significant difference in the 
median % methylation levels was found between the three cohorts (Figure 
65E and 66E).  
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4.2.10 Bivariate correlations between immunological variables 
 
Table 18: Correlation matrix of immunological variables (with statistically significant 
correlations in bold) 
 
 
 
 
 
 
 
Previous 
Oral 
Treatment 
Duration
% Treg
% 
Methylation  
FoxP3 
promoter
% 
Methylation  
FoxP3 TSDR
% TIGIT
% 
Methylation  
TIGIT
Ratio of 
TIGIT Treg 
to TIGIT T-
cells
IL-10 Levels TGFβ Levels
% RORγt 
Tcells
% 
Methylation 
RORC2
% 
Methylation 
TBXT2
% Tbet IL-22 Levels IL-17 Levels IFNγ Levels
Correlation Coefficient 1.000 0.189 -0.331 -.667** 0.051 -0.417 .369* 0.350 0.297 -0.055 0.367 0.231 -.377** -0.405 -0.355 -.544*
Sig. (2-tailed) 0.203 0.167 0.002 0.735 0.075 0.011 0.201 0.282 0.713 0.122 0.342 0.009 0.134 0.194 0.036
Correlation Coefficient 1.000 -0.110 -.479** .683** -.499** .425** 0.667** .792** 0.170 .419* -0.051 0.016 -.524* -.421* -0.140
Sig. (2-tailed) 0.576 0.010 0.000 0.007 0.001 0.189 0.000 0.194 0.026 0.798 0.906 0.010 0.046 0.524
Correlation Coefficient 1.000 0.143 -0.184 .515** -0.105 -0.108 -0.298 0.053 -0.369 -0.194 -0.124 0.519 .564* 0.243
Sig. (2-tailed) 0.469 0.348 0.005 0.597 0.725 0.322 0.789 0.053 0.412 0.529 0.069 0.045 0.424
Correlation Coefficient 1.000 -.394* .392* -0.322 -.561* -0.292 -0.007 -0.297 -0.107 0.053 .623* .700** 0.463
Sig. (2-tailed) 0.038 0.039 0.094 0.046 0.333 0.971 0.125 0.653 0.788 0.023 0.008 0.111
Correlation Coefficient 1.000 -0.355 0.227 0.306 .813** 0.183 0.209 -0.205 0.045 -0.286 -0.214 0.053
Sig. (2-tailed) 0.064 0.082 0.156 0.000 0.163 0.287 0.295 0.733 0.186 0.328 0.809
Correlation Coefficient 1.000 -0.080 -0.395 -0.110 -0.116 -.374* 0.022 -0.049 0.339 .590* 0.336
Sig. (2-tailed) 0.686 0.182 0.720 0.557 0.050 0.925 0.803 0.257 0.034 0.262
Correlation Coefficient 1.000 0.297 0.389 -0.125 0.268 -0.035 0.002 -0.350 -0.277 -0.362
Sig. (2-tailed) 0.169 0.067 0.343 0.168 0.858 0.989 0.101 0.201 0.090
Correlation Coefficient 1.000 0.272 -0.289 0.479 -0.091 -0.226 -.465* -0.291 -.797**
Sig. (2-tailed) 0.210 0.181 0.098 0.739 0.300 0.025 0.178 0.000
Correlation Coefficient 1.000 -0.355 0.221 0.472 0.241 -.420* -0.321 0.016
Sig. (2-tailed) 0.097 0.469 0.065 0.268 0.046 0.135 0.943
Correlation Coefficient 1.000 -0.062 -0.270 0.033 0.336 0.018 0.193
Sig. (2-tailed) 0.753 0.165 0.805 0.117 0.935 0.377
Correlation Coefficient 1.000 -0.178 0.126 -.668* -.575* -.620*
Sig. (2-tailed) 0.452 0.522 0.013 0.040 0.024
Correlation Coefficient 1.000 -0.044 -0.393 -0.342 0.081
Sig. (2-tailed) 0.826 0.132 0.194 0.765
Correlation Coefficient 1.000 0.235 0.083 .463*
Sig. (2-tailed) 0.280 0.706 0.026
Correlation Coefficient 1.000 .791** .567**
Sig. (2-tailed) 0.000 0.005
Correlation Coefficient 1.000 .435*
Sig. (2-tailed) 0.038
Correlation Coefficient 1.000
Sig. (2-tailed)
Correlation Matrix
S
p
e
a
rm
a
n
's
 r
h
o
P
re
v
io
u
s
 
O
ra
l 
T
re
a
tm
e
n
t 
D
u
ra
ti
o
n
%
 T
re
g
%
 
M
e
th
y
la
ti
o
n
  
F
o
x
P
3
 
p
ro
m
o
te
r
%
 
M
e
th
y
la
ti
o
n
  
F
o
x
P
3
 
T
S
D
R
%
 T
IG
IT
%
 
M
e
th
y
la
ti
o
n
  
T
IG
IT
R
a
ti
o
 o
f 
T
IG
IT
 T
re
g
 
to
 T
IG
IT
 T
-
c
e
ll
s
IL
-1
0
 
L
e
v
e
ls
T
G
F
β
 
L
e
v
e
ls
%
 R
O
R
γ
t 
T
c
e
ll
s
%
 
M
e
th
y
la
ti
o
n
 R
O
R
C
2
%
 
M
e
th
y
la
ti
o
n
 T
B
X
T
2
%
 T
b
e
t
IL
-2
2
 
L
e
v
e
ls
IL
-1
7
 
L
e
v
e
ls
IF
N
γ
 L
e
v
e
ls
 
 
200 
 
 
 
 
Table 19: Bivariate correlation of Treg 
expressing T-bet with Treg expressing TIGIT  
(additional to data in correlation matrix) 
 
 
Tbet_FoxP3 TIGIT_FoxP3 
Spearman's 
rho 
Tbet_FoxP3 Correlation 
Coefficient 
1.000 .431** 
Sig.  
(2-tailed) 
. .001 
N 60 60 
TIGIT_FoxP3 Correlation 
Coefficient 
.431** 1.000 
Sig.  
(2-tailed) 
.001 . 
N 60 60 
 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
4.2.10.1 Summary of significant positive correlations (from Tables 18  & 
19) 
Previous oral immunosuppressive treatment duration positively correlated 
with the ratio of TIGIT Treg to TIGIT T-cells (r=0.369, P<0.05). Treg levels 
positively correlated with TIGIT levels (r=0.683, P=<0.01) and the ratio of 
TIGIT Treg to TIGIT T-cells (r=0.425, P<0.01); serum TGF-β (r=0.752, P= 
<0.01), serum IL-10 (r=0.667, P<0.01) methylation at the RORC locus 
(r=0.419, P<0.05) across all subjects. TIGIT levels positively correlated with 
serum TGF-β (r=0.813, P<0.01). Tbet levels positively correlated with IFN-γ 
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levels (r=0.463, P<0.05). IL-22 and IL-17 levels positively correlated with 
IFN-γ levels (r=0.567, P<0.05, r=435, P<0.05). IL-22 levels positively 
correlated with IL-17 levels (r=0.791, P<0.01). Methylation at the FOXP3 
promoter positively correlated with methylation at the TIGIT locus (0.515, 
P<0.05) and serum IL-17 levels (0.564, P<0.05). The methylation at the 
FOXP3 TSDR locus positively correlated with methylation at TIGIT (0.392, 
P<0.05), serum IL-22 levels (0.623, P<0.05) and IL-17 levels (0.700, 
P<0.05). The methylation at the TIGIT locus positively correlated with serum 
IL-17 levels (r=0.590, P<0.05). Tbet+FoxP3+ cell levels positively correlated 
with TIGIT+FoxP3+ cell levels (r=0.431, P< 0.05). 
 
4.2.10.2 Summary of significant negative correlations (from Table 18) 
Previous oral immunosuppressive treatment negatively correlated with 
methylation of FoxP3 TSDR (r=-0.667, P<0.01), T-bet expression levels (r=-
0.377, P<0.01) and IFN-γ levels (r=-0.544, P<0.05). Treg levels negatively 
correlated with methylation at the FoxP3 TSDR (r=-0.479, P<0.05), 
methylation at the TIGIT locus (r=-0.499, P<0.01), serum IL-22 levels (r=-
0.524, P<0.05) and serum IL-17 levels  (r=-0.421, P<0.05). Methylation at 
FoxP3 TSDR also negatively correlated with serum IL-10 levels (r=-0.561, 
P<0.01). Serum IL-10 levels negatively correlated with serum IL-22 levels 
(r=-0.465, P<0.05) and serum IFN-γ levels (r=-0.797, P<0.01). TGF-β levels 
negatively correlated with IL-22 levels (r=-0.422, P<0.05). Methylation at 
RORC2 negatively correlated with IL-22 (r=-0.668, P<0.05), IL-17 (r=-0.575, 
P<0.05) and IFN-γ levels (r=-0.620, P<0.05).  
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4.2.11 Linear regression modelling of previous oral 
immunosuppressive treatment (Ln_Prev_Rx, log transformed variable) 
as a predictor of FoxP3 TSDR methylation 
 
 
Figure 67: Simple linear regression of the duration of the previous oral 
immunosuppression treatment (months) and DNA methylation of FoxP3 TSDR 
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Table 20: Summary of multiple linear regression model of methylation of FoxP3 TSDR 
 
Variable Coefficient  P-value 
Previous duration of 
oral 
immunosuppressive 
treatment (years) 
-5.919 0.002** 
Age (years) 0.073 0.478 
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4.2.11.1 Model 1 with previous oral immunosuppression duration as a 
predictor and FoxP3 methylation as the outcome  
 
Model 1 Variables Entered/Removeda 
Mode
l 
Variables 
Entered 
Variables 
Removed Method 
1 Ln_Prev_
Rx 
. Stepwise  
(Criteria:  
Probability-of-F-to-enter  
<= .050,  
Probability-of-F-to-remove  
>= .100). 
 
a. Dependent Variable: Meth_FOXP3_TSDR 
 
 
 
Model 1 Summaryb 
Model R R Square 
Adjusted R 
Square 
Std. Error of 
the Estimate 
Durbin-
Watson 
1 .675a .456 .424 6.38633 1.528 
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a. Predictors: (Constant), Ln_Prev_Rx 
b. Dependent Variable: Meth_FOXP3_TSDR 
 
 
ANOVAa 
Model 
Sum of 
Squares df 
Mean 
Square F Sig. 
1 Regressio
n 
581.388 1 581.388 14.255 .002b 
Residual 693.349 17 40.785   
Total 1274.737 18    
 
a. Dependent Variable: Meth_FOXP3_TSDR 
b. Predictors: (Constant), Ln_Prev_Rx 
 
 
Coefficientsa 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. B Std. Error Beta 
1 (Constant) 83.673 4.534  18.456 .000 
Ln_Prev_Rx -5.704 1.511 -.675 -3.776 .002 
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Coefficientsa 
Model 
Collinearity Statistics 
Tolerance VIF 
1 (Constant)   
Ln_Prev_Rx 1.000 1.000 
 
a. Dependent Variable: Meth_FOXP3_TSDR 
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4.2.11.2 Model 2 with previous oral immunosuppression duration as a 
predictor and FoxP3 methylation as the outcome, with adjustment for 
subject age  
 
Model 2 Variables Entered/Removeda 
Model 
Variables 
Entered 
Variables 
Removed Method 
2 Ln_Prev_Rx, 
Ageb 
. Enter 
 
a. Dependent Variable: Meth_FOXP3_TSDR 
b. All requested variables entered. 
 
 
Model 2 Summaryb 
Model R R Square 
Adjusted R 
Square 
Std. Error of 
the Estimate 
Durbin-
Watson 
2 .688a .473 .408 6.47712 1.488 
 
a. Predictors: (Constant), Ln_Prev_Rx, Age 
b. Dependent Variable: Meth_FOXP3_TSDR 
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ANOVAa 
Model 
Sum of 
Squares df 
Mean 
Square F Sig. 
2 Regression 603.487 2 301.744 7.192 .006b 
Residual 671.250 16 41.953   
Total 1274.737 18    
 
a. Dependent Variable: Meth_FOXP3_TSDR 
b. Predictors: (Constant), Ln_Prev_Rx, Age 
 
 
Coefficientsa 
Model 
Unstandardized 
Coefficients 
Standardize
d 
Coefficients 
t Sig. B Std. Error Beta 
2 (Constant) 81.101 5.805  13.970 .000 
Age .073 .100 .134 .726 .478 
Ln_Prev_ 
Rx 
-5.919 1.561 -.701 -3.793 .002 
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Coefficientsa 
 
Model 
Collinearity Statistics 
Tolerance VIF 
2 (Constant)   
Age .964 1.038 
Ln_Prev_Rx .964 1.038 
 
a. Dependent Variable: Meth_FOXP3_TSDR 
 
 
Collinearity Diagnosticsa 
Model Dimension Eigenvalue 
Condition 
Index 
Variance Proportions 
(Constant) Age 
Ln_Prev_ 
Rx 
1 1 2.871 1.000 .01 .01 .01 
2 .085 5.799 .00 .61 .58 
3 .044 8.106 .99 .38 .41 
 
a. Dependent Variable: Meth_FOXP3_TSDR 
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4.2.11.3 Distribution of residuals for Models 1 & 2 
 
 
Figure 68: Distribution of residuals for multiple linear regression model of the 
methylation of FoxP3 TSDR 
 
4.2.11.4 Summary of Results  
A simple linear regression of the duration of the previous oral 
immunosuppression treatment (months) and DNA methylation of FoxP3 
TSDR was significant (Figure 67). Model 1, a multivariate linear regression 
model of methylation of the FoxP3 TSDR, which included the duration of 
previous immunosuppressive treatment as a predictor, was also significant 
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(P=0.002) and explained around 42% of the variance in FoxP3 TSDR. 
Additional predictive variables, including TIGIT+, FoxP3+, IL-10 and TGF-β 
levels, added stepwise to the model were not significant and were therefore 
removed from the final model. In Model 2, age was added as a co-variate to 
adjust for the effect of age on DNA methylation, methylation of the FoxP3 
TSDR. The regression model remained significant, (P=0.006) despite 
adjustment for age, explaining around 41% of the variance in FoxP3 TSDR 
(Table 20). The residuals for the multiple regression model were checked for 
normal distribution (Figure 68). 
 
4.2.12 Logistic regression modelling of clinical remission with TIGIT+ 
Treg levels as a predictor 
 
 
Table 21: Summary of logistic regression model of clinical remission 
 
Variable Odds Ratio 95% C.I. P value 
TIGIT 
 (% expression) 
3.1 1.5, 6.5 0.020* 
Age 1.0 0.9, 1.1 0.365 
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4.2.10.1 Logistic regression model 
 
Omnibus Tests of Model Coefficients 
 
Chi-square df Sig. 
Step 1 Step 18.402 2 .000 
Block 18.402 2 .000 
Model 18.402 2 .000 
 
 
 
Model Summary 
Step -2 Log likelihood 
Cox & Snell R 
Square 
Nagelkerke R 
Square 
1 38.904a .308 .451 
 
a. Estimation terminated at iteration number 6 because 
parameter estimates changed by less than .001. 
 
 
 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 5.786 8 .671 
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Observed 
 
Classification Tablea 
Clinical_Remission 
Percentage 
Correct .00 1.00 
Step 1 Clinical_Remission .00 8 5 61.5 
1.00 3 34 91.9 
Overall Percentage   84.0 
 
a. The cut value is .500 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
Step 1a TIGIT 1.145 .373 9.433 1 .002 3.142 
Age .029 .032 .821 1 .365 1.029 
Constant -4.826 1.875 6.624 1 .010 .008 
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Variables in the Equation  
(Confidence Intervals) 
 
 
 
95% C.I.for EXP(B) 
Lower Upper 
Step 1a TIGIT 1.513 6.524 
Age .967 1.095 
Constant   
a. Variable(s) entered on step 1: TIGIT, Age. 
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4.2.10.3 Testing TIGIT as a biomarker of clinical remission 
 
 
Table 22: TIGIT+ Treg as a biomarker of clinical remission 
 
TIGIT Observed - 
Clinical 
Remission 
Observed - 
Active Disease 
Predicted - 
Clinical 
Remission 
34 (TP) 5 (FP) 
Predicted - Active 
Disease 
3 (FN) 8 (TN) 
where TP=true positive, FP= false positive,  
FN= false negative, TN=true negative  
 
Sensitivity (%) = TP / (TP + FN) x 100 = 92 
Specificity (%) = TN / (FP + TN) x 100 = 62 
False positive rate (%) = FP/ (FP + TN) = 38 
False negative rate (%) = FN/ (FN + TP) = 8 
 
4.2.10.3 Summary of Results 
A logistic regression model that included TIGIT levels and subject age 
(years) as predictors of clinical remission was significant (X2 (2) = 18.402, 
p<0.001) and a good fit for the data (Hosmer & Lemeshow test; X2 (8) = 
5.786, p=0.671).  
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It correctly classified 84% subjects and explained around 45% of the variance 
in clinical remission of sight-threatening non-infectious uveitis. TIGIT was a 
significant predictor of clinical remission, whereas age was not significant 
(Table 21). 
Peripheral blood TIGIT levels in the study population of patients with uveitis 
had a sensitivity of 92%, a specificity of 62%, a false positive rate of 38% and 
a false negative rate of 8% for detecting clinical remission (Table 22). 
 
4.3 Discussion 
In this study, the hypothesis that phenotypically stable Treg induced by 
immunosuppressive drugs are associated with sustained clinical remission of 
non-infectious uveitis was investigated. This was demonstrated by 
performing peripheral blood immunophenotyping of large group of patients, 
who had previously received immunosuppressive drug therapy and were in 
sustained clinical remission, and comparing these results with those from 
patients with active uveitis and control subjects.  Our data show that the 
frequency of CD4+CD25+FoxP3+ Treg, TIGIT+ Treg, T-bet+ Treg and the ratio 
of CD4+CD25+FoxP3+ Treg to Th1 (T-bet+CD4+) T-cells are higher in patients 
in clinical remission compared to patients with active disease. Tbet+FoxP3+ 
cell levels showed significant positive correlation with TIGIT+FoxP3+ cell 
levels. The levels of CD4+FoxP3+TIGIT+ Treg and CD4+FOXP3-TIGIT+ T-
cells in each subject sample were analysed as the ratio of 
CD4+FoxP3+TIGIT+ Treg to CD4+FOXP3-TIGIT+ T-cells and this ratio was 
significantly higher in the remission group compared to the active group. This 
suggested that TIGIT expression proportionally increased in the CD4+FoxP3+ 
compartment of T-cells in the clinical remission group compared to the active 
group, rather than increasing on all T-cells.  
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A novel approach of NGS bisulphate sequencing targeted towards T-cell 
genes of interest, was used to identify whether there was an epigenetic 
immune methylation pattern associated with clinical remission in uveitis.  The 
addition of a methyl group (-CH3) to DNA is a common epigenetic 
mechanism that cells use to switch genes ‘off’. Extensive methylation of 
cytosine in DNA is known to correlate with reduced gene transcription. In this 
study, PBMCs from patients in clinical remission had lower levels of DNA 
methylation at CpG sites within the FOXP3 TSDR, FOXP3 Promotor and 
TIGIT loci compared to patients with active disease, supporting the higher 
levels of FoxP3 and TIGIT expression detected by flow cytometry in these 
patients. Through in vitro functional studies, it is demonstrated that Treg from 
patients in clinical remission, a population in which there were high levels of 
Treg and TIGIT expression, are effective at suppressing T-cell proliferation. 
Together, these findings suggest that Treg from patients in clinical remission 
are polarised towards Type 1 inflammation and have a stable highly 
suppressive phenotype, characterised by higher intracellular T-bet and 
extracellular TIGIT expression, respectively, in comparison to subjects with 
active disease.  
The cytokine milieu in non-infectious uveitis has been previously been 
investigated by our group and others (Kramer, et al. 2007; Ooi, et al. 2006a; 
Ooi, et al. 2006b; Takase, et al. 2006; Torun, et al. 2005; Zhao, et al. 2017). 
The focus of this was on investigating serum levels of specific cytokines 
associated with the Treg, Th1 and Th17 subsets identified in the flow 
cytometric analysis. Intracellular cytokine levels of IL-10, IFN-γ and IL-17A 
were also evaluated in active disease at 0 months and 6 months after 
starting therapy, at which time, disease had resolved. It was found that 
patients in clinical remission had higher serum levels of IL-10 and TGF- β 
than patients with active disease. Whilst control subjects also had higher 
levels of IL-10 than active patients, the higher serum TGF- β differentiated 
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remission patients from controls and were perhaps related to high levels of 
Treg with suppressive function in this group. Tregs levels positively 
correlated with serum IL-10 and TGF- β levels, suggesting that Tregs may 
directly or indirectly influence the systemic cytokine milieu. Furthermore, 
increased intracellular expression of IL-10 by T-cells from active disease was 
increased 6 months after starting treatment, which corresponded with clinical 
resolution of disease. 
Subjects’ levels of Th1 and Th17 were evaluated by flow cytometric detection 
of their respective transcription factors, T-bet and RORγt, along with the 
corresponding serum cytokine levels of IFN-γ, IL-17 and IL-22 from 
peripheral blood samples. Upregulated T-bet expression in association with 
significantly increased IFN-γ levels has been previously demonstrated in 
patients with active uveitis secondary to Vogt-Koyanagi-Harada (VKH) 
syndrome, a bilateral chronic granulomatous panuveitis, which tends to be 
sight-threatening (Li, et al. 2005). Th17 cells have also been shown to be 
involved in ocular inflammation (Amadi-Obi, et al. 2007) and, more recently, 
B27+ anterior uveitis (Zhuang, et al. 2017). Paradoxical expression of effector 
CD4 T-cell transcription factors, such as T-bet and RORγt, by Treg has, 
however, been suggested to enhance Treg suppressive capacity in murine 
models of inflammation (Koch, et al. 2009; Levine, et al. 2017; Ohnmacht, et 
al. 2015; Sefik, et al. 2015). These models demonstrate that intestinal 
RORγt+FoxP3+ Treg induced in vivo by the local microbiota display a stable 
suppressive phenotype and exist in dynamic balance with pathogenic Th17 
(Ohnmacht, et al. 2015; Omenetti and Pizarro 2015). The local 
microenvironment, for example, the cytokine milieu and/or the microbiome, 
have been shown to regulate the Treg/Th17 balance and influence cell 
plasticity; disruption of this balance may lead to the development of 
inflammatory disease (Leung, et al. 2010; Lochner, et al. 2008; Omenetti and 
Pizarro 2015; Sefik, et al. 2015). Furthermore, during Type 1 inflammatory 
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responses, Treg may upregulate T-bet in response to IFN-γ production 
(Koch, et al. 2009). These T-bet+ Treg are phenotypically stable and 
selectively suppress Th1 (Levine, et al. 2017). 
In the current study, we show that in clinical remission and control groups, 
the levels of T-bet+ Treg and ratios of Treg to Th1 are higher and serum 
levels of IFN-γ levels are lower compared to active uveitis patients. We also 
found that Tbet+ Th1 levels in uveitis patients were overall lower in clinical 
remission compared to active and control subjects. Disease resolution in 
active patients over the course of 12 months appeared to be associated with 
an increase in levels of Treg and a decrease in levels of Th1. Intracellular 
expression levels of IFN-γ by CD4+ T-cells were also decreased at 6 months 
after starting treatment. However, RORγt+ Th17 and RORγt+ Treg levels did 
not significantly differ between the three subject groups. Treg are thought to 
regulate the expression of IL-22, a Th17 cytokine which facilitates 
inflammatory cell infiltration in uveitis (Kim, et al. 2016; Lin, et al. 2014). 
Although the ratio of Treg to Th17 was not significantly greater in clinical 
remission, it was noted that serum IL-17A and IL-22 levels were significantly 
lower in the patients in clinical remission, compared to active and control 
subjects. RORγt+ Treg levels were increased in all four active patients at 12 
months compared to baseline, as the disease clinically resolved. However, 
unlike Th1 cytokine levels, Th17 cytokine levels did not appear to 
consistently decrease when disease resolved in active patients. Three out of 
four active patients had increased serum levels of IL-17A at 12 months after 
starting treatment, compared to baseline. Intracellular expression levels of IL-
17A of by CD4+ T-cells in active disease also increased at 6 months after 
starting treatment. Our results show that Th17 express FoxP3+ during 
disease resolution, in response to immunosuppressive treatment, but 
suggest that Th17-mediated inflammation is not driving inflammation and that 
FoxP3+RORγt+ Treg are not significantly associated with clinical remission.  
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Previous studies have compared Treg levels between active uveitis, inactive 
uveitis and/or healthy control subjects but there has been variation in subject 
groups and clinical immunophenotyping. A study from Chen et al included 49 
patients with VKH syndrome with uveitis and without uveitis, and showed a 
decreased percentage of CD4+CD25high T-cells, a decreased frequency of 
FoxP3+ expression in CD4+CD25high T-cells and reduced functionality of 
CD4+CD25high ‘Treg’ in patients with active uveitis (Chen, et al. 2008). Yeh et 
al also demonstrated that patients with active uveitis (n=8) have lower 
percentages of CD4+FoxP3+ lymphocytes than patients with inactive disease 
(n=12) (Yeh, et al. 2009). In contrast to the current study, several patients in 
their series demonstrated evidence of systemic autoimmune disease, such 
as sarcoidosis and multiple sclerosis, which are, of themselves, associated 
with abnormal Treg populations or deficits in Treg suppressive function. 
Another study compared Treg levels in active and inactive uveitis patients 
and found that patients in remission on treatment (n=25) had significantly 
increased levels of CD4+ CD25+FoxP3+ Treg compared to active patients on 
treatment (n=6) (Ruggieri, et al. 2012). However, over half of the patients 
(53%) recruited to their study had a diagnosis of anterior uveitis, which is not 
usually sight-threatening and does not require systemic immunosuppression.  
Regarding the comparison of Treg levels in active patients with control 
subjects, the results from the literature are mixed. Two of aforementioned 
studies show a higher level of Treg in control subjects compared to uveitis 
patients (Chen, et al. 2008; Ruggieri, et al. 2012), however this could be due 
to the inclusion of patients with systemic disease in the uveitis groups.  In 
contrast, Yeh et al comment that they have previously observed that the 
percentages of CD4+FoxP3+ lymphocytes do not differ between patients with 
uveitis and control subjects (unpublished data) (Yeh, et al. 2009). Molins et al 
compared Treg levels and cytokine production in 21 patients with active non-
infectious uveitis with 18 controls (Molins, et al. 2015). They found that 
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PBMCs from uveitis patients produced lower levels of IL-10 than those from 
controls but no differences were observed in Treg levels. TGF-β levels were 
not measured and functional assays were not performed in this study. 
Recently, Zhuang et al compared 20 patients with active B27+ anterior uveitis 
with healthy controls and observed an increase in CD4+IL-17+ T cells, a 
decrease of CD4+CD25+FoxP3+ Treg and a higher ratio of Th17/Treg in 
peripheral blood of patients compared to controls (Zhuang, et al. 2017). The 
authors conclude that the imbalance of Th17 and Treg cells may play a vital 
role in the pathogenesis of B27+ anterior uveitis. Of note, patients with B27+ 
uveitis and anterior uveitis were excluded from the present study due to the 
typically non-sight-threatening anterior anatomic localisation of inflammation 
and systemic disease associations. 
There has been interest in glucocorticoid-resistant Th17 cells which are 
refractory to Treg mediated suppression (Basdeo, et al. 2015; Ramesh, et al. 
2014), and these have been previously investigated in sight-threatening 
uveitis (Lee, et al. 2009). Furthermore, a subset of ‘non-classic’ Th17-derived 
Th1 have been described, which are demethylated at RORC, and are 
thought to play a pivotal role in the establishment and persistence of 
inflammatory disease (Mazzoni, et al. 2015). These non-classic Th1 express 
CD161, a marker of steroid-resistant human Th17, induced by RORC 
(Maggi, et al. 2010). In the clinical setting, however, most cases of uveitis 
show a good clinical response to high dose corticosteroids. Second-line 
immunosuppressive drugs are usually prescribed because the dose of 
corticosteroids required to suppress disease activity is very high and disease 
recurs on tapering the dose, rather than because the disease is refractory to 
corticosteroids. Only one patient in the current study received biological 
therapy (Adalimumab), as the rest were clinically responsive to 
corticosteroids, with or without addition of conventional steroid-sparing 
agents. Twenty percent of the clinical remission group received previous 
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therapy with cyclosporine, which has been shown to selectively attenuate 
steroid-resistant Th17 and to be efficacious in the treatment of steroid-
refractory disease (Schewitz-Bowers, et al. 2015; Schewitz, et al. 2009). It is 
of note, in this study, that the clinical remission and control groups had 
significantly higher levels of RORC CpG methylation than the active group. 
Furthermore, within the active patient cohort, higher RORC % CpG 
methylation levels were observed at 12 months after starting/ changing 
immunosuppressive treatment, when disease had resolved. RORC CpG 
hypomethylation could, therefore, be a biomarker of clinical response to 
corticosteroid treatment and a potential predictor of clinical remission. 
The findings of the current study are consistent with previous studies in 
uveitis demonstrating that Treg levels are higher and more functional in 
patients with inactive disease, compared to both patients with active and 
control subjects. We have previously observed that in ocular Beҫhet’s 
Disease, peripheral blood Treg levels are increased by 3 months’ treatment 
with the immunomodulating therapy, pegylated interferon-α (pegIFNα), and 
that the increased levels of Tregs are still detectable at 12 months, six 
months after cessation of therapy (Lightman, et al. 2015). However, the 
expression of the co-inhibitory molecule TIGIT by Treg from patients in 
sustained clinical remission of disease, who are no longer on therapy, has 
not been previously investigated in uveitis. It is known that stable FoxP3 
expression is ensured, at least partly, by DNA demethylation at the FOXP3 
TSDR and that this infers commitment to the Treg lineage (Floess, et al. 
2007; Huehn, et al. 2009; Polansky, et al. 2008; Zheng, et al. 2010). In a 
genome-wide methylation analysis of nTregs from healthy individuals, it was 
found that hypomethylation at the TIGIT locus was one of the most 
significantly differentially methylated regions that distinguished naïve T-cells 
and nTreg; that it was not altered by activation and is required for FoxP3 
binding (Zhang, et al. 2013b). Other studies have demonstrated a key role 
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for TIGIT in Treg-mediated suppression of Th1 and Th17 subsets (Joller, et 
al. 2011; Joller, et al. 2014) and that TIGIT signalling in Treg directs their 
immunoregulatory phenotype in chronic disease settings (Kurtulus, et al. 
2015). Our data show that hypomethylation at FOXP3 TSDR, FOXP3 
promoter and TIGIT CpG sites, and higher levels of TIGIT expression by 
Treg, are associated with sustained clinical remission in relapsing and 
remitting sight-threatening non-infectious uveitis.  
Many significant correlations were discovered between immunological 
variables investigated in this study. Previous oral immunosuppressive 
treatment duration positively correlated with the ratio of TIGIT Treg to TIGIT 
T-cells and negatively correlated with methylation of FoxP3 TSDR, T-bet 
expression levels and IFN-γ levels. Treg levels negatively correlated with 
methylation at the FoxP3 TSDR, methylation at the TIGIT locus, serum IL-22 
levels and serum IL-17 levels. Treg levels positively correlated with TIGIT 
levels, the ratio of TIGIT Treg to TIGIT T-cells, serum TGF-β and serum IL-
10 levels. Treg levels also positively correlated with methylation at the 
RORC2 locus across all subjects, which in turn, negatively correlated with IL-
22, IL-17 and IFN-γ levels. TIGIT levels positively correlated with serum 
TGF-β. Methylation at the FOXP3 promoter positively correlated with 
methylation at the TIGIT locus and serum IL-17 levels. The methylation at 
the FOXP3 TSDR locus positively correlated with methylation at TIGIT, 
serum IL-22 levels and IL-17 levels and negatively correlated with serum IL-
10 levels. Methylation at the TIGIT locus positively correlated with serum IL-
17 levels. Tbet+FoxP3+ cell levels positively correlated with TIGIT+FoxP3+ 
cell levels. These results support previous evidence that Tregs and/or TIGIT 
levels, induced by immunosuppressive treatment, are associated low levels 
of DNA methylation at their loci and that they mediate some of their 
regulatory effect through the cytokine milieu.  
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It was further investigated whether clinical remission in non-infectious sight-
threatening uveitis could be modelled by a linear relationship with predictive 
immunological variables, after adjusting for co-variates in the model. Multiple 
regression analysis showed that the duration of previous oral 
immunosuppressive treatment was the strongest predictor of methylation of 
the FoxP3 TSDR, which was significantly associated with clinical remission 
in sight-threatening uveitis and which relationship was remained significant 
after adjusting for age. Logistic regression showed that peripheral blood 
TIGIT levels, but not subject age, were a significant predictor of clinical 
remission in sight threatening non-infectious uveitis. TIGIT levels had high 
sensitivity (92%) but low specificity (62%) and, therefore, a high false positive 
rate when used as a predictor of clinical remission of sight-threatening non-
infectious uveitis in the study population of uveitis patients. TIGIT levels 
explained almost half of the variance observed in the model of clinical 
remission, but there were clearly other factors, not accounted for in the 
model, which were also influencing clinical remission. 
Our study addressed a need to define and investigate sustained clinical and 
biological disease remission in sight-threatening non-infectious uveitis. The 
total number of subjects recruited to this study (n=60) represents one of the 
largest sample sizes of published clinical immunology studies of sight-
threatening non-infectious uveitis. To improve the specificity of this study 
towards detecting peripheral blood biomarkers associated with ocular 
inflammation, we excluded patients with known systemic diagnoses, for 
example, sarcoidosis or Behçet’s disease, and any other identifiable 
systemic inflammation. We were rigorous in our clinical phenotyping of the 
recruited subjects and undertook a comprehensive immunophenotypic 
analysis of CD4+ T-cells derived from these groups, including functional and 
epigenetic methylation studies, which has not been previously performed in 
uveitis patients. T-cell immunophenotyping by flow cytometry was performed 
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on freshly isolated subject PBMCs (within 4 hours of venepuncture) but 
additional intraocular sampling was not undertaken as part of this study. The 
thirty-seven patients in clinical remission recruited to the study demonstrated 
a good clinical ocular response to immunosuppressive therapy given 
systemically, supporting the fact that systemic Treg and their associated 
microenvironment influence ocular immunity and that peripheral blood 
biomarkers have utility in monitoring ocular disease. Phenotypic analysis of 
Treg, Th1 and Th17 subtypes was based on ‘master transcription factor’ 
expression, with prospective intracellular cytokine analysis only in selected 
subjects with active disease, followed up over a 12-month period. An in-
depth analysis of intracellular cytokine production and methylation at 
signature cytokine loci could be considered for a future study. The number of 
Treg functional assays that were performed as part of this study was limited 
by the remaining PBMC numbers after the immunophenotypic analysis, 
rendering firm conclusions from these results difficult.  The assay findings 
were in keeping with those from previous studies, which have demonstrated 
that in the inflammatory setting of autoimmune disease, Treg have reduced 
suppressive function (Bending, et al. 2014; Ehrenstein, et al. 2004). 
However, they could be confirmed as part of a further study. 
In summary, these study data show that CD4+ T-cells in chronic relapsing, 
remitting sight-threatening non-infectious uveitis deviate towards the Th1 
type and that Treg with upregulated levels of T-bet and TIGIT expression are 
associated with disease remission. These data provide supporting evidence 
that Treg are part of the mechanism of clinical remission in non-infectious 
uveitis, which has been previously demonstrated in EAU model studies only 
(Ke, et al. 2008; Silver, et al. 2015; Sun, et al. 2010). The overall lower T-bet 
expression and IFN-γ levels detected in patients who achieve sustained 
clinical remission may be related to potent suppression of Type 1 
inflammation by phenotypically stable Treg induced by systemic 
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immunosuppressive therapy. This is an important finding because a recent 
study in mice has shown that Treg expressing T-bet have a stable and 
functional phenotype, which potentiates suppression of Th1 autoimmunity 
(Levine, et al. 2017), but it has not yet been demonstrated in clinical studies. 
These results are also consistent with evidence from EAU that relapsing, 
remitting uveitic disease is closely associated with a Th1-like phenotype 
whereas monophasic inflammation is associated with a Th17-like phenotype 
(von Toerne, et al. 2010).  
Finally, these data are relevant to the recent interest in quantitative 
identification and isolation of viable, functional Treg for downstream clinical 
purposes, which includes their generation ex vivo for immunomodulating 
therapies (Foussat, et al. 2017; Horwitz, et al. 2004). This requires reliable 
surface markers that are selectively expressed on functional Treg. Putative 
Treg surface markers include Helios (Thornton, et al. 2010) and low CD127 
(Liu, et al. 2006) but there has been some debate in the literature about their 
reliability. The results of this study provide evidence that TIGIT has utility as 
a marker of functional Treg for immunomodulatory therapy, and that low 
levels of TIGIT could be a biomarker for increased risk of disease relapse in 
non-infectious uveitis. 
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Chapter 5 Patient Perspectives of Sight-threatening 
Retinal Disease and Pilot Health Behaviour Change 
Intervention 
 
5.1 Background and study rationale 
 
5.1.1 Study aim 
To investigate perspectives and health behaviours of patients with sight-
threatening non-infectious retinal disease (which does not have curative 
treatment) and identify suitable interventional approach(es) which could 
serve to increase sense of agency and/or self-efficacy of affected individuals, 
in order to potentially change the course of their disease and/or its 
consequences.  
 
5.1.2 Objectives 
 
• Conduct individual interviews with patients with sight-threatening non-
infectious uveitis recruited from prospective study described in 
Chapters 3&4 to characterise their experience of uveitis and its 
treatment. 
 
• Conduct a focus group of patients with dry age-related macular 
degeneration (AMD) to identify perspectives on treatment and an 
evidence-based lifestyle intervention.  
 
 
 
228 
 
 
 
 
• Analyse potential problems identified in terms of perceived problems/ 
unmet needs and/or health behaviours, which could be further 
addressed. 
 
• Identify a target need and/or behaviour, and design a pilot 
intervention. 
 
• Test pilot intervention with focus group patients and perform a 
preliminary evaluation of effectiveness, in terms of engagement with 
intervention. 
 
5.1.3 Study design, setting and participants 
Design: Observational Case Series 
Setting: NHS tertiary referral centre for ophthalmology, NIHR Biomedical 
Research Centre for Ophthalmology and local community locations in 
London, UK 
Participants:  4 patients prospectively recruited from a specialist uveitis 
clinic in tertiary care centre for ophthalmology in the UK and 12 patients with 
a diagnosis of dry AMD. 
 
5.1.4 Ethical approvals and consents 
Research performed as part of this thesis adhered to the tenets of the 
Declaration of Helsinki and was carried out in accordance with the 
recommendations of the UK National Research Ethics Service (NRES) – 
London Harrow Committee and the Moorfields Eye Hospital National Health 
Service (NHS) Foundation Trust, Department of Research and Development 
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(13/LO/1653; 16039). A National Institute of Health Research (NIHR) 
Biomedical Research Centre (BRC) film and photography release consent 
form was signed by all subjects who attended the ‘Eating for Eye Health’ 
engagement focus group and cooking day. 
 
5.1.5 Rationale for qualitative data collection 
There is a paucity of opportunity for doctors, especially those in training, to 
learn about the psycho-social aspects of eye disease within routine clinical 
education and practice. To address this issue, some emic (from the 
perspective of the subject) methodologies were introduced into the research 
plan for the thesis. This research study was partly informed by a concurrent 
pilot clinical education project funded by a UCL ‘Liberating the Curriculum’ 
grant. This clinical education project was delivered in consultation with the 
eye research charity, Fight for Sight, in order to assist doctors in delivering 
patient-centred care to subjects with visual impairment and is summarised in 
the following short report [Gilbert, Rose] (Rose, et al. 2018): 
‘Despite its importance in primary and emergency care, ophthalmology is felt 
by medical students and physicians to be under-represented in the medical 
undergraduate and foundation curriculum. Furthermore, there is a paucity of 
opportunity for students and junior doctors to interact with and learn from 
members of the visually impaired community. Focus groups of visually-
impaired patients have highlighted the disparity between clinician and patient 
perspectives of eye disease. Successful medical education encourages 
clinicians to promote health whilst respecting individuals’ self-perceived 
needs and voluntary choices. However, the opposing forces of increased 
training expectations and reduced training resources could greatly impact on 
this. Junior medical trainees may struggle to administer patient-centred care 
if they have not previously encountered specific patient groups during their 
training. Theoretically constructed educational interventions which 
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incorporate patient perspectives have been previously described to address 
this. 
Electronic virtual patients (e-patients) were incorporated into existing online 
and taught clinical ophthalmology courses at our institution, providing an 
opportunity for the learner to partake in fictional clinical ophthalmology 
scenarios without causing any harm to a real patient. The online scenarios 
were presented in both linear and interactive non-linear branching formats, 
the latter allowing users to determine their own path through the case, and to 
explore potential clinical consequences of their choices. These clinical 
programmes were further developed through an institutional ‘inclusive 
education’ grant in consultation with the eye research charity, Fight for Sight, 
to include the ‘patient perspective’ of eye disease. Following completion of 
online material and lecture attendance, course participants were invited to 
attend a tutorial and a half day seminar on the patient perspective of eye 
disease. During the tutorial, students were supported by teaching assistants 
in planning a written assignment and an oral presentation on a clinical 
ophthalmology topic of their choice. They were encouraged to consider the 
impact of eye disease on the patient. Following the tutorial, students 
presented their clinical topics to patients at a half day seminar and they, in 
turn, listened to four ‘expert’ patients talk about their experience of having an 
eye disease. Outcomes were evaluated through online and paper student 
satisfaction surveys (n=80). 
Both linear and branching e-patient scenarios had ‘very good’ levels of 
satisfaction amongst students (83% vs 86%), however the branching 
scenario was reported as being ‘more authentic’ (91% vs 60%), since it 
simulated the real-life experience of managing a patient with eye disease.  
The ‘patient perspectives’ seminar helped students appreciate the impact of 
eye disease on patients. For example, patients described receiving their 
diagnosis as ‘the beginning’ of their clinical journey, rather than ‘the end’ as 
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some students perceived it, which encouraged students to consider their 
style of communication. All students reported increased levels of confidence 
in caring for real-life patients with visual impairment after course completion. 
Whether completion of this programme by clinicians positively impacts 
clinical communication, patient safety and patient satisfaction requires further 
investigation.’ 
The methodological approach to this study was informed by The Stereotype 
Content Model (SCM), which ‘aims to capture the texture of each group’s 
situation, at the same time identifying the fundamental underlying dimensions 
that help explain some shared experiences…[It] starts by analysing what 
people need to know about each other, in order to function in the same social 
space.’ (Fiske, et al. 2007; Fiske, et al. 2002; Fiske 2012) 
Qualitative methodology, therefore, in the form of interviews and focus 
groups, was utilised in this study in order to allow study participants to 
express themselves in a less constrained way than would be the case with 
data collected via questionnaire (Wilkinson 2004). It was thought that the 
accounts elicited by interviews and focus groups would have the potential to 
provide unexpected insights into patient perceptions of treatment, including 
factors that may not have been previously considered relevant (Wilkinson 
2004). 
 
5.1.6 Rationale for targeting health behaviours in chronic disease 
Health-related behaviours can contribute to major causes of mortality and 
morbidity. Chronic diseases, which include autoimmune diseases, in addition 
to more common diseases such as cardiovascular disease (CVD), are a 
major cause of death and disability (NICE 2007). Many of these diseases, for 
example, CVD, have well known associations with behaviours and lifestyle 
factors that can be changed (e.g. smoking tobacco and diet), so-called 
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‘modifiable risk factors’. Behaviour is known to be influenced by ‘a range of 
socio-economic, cultural and environmental conditions, social and 
community networks and individual factors, such as age’. Behaviour change 
interventions may be defined as ‘coordinated sets of activities that seek to 
change specific behaviours’ (NICE 2007) 
It has been determined that ‘a combination of interventions that tackle 
population, community and individual-level factors are needed to help people 
change their behaviour in the longer term’ and that ‘the following approaches 
can help: 
• Using evidence-based principles and behaviour change techniques 
(the smallest “active” component of an intervention designed to 
change behaviour). 
• Having a theoretical basis for interventions. This also helps in 
understanding why an intervention is effective or not.’ 
(NICE 2007) 
5.1.7 Using theoretical models to predict health behaviour and/or 
design interventions 
Adapted from UCL MSc in Health Psychology Module 4 ‘Health Related 
Behaviours and Cognition’ Essay Assignment Submission (Gilbert 2017, 
unpublished): 
‘Social cognition models (SCMs) (Conner 2005) were developed to examine 
the role of social cognitions in determining health-related behaviour. ‘Social 
cognitions’, in the health context, refer to an individuals’ thoughts and 
feelings associated with  performing or not performing a particular health 
behaviour. (Conner 2005). It was hypothesised that individual differences in 
health behaviours, often attributed to socio-demographics factors, such as 
gender and socio-economic status (Blaxter 1990), might be predicted by the 
sets of social cognitions described by SCMs. Social cognitions represent a 
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useful focus for health research because psychological factors are potentially 
more amenable to change than socio-demographic factors (NICE 2007). 
Prominent examples of SCMs include: the Health Belief Model (HBM) 
(Abraham 2005; Janz and Becker 1984; Rosenstock 1974), Protection 
Motivation Theory (PMT) (Conner 2005; Maddux and Rogers 1983), the 
Extended Parallel Processing Model (EPPM)  (Witte 1992), the Theory of 
Planned Behaviour (TPB) (Azjen 1991) and Social Cognitive Theory (Self 
Efficacy) (SCT) (Bandura 2000).  
The HBM (Abraham 2005; Janz and Becker 1984; Rosenstock 1974), the 
oldest and most widely used SCM, focuses on two health cognitions: 
perception of threat (perceived severity and susceptibility) from illness and 
evaluation of behaviours to counteract the perceived threat (including beliefs 
about benefits and barriers to performing the behaviour). Cues to action, as 
triggers of the health behaviour, are also included in this model. The PMT 
(Conner 2005; Maddux and Rogers 1983) is considered an extended, 
revised version of the HBM, which includes an appraisal regarding the illness 
threat and the coping process of alternative behaviours which might diminish 
the threat. The EPPM (Witte 1992)  is also concerned with aspects of an 
individual’s cognitions regarding health threat perception (perceived 
susceptibility and perceived severity) but was extended to involve ‘efficacy 
perception’. In the EPPM, efficacy perception describes the effects of 
response efficacy (beliefs regarding the utility of the behaviour in averting a 
threat) and self-efficacy (beliefs of one’s own ability to perform the behavior). 
The TPB (Azjen 1991) specifies the factors that determine an individuals’ 
conscious decision to perform a behaviour. This model posits that 
behavioural action can be predicted by intention to act, based on attitudes 
towards the behaviour, subjective norms and perceived behavioural control. 
Furthermore, attitude is determined by behavioural beliefs weighted by 
evaluation of behavioural outcomes; subjective norms are determined by 
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normative beliefs weighted by motivation to comply with these beliefs; and 
perceived behavioural control is determined by perceived internal and 
external resources weighted against perceived opportunities to perform the 
behaviour. In the SCT (Bandura 2000), three factors determine health 
behaviours: self-efficacy, proximal goals and outcome expectancies. 
Proximal goals regulate effort and guide action and are similar to the concept 
of intention. Outcome expectancies are similar to the behavioural beliefs of 
the TPB but can be further subdivided into physical, social and self-
evaluative beliefs depending on the context.   
In a meta-analysis of 18 studies (2,702 subjects) conducted to determine 
whether the HBM could longitudinally predict behaviour, only two of the 
constructs, perceived benefits and barriers, were found to be consistently 
strong predictors of behaviour (Carpenter 2010). The inconsistency in 
predictive power of the constructs within the HBM has also proved 
problematic in other SCMs. This issue could be related to the variability in 
measurement of the central constructs during the research (Glanz 2008). 
The method of data collection in research using SCMs is often a self-
reported questionnaire, which can be subject to self-presentation/ social 
desirability bias and recall bias. Furthermore, it has been suggested that 
questionnaire studies might change or create cognitions and/or behaviour, 
thereby introducing artefact into SCMs studies through ‘mere measurement 
effects’ (Godin, et al. 2008; Ogden 2003). However, an overlap in SCM 
variables has also been described (Conner 1996; Ogden 2003), particularly 
in the domains of intention, self-efficacy and outcome expectancies, which 
have strong relationships with health behaviours across several studies 
(Conner 2005). This suggests that the power of SCMs to predict behaviour 
might be attributed to these individual variables rather than ‘the set’ of 
cognitions described in each model.  
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It has been argued that studies of health research using SCMs have not 
strongly supported the specific model used in the study design (in that the 
variables were not predictive of health behaviours and/or that the variance 
explained was low) yet the models were not rejected (Ogden 2003). 
Therefore, the theory underlying the conceptual basis of SCMs is not being 
appropriately tested (Ogden 2003). Furthermore, the study design often used 
to test SCMs is cross-sectional or prospective with a focus on finding 
correlates of health behavior, rather identifying relationships. Experimental or 
quasi-experimental study designs using SCMs would assist in determining 
causation for repeated behaviours, where strong past-future relationship, 
rather than intention, might predict that the behaviour is likely to continue in 
the future (Weinstein 2007). Correlational studies can, therefore, lead to an 
overestimation in the strength of the relationship between the SCM 
constructs and health behaviour (Steptoe 2011). The prospective study 
design used to test SCMs also assumes ‘intention stability’, which has been 
shown to influence the intention-behaviour relationship (Sheeran and 
Abraham 2003). Further criticisms of SCMs include the lack of explicit 
inclusion of affective influences within the model and lack of focus on the 
volitional phase of action (Steptoe 2011). The Theory of Planned Behaviour 
(Conner 1998) and Protection Motivation Theory (Milne, et al. 2002) were 
subsequently extended include these respective domains. 
Stage models, notably the Transtheoretical Model of Change (TTM) 
(Prochaska 1984), are a different form of SCM which describe health 
behaviours as encapsulating several discrete stages rather than linear. 
However, the actual ‘stages’ of the TTM have been criticised and, for this 
reason, it does not necessarily represent an improvement on the previously 
described SCMs, in terms of its ability to describe behaviour change (Steptoe 
2011). 
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Using models, informed by theory, to explain individual behaviour in the 
context of health, is useful from the perspective of researchers and is 
consistent with an evidence-based approach to public health and medicine 
(Glanz 1997; Ogden 2003). Examples of applications of SCM in public health 
research include: the use of HBM in the prediction of individuals’ adherence 
to malaria prophylaxis regimens following return from travel (Abraham, et al. 
1999) and in the investigation of factors influencing the decision to take a 
genetic test for colon cancer risk (Bunn, et al. 2002); and the application of 
the SCT model in determining the relationship between psychosocial factors 
and physical activity (Fisher, et al. 2011).  Behavioural interventions involving 
more extensive use of theory have been shown to be associated with 
increases in treatment effect size and, in the case of TPB, more substantial 
effects on behaviour (Webb, et al. 2010).  
However, a methodological approach which classifies behaviour change 
interventions (Abraham and Michie 2008) and uses models to understand 
individual behavior in the context of a wider system (Michie, et al. 2011) is 
likely to provide a more comprehensive explanation of behaviour change, 
than using individual social cognitions alone. A simple model, such as the 
COM-B model of behaviour in context (Michie, et al. 2011) is potentially 
amenable to use by health-care researcher without a specialist psychology 
background, and might assist in the generation of evidence to explain 
behaviour in varied healthcare settings (Figure 69).  
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Figure 69: The COM-B (Capability, Opportunity, Motivation - Behaviour) Model of 
Behaviour in Context 
 
Behaviour change taxonomy (Abraham and Michie 2008) might also help to 
identify which models are suitable for targeting specific types of health 
cognition and/or behaviour, to promote change.’  
 
5.1.8 Subject selection and recruitment 
Patients with two forms of sight-threatening non-infectious retinal disease 
were selected for this study:  
1. non-infectious uveitis  
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2. the dry form of age-related macular degeneration (AMD).  
A total of 4 patients with a diagnosis of active idiopathic non-infectious uveitis 
were consecutively recruited to this study from Moorfields Eye Hospital, 
London, UK between November 2014 and December 2016. Patients with 
active uveitis only were included in this study because they would be started 
on treatment, whereas those in clinical remission would not, and they would 
be undergoing 3 further follow-up appointments over the course of 12 
months, during which time they could be interviewed. Inclusion criteria for 
patients with uveitis were as follows: age 18 to 59 years; a current or 
previous diagnosis of non-infectious intermediate, posterior or pan-uveitis as 
per standardization of uveitis nomenclature (SUN) (Jabs et al., 2005); and 
the absence of known associated infectious disease or systemic 
inflammatory disease. Eligibility for recruitment was further determined by 
uveitic disease activity.  To meet the criteria for ‘active’ disease, patients 
were required to have new onset of uveitic disease occurrence at the time of 
recruitment (a new diagnosis or reactivation of existing disease), which was 
regardless of treatment status. Disease activity was determined by clinical 
symptoms, examination with slit lamp biomicroscopy and clinical imaging 
(optical coherence tomography, fundus autofluorescence and fluorescein 
angiography). Patients who met the study inclusion criteria and who were 
clinically assessed to have active disease (i.e. anterior chamber cells ≥0.5+, 
vitreous cells ≥0.5+, inflammatory cystoid macular oedema, optic disc 
oedema, active vasculitis, or new/ active chorioretinal lesions) were 
considered eligible as ‘active’ patients in the study.  
Patients with dry AMD were recruited via the NIHR Moorfields Biomedical 
Research Centre, using an existing electronic database of patients who had 
registered their interest in involvement with research. An invitation email with 
the following text attachment was sent out to all patients with a diagnosis of 
dry AMD (approximately 40) in July 2015: 
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“Dear --- 
As part of our Research Community at the NIHR Moorfields BRC, we are 
always keen to inform you of any research engaging opportunities that you 
may be interested in. The NIHR Moorfields BRC has recently been asked to 
help organise a project called “Eating for Eye Health”. 
“Eating for Eye Health” is a public engagement project initiated by research 
students and clinicians at UCL Institute of Ophthalmology and Moorfields 
Eye Hospital to raise awareness about nutrition and eye health, particularly 
for the older generation.  
There is evidence that good nutrition can benefit eye health and we are keen 
to explore this! Through this project, we aim to explore simple ways of 
improving nutrition for the older generation, especially involving people who 
have received a diagnosis of "dry" age-related macular degeneration (AMD) 
for which there is currently no treatment.  
Initially, we intend to hold a focus group event to discuss the relationship 
between nutrition and eye health, and to find out patients’ views on diet, in 
addition to a food tasting. Together we will compile a list of appealing 
antioxidant-rich recipes! 
The focus group is a free event that is aimed at dry AMD patients and 
relatives. The focus group is to be held at---- 
As spaces are limited, they will be given on a first come first served basis. If 
you are interested in attending, please contact us via email at --- or by 
telephone on ---. 
For more information on the project, please visit 
http://www.brcophthalmology.org/eating-eye-health. If you have any 
questions, please feel free to contact us via the telephone number above. 
Thank you.”  
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5.1.9 Rationale for including patients with dry AMD in the focus group 
study on an evidence-based lifestyle intervention 
The JLA PSP list, which described unanswered questions about ocular 
inflammatory disease, prioritised by patients, includes the following research 
question:  
‘Can diet or lifestyle changes prevent uveitis from developing?’(JLA 2017b) 
Previous rodent model studies have investigated the use of anti-oxidants 
(vitamin E in the context of deficiency) (Cid, et al. 1992) and omega-3 fatty 
acids (Shoda, et al. 2015) in uveitic inflammatory disease and have found 
them to have an anti-inflammatory effect. Case studies of uveitis in 
association with coeliac disease have also shown an improvement in ocular 
inflammation on commencing a gluten-free diet (Klack, et al. 2011; Krifa, et 
al. 2010).  However, there is currently no large scale epidemiological or 
clinical trial evidence to support dietary and/or lifestyle modification 
interventions in uveitis. Since uveitis is an uncommon disease, it is likely to 
be difficult to gather study evidence of sufficient power to support a lifestyle 
intervention for patients with uveitis. AMD, however, is a common disease 
affecting older people and there is some evidence from large scale 
epidemiological studies (Hogg, et al. 2017; Wu, et al. 2015) and clinical trials 
of carotenoid antioxidant supplementation (Age-Related Eye Disease Study 
Research 2001) to support that a lifestyle intervention, in the form of 
improved diet might help to protect against disease progression. AMD shares 
some similarity with uveitis in that it is sight-threatening retinal disease with 
an immunological and/or inflammatory component to disease pathogenesis 
(Ambati, et al. 2013). In contrast to non-infectious uveitis, where 
corticosteroids and other immunosuppressive drugs might be used to 
manage inflammation and prevent sight loss, there is no currently no 
licenced drug treatment available to prevent sight loss in patients with dry 
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AMD. Due to the existence of some clinical evidence supporting dietary 
intervention in AMD (but not in uveitis) and the lack of any approved drug 
therapy for dry AMD, the decision was made to invite patients with dry AMD 
to attend a focus group study to find out their views on a potential lifestyle 
intervention. 
 
5.1.10 Interviews of patients with uveitis 
Interviews with uveitis patients were conducted at baseline, 2 month, 4 
month and 12 month patient visits. The format of the interview was 
unstructured and the duration of each interview was approximately 10 
minutes at the end of the clinical consultation. The interviews took place in a 
semi-private clinical cubicle space in a hospital tertiary centre for 
ophthalmology in London, UK. 
 
5.1.11 Focus group for patients with dry AMD 
Patients with dry AMD were invited to a focus group event to discuss the 
relationship between nutrition and eye health, and to find out their views on 
diet, in addition to a food tasting. The focus group took place in a public 
venue: a reserved area in POD, London, UK, which is part of a chain of 
‘healthy’ food outlets with a nutritionist-designed menu. The event began with 
an introduction to the focus group project followed by short presentations 
from NHS clinicians about the ‘AREDS study’ and about the evidence 
supporting the protective effects of the Mediterranean diet against the 
development of neurodegeneration and dementia.  
Participants were offered a selection of ‘healthy fast food’, provided by the 
venue, including: falafel, tomato and Lebanese red pepper wraps, salmon, 
cream cheese and wasabi sandwiches, a vegetable dipping platter, ‘slow 
burner’ salad with lentils and Turkish cheese, blackcurrant superfood pots, 
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bee pollen bircher yoghurts and handmade ‘superfruit booster’ bars (Figure 
70).  
 
Figure 70: Healthy food selection provided for focus group participants at POD City 
Road 
 
During the food tasting, there was a facilitated discussion to find out 
participants’ awareness of how diet and nutrition influence health and 
whether they would be interested in participating  This discussion was 
started with the following questions, informed by the ‘capability’, ‘opportunity’  
and ‘motivation’ components of the COM-B questionnaire (COM-B-Q) 
(Michie 2014) : 
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Capability: 
• Did you know about the links between diet/ lifestyle and AMD? Was 
this mentioned to you when you were diagnosed with your eye 
condition? 
• What sort of diet or foods do you think might be beneficial for the 
eyes? 
• Are you able to cook for yourself at home? 
• Is there anything that makes it difficult for you to cook or eat some of 
the foods we have talked about? 
 
Opportunity 
Would it help you to change your diet or eat a greater variety of healthy food 
if you: 
• Had more time to do it? 
• It was more affordable? 
• Had more people around you doing it? 
• Had more encouragement and/or support? 
 
Motivation: 
If there was option of participating in a free community project about ‘eating 
for eye health’, would you: 
• Feel that you wanted to do it? 
• Believe that I would be a good thing to do? 
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• Feel that you would be able to participate regularly? 
Participants were invited to share stories of how their eye problems 
have impacted their lifestyle and their thoughts on the changing trends in diet 
and nutrition. The focus group was concluded with a short survey, related to 
fruit and vegetable consumption habits, designed by an NHS dietician 
(Figure 71) and an evaluation of the event by the participants. The evaluation 
consisted brief questions displayed in large print a poster, on which 
participants were asked to stick a coloured post-it to indicate a ‘yes’ or ‘no’ 
response. The questions were as follows: 
• Did you enjoy the event? 
• Have you found the event useful? 
• Have you learned something new? 
• Did you like the food served? 
• Has this event made you think about what you eat at home? 
• Would you like to participate in a future community event to help you 
make changes your diet? 
 
Over the past 12 months... 
 
How often did you drink orange juice or grapefruit juice? Fresh or 
Bottled? 
NEVER  1-6 times per year  7-11 times per year  
1 time per month  2-3 times per month  1 time per week  
2 times per week  3-4 times per week  5-6 times per week  
1 time per day  2 or more per day  other  
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How often did you drink tomato juice or vegetable juice? Fresh or 
Bottled? 
 
How often did you eat COOKED greens (such as spinach, kale, collard, 
mustard, chard)? 
NEVER  1-6 times per year  7-11 times per 
year 
 
1 time per month  2-3 times per month  1 time per week  
2 times per week  3-4 times per week  5-6 times per 
week 
 
1 time per day  2 or more per day  other  
 
How often did you eat RAW greens (such as spinach, kale, collard, 
mustard, chard)? 
NEVER  1-6 times per year  7-11 times per 
year 
 
1 time per month  2-3 times per month  1 time per week  
2 times per week  3-4 times per week  5-6 times per 
week 
 
1 time per day  2 or more per day  other  
  
NEVER  1-6 times per year  7-11 times per year  
1 time per month  2-3 times per month  1 time per week  
2 times per week  3-4 times per week  5-6 times per week  
1 time per day  2 or more per day  other  
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How often did you eat carrots (fresh or frozen)? 
NEVER  1-6 times per year  7-11 times per 
year 
 
1 time per month  2-3 times per month  1 time per week  
2 times per week  3-4 times per week  5-6 times per 
week 
 
1 time per day  2 or more per day  other  
 
How often did you eat peppers? 
NEVER  1-6 times per year  7-11 times per 
year 
 
1 time per month  2-3 times per month  1 time per week  
2 times per week  3-4 times per week  5-6 times per 
week 
 
1 time per day  2 or more per day  other  
 
 
How often did you eat salad (lettuce)? 
NEVER  1-6 times per year  7-11 times per 
year 
 
1 time per month  2-3 times per month  1 time per week  
2 times per week  3-4 times per week  5-6 times per 
week 
 
1 time per day  2 or more per day  Other  
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How often did you eat oily fish (mackerel, salmon, sardines)? 
NEVER  1-6 times per year  7-11 times per 
year 
 
1 time per month  2-3 times per month  1 time per week  
2 times per week  3-4 times per week  5-6 times per 
week 
 
1 time per day  2 or more per day  other  
 
How often did you eat eggs? 
NEVER  1-6 times per year  7-11 times per 
year 
 
1 time per month  2-3 times per month  1 time per week  
2 times per week  3-4 times per week  5-6 times per 
week 
 
1 time per day  2 or more per day  other  
 
How often did you eat vegetable soup? 
NEVER  1-6 times per year  7-11 times per 
year 
 
1 time per month  2-3 times per month  1 time per week  
2 times per week  3-4 times per week  5-6 times per 
week 
 
1 time per day  2 or more per day  other  
 
Figure 71: ‘Food propensity’ survey for dry AMD patients 
 
5.1.12 Designing and piloting a complex behaviour change intervention  
A behaviour change intervention, with a focus on promoting a diet that could 
be beneficial to eye health, was designed according to the APEASE 
(Acceptability, Practicability, Effectiveness/cost-effectiveness, Affordability, 
 
 
248 
 
 
 
 
Safety/side-effects, Equity) criteria for designing and evaluating interventions 
and the COM-B (Capability, Opportunity , Motivation and Behaviour) model 
of behaviour change (Michie 2014; Michie, et al. 2011). This approach was 
used to inform the intervention because, in contrast to the social cognition 
models which focus on individual social cognitions, the COM-B model 
considers the individual within a system, involving the interacting model 
components (Capability, Opportunity, Motivation and Behaviour). 
Furthermore, it was identified that this was a ‘complex intervention’ (Craig, et 
al. 2008) due to the following study attributes: 
• The number and difficulty of behaviours required by those delivering 
or receiving the intervention 
• The number and variability of outcomes 
• The degree of flexibility or tailoring of the intervention permitted 
Evaluations of complex interventions are often undermined by problems of 
acceptability, compliance, delivery of the intervention, recruitment and 
retention, therefore it is advised that pilot studies are conducted to ascertain 
feasibility of the intervention (Craig, et al. 2008). With these principles in 
mind, a pilot ‘Eating for Eye Health’ community kitchens project was 
designed, as follows: 
Aim: To raise awareness of research that suggests nutrition may help 
protect against the progression of dry AMD and to encourage older people to 
regularly eat food that could support eye health. 
Method: A community kitchens intervention model adapted from a previous 
NHS-funded community kitchens project, designed to target older people 
from lower socio-economic backgrounds, in the London Borough of Islington 
to include recipes with a higher antioxidant content to benefit eye health and 
relevant support for individuals with vision impairment. 
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Evaluation/ outcome measure: Event attendance/ participant engagement, 
rating of food taste acceptability prepared and served at the event (2-point 
scale: ‘thumbs up’ or ‘thumbs down’ after eating food served at each course) 
and self-rating cooking skills and ‘confidence’ scores (1-10) rated before and 
after the event. 
 
5.2 Results 
 
5.2.1 Interviews with uveitis patients 
 
Patient 1, 23 year old female 
‘Uveitis has changed my life completely, where do I even start?’  
Patient 1 described a gradual deterioration in her vision over the few years 
since she had her diagnosis of uveitis, which more recently became ‘drastic’ 
due to the development of a secondary cataract. She said she can ‘barely 
make out anything from my left eye’, and said that it was causing her eye 
strain and headaches. She felt that the problems with her vision were 
affecting her work as a clerk at a local branch of a bank, and the cataract 
was making it difficult to focus and causing her making mistakes. Even 
though her line manager at work was aware of her eye condition, she felt 
anxious about asking for help and, even making eye contact with colleague, 
in case they could see that she had an eye problem. Although she was ‘not 
sure on the medical side of things’, she feels that being on 
immunosuppressive medication for 3 and a half years must have ‘impacted 
her body’ because she noticed weight gain, back pain and increased 
frequency of mood swings. She said that she also felt tired all the time and 
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lacked energy, ‘Who knows what risks it may carry for my future, such as 
pregnancy or even my normal health in the long run?’ 
 
Patient 7, 41 year old male 
‘If I don’t work, I don’t get paid’ 
Patient 7 was a self-employed builder who had previously been on long-term 
high dose corticosteroids for uveitis (which were not tapered according to 
usual clinical practice) at his local hospital in East London. This experience 
had left him with ‘bad teeth’ and a distrust of doctors. He reported severe 
mood swings, including ‘angry outbursts’, mainly directed at his family, when 
he was taking high doses of corticosteroids. His job involved frequent travel 
to different building sites around the UK, so he found it difficult to attend his 
hospital appointments, especially if it meant loss of wages. He had difficulties 
remembering to take his medication and picking up repeat prescriptions, 
however, he described receiving good support for medication compliance 
from his wife, who was a registered nurse. 
 
 
Patient 12, 18 year old male 
‘My mates went off and got jobs but [because of uveitis], I haven’t been able 
to get one.’ 
Patient 12 was a long-term patient of the uveitis clinic, who had, until 
recently, been attending the paediatric clinic. His parents were separated 
and he lived mostly with his father. When he stayed with his mother, he said 
there seemed to be more confusion over his medication dosage and he said 
that she would ‘sometimes forget to take him to hospital appointments’. He 
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said that he did not apply for work experience because he was worried about 
uveitis flare-ups and also because when ‘I’m on steroids, my face swells up 
like a chipmunk’. He said he would like a treatment that would make the 
uveitis ‘go away for good’, so he could apply for an apprenticeship as an 
electrician. 
 
Patient 13, 32 year old female 
‘Trying to balance everything is difficult but uveitis makes it worse.’ 
Patient 13 developed a post-partum flare up of uveitis. When she decided to 
return to her job as an estate agent she said that, ‘even with family support, I 
struggled’ to manage the demands of working, caring for a young baby and 
managing her uveitis. She disliked the weight gain she associated with oral 
corticosteroids but felt that they were more effective than the intraocular 
steroid treatment she had received in the past. After returning to work, she 
felt nervous about asking her employer for time off to attend hospital 
appointments as she felt this made ‘a bad impression’. 
 
5.2.2 Focus group for AMD patients 
The food intake questionnaire results indicated that the study participants 
had a fair intake of vegetables with 12 (100%) of focus participants reporting 
that they ate cooked greens, raw greens, carrots (raw and cooked), peppers 
and salad at least once per week (mean: twice a week, range: 1-6 times per 
week). The mean frequency of egg consumption was twice a week (range: 
twice a month to 3-4 times per week). However, the intake of fresh or bottled 
fruit juice, vegetable juice, vegetable soup and oily fish was generally lower, 
with 1-2 per month being the most frequent response. Analysis of the group 
discussion highlighted some of the ‘barriers’ that patients with visual 
impairment experienced towards making healthy dietary changes and, 
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particularly, cooking for themselves. These included: a lack of clear, practical 
information about nutrition from health professionals (fruit/ vegetable juice 
was thought to be unhealthy due to its sugar content, whereas the 
bioavailability of  micronutrients was not considered); confusing health 
information in the media; the difficulties of cooking with visual impairment; 
lack of confidence in preparing particular foods, such as fish, and using 
unfamiliar ingredients; fear of having to ask for help from others; and, 
significantly, the sense of isolation, hopelessness or even, shame, which can 
be brought up by the experience of having an untreatable progressive sight-
threatening eye condition. Further qualitative analysis of  the focus group 
discussion, using the COM-B framework, identified that behaviour 
intervention should target increasing participants’ capability and opportunity. 
The data suggested that the group was very motivated, so the motivation 
domain was not targeted in the intervention. The COM-B diagnostic tool 
(Michie 2014) was then used to identify what needed to change in order for 
focus group participants to make the behaviour change towards healthy 
cooking and eating. Targeting physical and psychological capability 
suggested that interventions which aimed to increase participants 
knowledge, skills and self-efficacy (confidence) regarding eating for eye 
health, in assistance to providing individualised physical assistance might be 
effective in changing behaviour. Targeting opportunity suggested that 
interventions that would increase social opportunity, provide the necessary 
materials at a low cost and would support participants in the behaviour 
change would be effective. A telephone consultation with the Macular 
Society, a patient charity which ‘supports those with macular degeneration, 
their families and their carers’ helped to guide how physical assistance might 
be offered to the project participants. Based on this advice, participants who 
had registered their interest in a further project event were contacted via 
email to ask them whether they would like to discuss any particular 
expectations or personal needs regarding their attendance of a further event, 
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for example, a cookery day.  No registered participants indicated any special 
needs in this area. Therefore, the evidence from the focus group, the COM-B 
model and consultation with a patient charity informed the design of a 
community cookery day, to which the focus group participants were invited. 
 
5.2.3 Community cookery day 
Community Cookery Day was held at St Luke's Community Centre, near 
Moorfields Eye Hospital, London, UK. 8 out of 12 participants from the focus 
group attended, in addition to two further participants. A three-course menu 
of ‘Easy Recipes for Eye Health’ was devised, which included: butternut 
squash, turmeric and brazil nut soup; salmon fillet with red onion and 
peppers (Figure 74); baked sweet potatoes; spinach, orange and linseed 
salad; and apple and blackberry sponge pudding.  The event was opened 
with a ‘food bingo’ icebreaker activity (Figure 72), an explanation about how 
the day would run, and a health and safety briefing about basic food hygiene.  
 
 
254 
 
 
 
 
 
Figure 72: Food bingo icebreaker activity 
 
Participants were informed about the importance of consuming a variety of 
colourful fruits and vegetables, how to prepare food to optimise absorption of 
nutrients and about the importance of bowel health in the absorption of 
nutrients from food.  
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Figure 73: Chopping vegetables at the cookery day 
 
The project participants showed a high level of engagement with the cookery 
activity, which involved preparing the specific part of the menu assigned to 
them (Figure 73), for example, the soup or the salad. Whilst the main course 
(Figure 74) was cooking in the oven, there was a ‘food tasting’ activity, which 
featured a selection of so-called ‘superfoods’, for example sauerkraut, dark 
chocolate with raw cocoa nibs, and merlot grape juice. A dietician explained 
some of the science behind the ‘superfoods’ and answered the participants’ 
questions. When the food was ready, participants sat down together to enjoy 
the meal, with the dietician explaining the intended health benefits of the 
ingredients whilst each course was served. Participants were asked to rate 
each course of the meal by holding up a ‘thumbs up’ or ‘thumbs down’ sign 
to indicate taste acceptability of the food.  
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Figure 74: Main course meal of salmon fillet with red onion and peppers at the 
cookery day 
 
The post-event feedback was very positive and with all participants reporting 
an increase in confidence levels after the cookery session, and 8 out of 10 
participants reporting a confidence level of 7 or above about cooking for 
themselves with the recipes provided.  ‘Eat Colourful!’ was the project’s 
simple take home message. The attendees said that they particularly 
enjoyed the sense of community with others who shared their experiences of 
coping with dry AMD. Therefore, the pilot intervention appeared to be well 
received and successful in providing opportunity for healthy behaviour 
change and increasing participants’ self-efficacy and capability (confidence) 
in making the change. The event was recorded to create a promotional video 
for the project and a summary information booklet was created from the 
project findings and recipes for wider distribution. 
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5.3 Discussion 
This study was undertaken to investigate the perspectives of patients with 
sight-threatening retinal disease. The qualitative analysis of perspectives of a 
small case series of patients with uveitis revealed some common themes, 
which included dissatisfaction with the side effects and long effects of oral 
immunosuppression, unpredictability of the disease flare ups, including the 
negative impact that this had on social relationships, childcare, work life and 
financial income and the impact of sight loss. These findings confirmed some 
of the themes of the JLA PSP on ocular inflammatory disease (JLA 2017b). It 
also confirms recent observations that,  
‘Intermediate uveitis, posterior uveitis, and panuveitis require systemic 
therapies more than perhaps any other set of ophthalmic conditions, with a 
significant potential for medication adverse effects. The need for monitoring 
can itself be a significant burden on patients, which affects their functionality 
and sense of wellbeing… [and] noninfectious intermediate uveitis, posterior 
uveitis, and panuveitis differ from other common eye conditions, such as 
cataract, glaucoma, or macular degeneration, in that they affect a younger 
population that is often still of working or school age. These individuals are 
not merely worried about their vision, but also about remaining capable of 
providing for themselves and their families.’ (Burkholder and Ramulu 2017) 
The pilot ‘Eating for Eye Health’ community kitchens described an approach 
to supporting dietary change for eye health and general wellbeing in 
participants with a diagnosis of dry AMD. Depth interviews with project 
participants indicated that the symptoms of dry AMD are insidious, and may 
start with difficulty in reading small print or writing. In the early phase, 
patients may attribute these difficulties to the wrong glasses prescription or 
even brush them off as a normal part of ‘getting older’. The diagnosis of an 
untreatable and progressive sight condition was described as ‘quite a shock’, 
which left affected individuals at a loss as to how to cope. In the clinical 
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setting of an NHS hospital, doctors are often limited to giving lifestyle advice 
about eye protection or explaining that dry AMD may further progress to the 
wet form of AMD. Treatment is available for the wet form of AMD (but not the 
dry form, as stated earlier) through regular drug injections to the eye, which 
often improve vision but are not curative.  For many, this is appeared to be a 
frustrating situation.  Clinicians are conscious of the adverse impact of AMD, 
but sometimes fall short of communicating advice that might help support 
patients through the aftermath of this diagnosis. Patients do not always feel 
confident in speaking up about their concerns, particularly in a busy clinic. 
Those with untreatable eye conditions, such as dry AMD, are often 
discharged from hospital follow-up, with advice to self-monitor their condition 
and to ‘come back if it gets worse’. This approach may leave patients feeling, 
at best, anxious and, at worst, literally and metaphorically ‘left in the dark’ by 
healthcare professionals. Raising awareness of the research suggesting that 
lifestyle modifications might benefit eye health is, therefore, important. 
However, simply passing on an information leaflet to patients is not an 
adequate solution; it is also crucial to offer support and encouragement to 
patients in implementing these changes into their lives, particularly in the 
context of an eye disease that causes progressive deterioration of vision. 
Evidence from large clinical trials suggests that antioxidant vitamin 
supplements may help protect against the progression of AMD (Age-Related 
Eye Disease Study Research 2001) and it known that these key nutrients are 
found in a wealth of brightly coloured foods, such as red peppers, butternut 
squash, kale and summer berries, all of which have benefits that extend 
beyond AMD. Thus, following a successful bid for funding and support from 
UCL Culture, the ‘Eating for Eye Health’ engagement project was born. 
Through supporting patients in cooking and eating antioxidant-rich food via a 
community kitchens project, the project created an environment conducive to 
behaviour change for eye health.  
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There is a tendency for health care professionals to engage with patients on 
their own terms, rather than the patients’ terms. The ‘Eating for Eye Health’ 
project highlighted the importance of team-work and communication in 
creating successful partnerships between healthcare professionals, patients 
and local communities. The scientific evidence to support nutritional 
approaches to eye health is emerging at a time when novel approaches to 
nutrition and diet are being brought to attention of the public, through popular 
media. Whilst information in newspapers, magazines or on the internet might 
be misleading or inaccurate, it is readily available and communicated in an 
understandable way to the general public. It was intended that ‘Eating for 
Eye Health’ would facilitate connection and two-way dialogue between health 
professionals with specialist knowledge and those who actually have 
experience of living with dry AMD.  
It is well recognised that social engagement improves resilience and 
supports healthy aging (Mendes de Leon 2005; Ozbay, et al. 2007). The 
contemporary concept of ‘positive health’, which takes into account an 
individual’s psycho-social wellbeing, in addition to their physical health and 
body functioning, may be addressed through community engagement. The 
National Institute for Health and Care Excellence (NICE) has noted that, 
‘Community engagement is a highly complex area with several important 
purposes. These include empowering people within communities to gain 
more control over their lives and to play a part in decisions that affect their 
health and wellbeing’(NICE March 2016). 
A practical way to operationalise these concepts within the NHS is through 
‘social prescribing’ (Brandling and House 2009; Kimberlee 2016). This is 
sometimes referred to as community referral and is a means by which health 
professionals, in the primary care setting, may refer patients to a range of 
local, non-clinical services. Through recognising that peoples’ health is 
determined primarily by a range of social, economic and environmental 
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factors, social prescribing seeks to address peoples’ wider health needs in a 
more integrated way. It may also support individuals in feeling a greater 
sense of agency regarding their health conditions. Holistic social prescribing 
has been shown to be beneficial to supporting patients’ health and wellbeing, 
as well as reducing the demands on GPs and hospitals (Kimberlee 2016; 
Polley M.J. 2017). Evidence suggests that patients with AMD are under-
consuming nutrients considered to be useful for their condition and that 
individuals, who are able to cook a hot meal, consume significantly more 
lutein and zeaxanthin than those who are not able to (Stevens, et al. 2015).  
It is therefore essential to design more effective dietary education and 
dissemination methods for people with, and at risk of, AMD (Stevens, et al. 
2015). The community kitchens model, described here, is a specific example 
of how social prescribing might be applied in communities to address 
potential nutritional deficiencies, which may detrimentally influence clinical 
outcomes for eye disease. Older people with visual impairment are at 
increased risk of social isolation, loneliness and psychological distress 
(Matthews, et al. 2017), which are, in turn, associated with a greater risk of 
all-cause mortality (Russ, et al. 2012; Steptoe, et al. 2013). Study findings 
suggest that it is possible to reduce loneliness by using educational 
interventions focused on social networks maintenance and enhancement 
(Cohen-Mansfield and Perach 2015). Community kitchens have the potential 
to improve social interactions and nutritional intake of participants and their 
families (Herbert, et al. 2014; Iacovou, et al. 2013). Overall, evaluation 
findings from Eating for Eye Heath were in keeping with published evidence 
that community kitchens programmes have positive effects on participants' 
cooking skills confidence and reduce barriers of cost, waste, and knowledge 
(Garcia, et al. 2017) 
Interestingly, ophthalmology patients from a previously published focus 
group study emphasized their expectations related to communication and 
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interpersonal relationships over and above technical medical interventions, 
for example, prescription medication and diagnostic testing (Dawn, et al. 
2003). As a result, there is a growing appreciation amongst eye-care 
professionals that the patient is uniquely placed to understand the impact of 
disease and can use that position to transform ophthalmic care at the 
individual and collective level, from research to delivery of care (Dean, et al. 
2017). Numerous initiatives exist to support patient and public involvement 
(PPI) in eye research, such as the JLA PSP which helped to inform the 
research in this thesis (JLA 2017a). A public engagement (PE) approach, 
however, simultaneously captures the patient and the public voice in its 
inherent appreciation that patients are part of the ‘public’ community. PE 
seeks to facilitate public conversations which are not wholly shaped by a 
‘research agenda’, as is often the case in PPI. A combination of these 
approaches may be valuable in capturing patient perspectives of disease 
and developing patient-reported outcomes. 
In summary, although the two groups with uveitis and AMD shared the 
experience of sight-threatening non-infectious retinal disease, they did differ 
considerably in subject age (the group with AMD being considerably older), 
disease characteristics and in how the disease impacted them. For the 
patients with uveitis, who were of working age, inflammatory flare-ups 
caused a significant disruption to working life and many of treatment side 
effects were unacceptable to them. The older patients with AMD, on the 
other hand, reported more symptoms of psychological distress related to the 
progressive, incurable nature of their condition and fear of isolation and/or 
loss of independence. However, the success of a non-clinical intervention in 
improving participant wellbeing and the observed positive effects of social 
engagement, suggest that there is value in investigating non-clinical 
interventions to support health and/or wellbeing of patients with sight-
threatening uveitis. 
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Chapter 6 Summary Discussion, Study Limitations 
and Future Directions 
 
The aims of this thesis were to individualise management of patients with 
non-infectious uveitis by investigating potential differences in clinical 
phenotypes of non-infectious uveitis, immunophenotyping of clinical 
remission of sight-threatening non-infectious uveitis and patient perspectives 
of sight-threatening retinal disease. 
Chapter 2 was a clinical epidemiological survey to determine whether there 
were clinical phenotypic differences in multifocal choroiditis (MFC) and 
punctate inner choroidopathy (PIC), two subtypes of non-infectious uveitis 
with similar clinical characteristics, when classified using a standardised 
approach. Following classification as PIC or MFC, statistically significant 
differences were found in age, gender and refractive error (spherical 
equivalent). Qualitative analysis of OCT imaging did not reveal any 
significant differences in the anatomical involvement of lesions between PIC 
and MFC. It was concluded that the data supported some stable phenotypic 
differences, with PIC demonstrating a greater predilection for young, myopic 
women and CNV development than MFC. These could represent important 
differences in pathophysiology and have relevance for individualised 
management.  
Despite efforts to standardise the classification, many of the clinical 
measurements retained a level of subjectivity. Although the sample size was 
the largest of previous studies of eyes with these conditions, it is still small 
compared to studies of more common eye conditions. The number of 
subjects/ eyes imaged during an active phase of disease activity was low, 
compared to those imaged during inactive phases. These numbers were 
similar for both MFC and PIC, which is more likely to reflect infrequent 
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disease activity during the observation period, than challenges in the 
detection and imaging of disease activity (which would be more plausible for 
PIC than MFC). Mean lesion size in this study was based on AF images. Due 
to the clear delineation of lesion borders on AF images, a standardised 
image scale and a higher number of images available for analysis, this 
meant that the measurements taken had greater reliability and validity than 
measurements taken from colour fundus photos. However, given that areas 
of chorioretinal atrophy may enlarge over time in myopic eyes, retrospective 
clinical differentiation between these two diseases, based on lesion size, 
remains challenging. Evidence of clinical inflammation, required for our sub-
classification of MFC and PIC, was determined from retrospective review of 
clinical documentation and imaging. Since inflammation (if it occurs in MFC) 
is episodic, it is possible that this may not have been captured during a clinic 
visit. Nevertheless, the fact that the MFC group had a higher proportion of 
subjects with ERMs supports a higher prevalence of intraocular inflammation 
in this group and suggests a reasonable level of accuracy in our disease 
classification according to inflammation. In our study, a standardised manual 
caliper measurement approach was used to measure choroidal thickness, 
although we did not adjust for age, myopia or CNV. Since we showed that 
PIC was associated with a significantly higher proportion of subjects with 
myopia, CNV and a higher degree of myopic refractive error than MFC, the 
influences of disease classification and inflammatory activity on choroidal 
thickness were likely underestimated.  
In summary, the phenotypical differences that we identified between PIC and 
MFC should be further investigated, in conjunction with clinical imaging and 
pathophysiological data, in future studies.  In particular, it would be useful to 
obtain more high resolution SD-OCT and EDI-OCT images and wide field 
fundus photos during active disease phases and to monitor disease 
progression over a longer follow-up period. Since we are entering an era of 
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‘personalised’ or ‘stratified’ approaches to disease management, it seems 
appropriate to sub-classify idiopathic non-infectious uveitis syndromes, 
where the evidence supports this, because it may have implications for 
disease management. Individualised treatment approaches are, in theory, 
much more favourable than standard “blockbuster” systemic 
immunosuppression with their associated morbidity. Going forward, it is 
suggested that in order to best utilise the increasing range of targeted 
immune modulating drugs coming to market, it is important to have non-
infectious uveitis classifications, which are supported by clinical evidence, in 
addition to clinician opinion. 
In the laboratory studies described in Chapters 3 and 4 laboratory studies, 
the aim was to improve the phenotyping of sight-threatening non-infectious 
uveitis to allow more individualised patient management, with a focus on 
immunophenotypic analysis of patients in clinical remission. It was 
investigated whether there is a peripheral blood immunophenotype 
associated with sustained clinical remission, using a prospective recruitment 
of 60 subjects (50 intermediate, posterior and panuveitis patients and 10 
control subjects). The frequency of CD4+CD25+FoxP3+ Treg, TIGIT+ Treg, T-
bet+ Treg and the ratio of Treg to Th1 was significantly higher in quiescent 
patients in long term drug-free remission compared to patients with active 
uveitic disease. Treg from a patient in clinical remission demonstrated a high 
level of in vitro suppressive function compared to Treg from control subject 
and Treg from a patient with untreated active disease. Targeted epigenetic 
CpG methylation analysis of PBMCs from selected patients and controls, 
using a Next Generation Sequencing (NGS) bisulphate sequencing approach 
showed significantly lower methylation levels at FOXP3 TSDR, FOXP3 
Promoter and TIGIT sites and higher levels of RORC methylation in patients 
in clinical remission compared to those with active disease. Bivariate 
correlations demonstrated that DNA methylation was associated with the 
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observed levels of TIGIT+ Treg and that this in turn influenced the cytokine 
microenvironment. Clinical remission was associated with significantly higher 
serum levels of TGF-β and IL-10, which positively correlated with Treg levels, 
and lower serum levels of IFNγ, IL-17A and IL-22 compared to patients with 
active disease. 
It was shown that duration of previous oral immunosuppressive treatment 
was the strongest predictor of methylation of the FoxP3 TSDR, which was 
significantly associated with clinical remission in sight-threatening uveitis and 
that that relationship was still significant after adjusting for subject age. 
Furthermore, peripheral blood TIGIT levels, but not subject age, were a 
significant predictor of clinical remission in sight threatening non-infectious 
uveitis. TIGIT levels had high sensitivity (92%) but low specificity (62%) and, 
therefore, a high false positive rate when used as a predictor of clinical 
remission of sight-threatening non-infectious uveitis in the study population of 
uveitis patients. Whereas a high false positive rate for a screening test for 
disease (where subjects without the disease may falsely test positive) may 
be acceptable in certain situations, it is a significant limitation in 
consideration of TIGIT+ as a biomarker for clinical remission, because there 
is a high likelihood that it may indicate that a patient is clinical remission 
when they actually have active disease. Use of TIGIT+ Treg, as a single 
surrogate marker for clinical remission of uveitis may not add much value to 
current clinical practice, wherein clinical remission is determined through 
clinical assessment of disease activity. It is also possible that the calculated 
test sensitivity, specificity, false positive and negative rates could have been 
skewed by the overweighting of the sample towards remission patients rather 
than active patients. TIGIT levels explained almost half of the variance 
observed in the model of clinical remission, but there may be other clinically 
relevant factors, not accounted for in the model, which were also influencing 
clinical remission. These would need to be further investigated in order to 
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develop better models for predicting clinical remission for individual patients, 
which could augment standard clinical assessment of patients. 
The total number of subjects recruited to this study (n=60) represents one of 
the largest sample sizes of published clinical immunology studies of sight-
threatening non-infectious uveitis. However, the group was weighted towards 
subjects in clinical remission, which limits the validity of the study findings. 
The thirty-seven patients in clinical remission recruited to the study, however, 
demonstrated a good clinical ocular response to immunosuppressive therapy 
given systemically, supporting the fact that systemic Treg and their 
associated microenvironment influence ocular immunity and that peripheral 
blood biomarkers have utility in monitoring ocular disease. T-cell 
immunophenotyping by flow cytometry was performed on freshly isolated 
subject PBMCs (within 4 hours of venepuncture) but additional intraocular 
sampling was not undertaken as part of this study. Although not easily 
feasible, a further study could validate these findings in uveitic ocular tissue 
and/ or vitreous humour. Phenotypic analysis of Treg, Th1 and Th17 
subtypes was based on ‘master transcription factor’ expression, with 
prospective intracellular cytokine analysis only in selected subjects with 
active disease, followed up over a 12-month period. An in-depth analysis of 
intracellular cytokine production and methylation at signature cytokine loci 
could be considered for a future study. The number of Treg functional assays 
that could be performed as part of this study was limited by the remaining 
PBMC numbers after the immunophenotypic analysis. Since Treg are a ‘rare’ 
cell population, further studies would require a larger blood sample (than 
30ml) to allow functional assays to be performed alongside 
immunophenotypic analysis. Therefore, functional study findings should 
ideally be confirmed using larger blood samples in more subjects. 
The results of this study provide evidence that TIGIT has utility as a marker 
of functional Treg for immunomodulatory therapy, and that low levels of 
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TIGIT may be a biomarker for increased risk of disease relapse. This could 
help to individualise patient treatment by assisting in determining whether 
systemic immunosuppressive drugs are inducing functionally suppressive 
Treg, and helping to inform clinical decision making. For example, to assist in 
determining whether the patient is in biological remission, in addition to 
having clinically inactive disease, and whether immunosuppressive treatment 
can be tapered. Finally, these data are relevant to the recent interest in 
quantitative identification and isolation of viable, functional Treg for 
downstream clinical purposes, which includes their generation ex vivo for 
immunomodulating therapies (Foussat, et al. 2017; Horwitz, et al. 2004). 
TIGIT may prove to be a useful biomarker for identifying functional Treg for 
these therapies. Treg-based treatments may be a preferable option for 
patients with sight-threatening non-infectious uveitis because they aim to 
specifically enhance naturally-occurring mechanisms by which an individual 
regulates inflammation, at the immune cell level, and they potentially avoid 
the wide range of systemic side effects of conventional immunosuppression. 
However, further investigation of this is required. 
The aim of the public engagement and qualitative analysis work described in 
Chapter 5 was to engage with patients who have sight-threatening non-
infectious retinal disease (which does not have curative treatment) and 
identify suitable interventional approach(es) which could serve to increase 
sense of agency and/or self-efficacy of affected individuals, in order to 
potentially change the course of the disease.The qualitative analysis of 
perspectives of a small case series of patients with uveitis revealed some 
common themes, which included dissatisfaction with the side effects and 
long effects of oral immunosuppression, unpredictability of the disease flare 
ups, including the negative impact that this had on social relationships, 
childcare, work life and financial income and the impact of sight loss. These 
findings confirmed some of the themes of the JLA PSP on ocular 
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inflammatory disease (JLA 2017b) and could help to inform patient-reported 
outcomes, which measure treatment success in the patient’s terms rather 
than the clinician’s.  
The pilot behaviour change intervention appeared to be well received and 
successful in providing opportunity for healthy behaviour change and 
increasing participants’ self-efficacy and capability (confidence) in making the 
change. Public engagement helps to foster support, within, and, between, 
communities, due to its preferential focus on the interface between research 
and wider society.  Successful engagement with the dry AMD community 
meant Eating for Eye Health was not only a project about engaging 
participants with research on how to ‘eat right for their sight’ but it also 
opened a conversation regarding their unmet needs for support. Community 
kitchens methodology in PE is likely to contribute a unique perspective on 
the interplay between food, communities and the health of individuals, the 
project has the potential to contribute to the growing body of evidence 
suggesting that community engagement and social prescribing can positively 
impact health and wellbeing.  Through the creation of a community, it is also 
hoped that awareness will be raised about AMD, which could attract public 
funding to this area and facilitate engaged research into improving clinical 
outcomes, including positive health. 
Limitations to this study include the fact that it consisted of a small case 
series and that the findings were subjective and, therefore, not necessarily 
applicable to a wider population. Community kitchens interventions are 
potentially expensive and challenging to scale. This is relevant because the 
success of the project described in Chapter 5 appeared to be related, at least 
in part, to the small group size, which allowed participants to be receive more 
individual attention. Individuals who participate in studies and engagement 
projects tend to be of higher socio-economic status, more motivated to 
change behaviour and to improve their health than those who do not 
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participate in studies, which potentially perpetuates health inequalities. There 
is also the challenge of measuring the impact of the lifestyle intervention on 
altering the course of a disease, which requires precise surrogate endpoints, 
and are likely to require monitoring over a long period of time in order to see 
any effect (often longer than required with an drug intervention).  The next 
stage of the work could involve a ‘needs assessment’ of different patient 
populations with visual impairment; an investigation into how to expand the 
community kitchens project and/or improve outreach to disadvantaged 
groups; or an evaluation of social, economic and health impacts of 
community kitchens and social prescribing on participants.  
In summary, this thesis demonstrates that a mixed methods approach, where 
qualitative methodologies were explored alongside more conventional 
biomedical quantitative methods, could have value in developing 
individualised patient-centred therapeutic approaches for sight-threatening 
non-infectious uveitis. 
 
  
 
 
270 
 
 
 
 
References 
Abraham, C. & Sheeran, P. 
 2005 Health belief model. In Predicting Health Behaviour: Research and Practice 
with Social Cognition Models 
2nd edition: Buckingham UK: Open University Press. 
Abraham, C., S. Clift, and P. Grabowski 
 1999 Cognitive predictors of adherence to malaria prophylaxis regimens on 
return from a malarious region: a prospective study. Soc Sci Med 48(11):1641-54. 
Abraham, C., and S. Michie 
 2008 A taxonomy of behavior change techniques used in interventions. Health 
Psychol 27(3):379-87. 
Agarwal, R. K., and R. R. Caspi 
 2004 Rodent models of experimental autoimmune uveitis. Methods Mol Med 
102:395-419. 
Agarwal, R. K., P. B. Silver, and R. R. Caspi 
 2012 Rodent models of experimental autoimmune uveitis. Methods Mol Biol 
900:443-69. 
Age-Related Eye Disease Study Research, Group 
 2001 A randomized, placebo-controlled, clinical trial of high-dose 
supplementation with vitamins C and E, beta carotene, and zinc for age-related 
macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 
119(10):1417-36. 
Ahnood, D., et al. 
 2017 Punctate inner choroidopathy: A review. Surv Ophthalmol 62(2):113-126. 
Akbar, Arne N., et al. 
 2007 The dynamic co-evolution of memory and regulatory CD4+ T cells in the 
periphery. Nature Reviews Immunology 7:231. 
Akimova, T., et al. 
 2011 Helios expression is a marker of T cell activation and proliferation. PLoS 
One 6(8):e24226. 
Allan, S. E., et al. 
 2007 Activation-induced FOXP3 in human T effector cells does not suppress 
proliferation or cytokine production. Int Immunol 19(4):345-54. 
Allen, M., and J. Bellstedt 
 1996 Attitudes toward blindness and blind people: what do we believe? Abnf j 
7(3):72-7. 
Amadi-Obi, A., et al. 
 
 
271 
 
 
 
 
 2007 TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and 
inhibited by IL-27/STAT1. Nat Med 13(6):711-8. 
Ambati, Jayakrishna, John P. Atkinson, and Bradley D. Gelfand 
 2013 Immunology of age-related macular degeneration. Nature reviews. 
Immunology 13(6):438-451. 
Amer, R., and N. Lois 
 2011 Punctate inner choroidopathy. Surv Ophthalmol 56(1):36-53. 
Armitage, C. J., and M. Conner 
 2001 Efficacy of the Theory of Planned Behaviour: a meta-analytic review. Br J 
Soc Psychol 40(Pt 4):471-99. 
Atan, D., et al. 
 2011 Punctate inner choroidopathy and multifocal choroiditis with panuveitis 
share haplotypic associations with IL10 and TNF loci. Invest Ophthalmol Vis Sci 
52(6):3573-81. 
Azjen, I.  
 1991 The Theory of Planned Behaviour. Organizational Behavior and Human 
Decision Processes 50:179-211. 
Baecher-Allan, C., et al. 
 2001 CD4+CD25high regulatory cells in human peripheral blood. J Immunol 
167(3):1245-53. 
Baltmr, A., S. Lightman, and O. Tomkins-Netzer 
 2014 Examining the choroid in ocular inflammation: a focus on enhanced depth 
imaging. J Ophthalmol 2014:459136. 
Bandura, A. 
 1977 Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 
84(2):191-215. 
— 
 2000 Health promotion from the perspective of social cognitive theory. In 
Understanding and changing health behaviour. C.A. P. Norman, & M. Conner, ed. 
Pp. 299-339. Reading, UK: Harwood. 
Baron, U., et al. 
 2007 DNA demethylation in the human FOXP3 locus discriminates regulatory T 
cells from activated FOXP3(+) conventional T cells. Eur J Immunol 37(9):2378-89. 
Barry, Robert J., et al. 
 2014 Pharmacotherapy for uveitis: current management and emerging therapy. 
Clinical Ophthalmology (Auckland, N.Z.) 8:1891-1911. 
Basdeo, S. A., et al. 
 
 
272 
 
 
 
 
 2015 Polyfunctional, Pathogenic CD161+ Th17 Lineage Cells Are Resistant to 
Regulatory T Cell-Mediated Suppression in the Context of Autoimmunity. J 
Immunol 195(2):528-40. 
Becker, C. M., et al. 
 2009 Validity evidence for the Salutogenic Wellness Promotion Scale (SWPS). Am 
J Health Behav 33(4):455-65. 
Becker, Craig M., et al. 
 2015 The Salutogenic Wellness Promotion Scale for Older Adults. American 
Journal of Health Education 46(5):293-300. 
Bending, David, et al. 
 2014 Hypomethylation at the Regulatory T Cell–Specific Demethylated Region in 
CD25(hi) T Cells Is Decoupled from FOXP3 Expression at the Inflamed Site in 
Childhood Arthritis. The Journal of Immunology Author Choice 193(6):2699-2708. 
Bennett, C. L., et al. 
 2001 The immune dysregulation, polyendocrinopathy, enteropathy, X-linked 
syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27(1):20-1. 
Benoist, C., and D. Mathis 
 2012 Treg cells, life history, and diversity. Cold Spring Harb Perspect Biol 
4(9):a007021. 
Bhat, J., et al. 
 2017 Stochastics of Cellular Differentiation Explained by Epigenetics: The Case of 
T-Cell Differentiation and Functional Plasticity. Scand J Immunol 86(4):184-195. 
Blaxter, Mildred 
 1990 Health & Lifestyles: Routledge. 
Bloch-Michel, E., and R. B. Nussenblatt 
 1987 International Uveitis Study Group recommendations for the evaluation of 
intraocular inflammatory disease. Am J Ophthalmol 103(2):234-5. 
Brandling, Janet, and William House 
 2009 Social prescribing in general practice: adding meaning to medicine. The 
British Journal of General Practice 59(563):454-456. 
Brown, J., Jr., and J. C. Folk 
 1998 Current controversies in the white dot syndromes. Multifocal choroiditis, 
punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ocul 
Immunol Inflamm 6(2):125-7. 
Brown, J., Jr., et al. 
 1996 Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, 
and the diffuse subretinal fibrosis syndrome. Ophthalmology 103(7):1100-5. 
Brunkow, Mary E., et al. 
 
 
273 
 
 
 
 
 2001 Disruption of a new forkhead/winged-helix protein, scurfin, results in the 
fatal lymphoproliferative disorder of the scurfy mouse. Nature Genetics 27:68. 
Bunn, J. Y., et al. 
 2002 Factors influencing intention to obtain a genetic test for colon cancer risk: a 
population-based study. Prev Med 34(6):567-77. 
Burkholder, B. M., and P. Y. Ramulu 
 2017 Improving more than just vision in noninfectious uveitis. JAMA 
Ophthalmology 135(6):518-519. 
Calleja, S., et al. 
 2012 Adalimumab specifically induces CD3(+) CD4(+) CD25(high) Foxp3(+) 
CD127(-) T-regulatory cells and decreases vascular endothelial growth factor 
plasma levels in refractory immuno-mediated uveitis: a non-randomized pilot 
intervention study. Eye (Lond) 26(3):468-77. 
Carpenter, C. J. 
 2010 A meta-analysis of the effectiveness of health belief model variables in 
predicting behavior. Health Commun 25(8):661-9. 
Caspi, R. 
 2008 Autoimmunity in the immune privileged eye: pathogenic and regulatory T 
cells. Immunol Res 42(1-3):41-50. 
Caspi, R. R. 
 2010 A look at autoimmunity and inflammation in the eye. J Clin Invest 
120(9):3073-83. 
— 
 2011 Understanding autoimmune uveitis through animal models. The 
Friedenwald Lecture. Invest Ophthalmol Vis Sci 52(3):1872-9. 
— 
 2014 Understanding autoimmunity in the eye: from animal models to novel 
therapies. Discov Med 17(93):155-62. 
Castiblanco, Claudia, and C. Stephen Foster 
 2014 Review of Systemic Immunosuppression for Autoimmune Uveitis. 
Ophthalmology and Therapy 3(1-2):17-36. 
Channa, R., et al. 
 2012 Characterization of macular lesions in punctate inner choroidopathy with 
spectral domain optical coherence tomography. J Ophthalmic Inflamm Infect 
2(3):113-20. 
Chatila, Talal A., et al. 
 2000 JM2, encoding a fork head–related protein, is mutated in X-linked 
autoimmunity–allergic disregulation syndrome. The Journal of Clinical Investigation 
106(12):R75-R81. 
 
 
274 
 
 
 
 
Chavele, K. M., and M. R. Ehrenstein 
 2011 Regulatory T-cells in systemic lupus erythematosus and rheumatoid 
arthritis. FEBS Lett 585(23):3603-10. 
Chen, L., et al. 
 2008 Diminished frequency and function of CD4+CD25high regulatory T cells 
associated with active uveitis in Vogt-Koyanagi-Harada syndrome. Invest 
Ophthalmol Vis Sci 49(8):3475-82. 
Chen, S. N., and J. F. Hwang 
 2014 Ocular coherence tomographic and clinical characteristics in patients of 
punctuate inner choroidopathy associated with zonal outer retinopathy. Ocul 
Immunol Inflamm 22(4):263-9. 
Cid, L., et al. 
 1992 Anti-inflammatory effects of vitamin E on experimental lens-induced 
uveitis. Int Ophthalmol 16(1):27-32. 
Clare, Anthony 
 1980, 2001 Psychiatry in Dissent: Routledge, Tavistock Press. 
Clucas, C., and L. S. Claire 
 2017 How Can Respectfulness in Medical Professionals Be Increased? A Complex 
But Important Question. J Bioeth Inq 14(1):123-133. 
Cohen-Mansfield, J., and R. Perach 
 2015 Interventions for alleviating loneliness among older persons: a critical 
review. Am J Health Promot 29(3):e109-25. 
Conner, M. & Armitage, C. J. 
 1998 Extending the theory of planned behaviour: a review and avenues for 
further research 
Journal of Applied Social Psychology 28:1430-1464. 
Conner, M. and Norman, P. (Eds) 
 1996 Predicting Health Behaviour. Buckingham, UK: Open University Press. 
Conner, M., Norman, P. (Eds) 
 2005 Predicting Health Behaviour: Research and Practice with Social Cognition 
Models: Maidenhead: Open University Press. 
Cottrell, T. and Rosen, A. 
 2013 Mechanisms of Autoimmunity. In Clinical Immunology: Principles and 
Practice. R.R. Rich, ed: Elsevier Saunders. 
Craig, Peter, et al. 
 2008 Developing and evaluating complex interventions: the new Medical 
Research Council guidance. BMJ 337. 
Curotto de Lafaille, Maria A., and Juan J. Lafaille 
 
 
275 
 
 
 
 
 2009 Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a 
Division of Labor? Immunity 30(5):626-635. 
Damsker, J. M., A. M. Hansen, and R. R. Caspi 
 2010 Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci 
1183:211-21. 
Daniel, E., et al. 
 2012 Risk of hypotony in noninfectious uveitis. Ophthalmology 119(11):2377-85. 
Davis, Janet L., et al. 
 2010 Scale for Photographic Grading of Vitreous Haze in Uveitis. American 
Journal of Ophthalmology 150(5):637-641.e1. 
Dawn, A. G., C. Santiago-Turla, and P. P. Lee 
 2003 Patient expectations regarding eye care: focus group results. Arch 
Ophthalmol 121(6):762-8. 
De Meyer, V., et al. 
 1999 Multifocal choroiditis with panuveitis and punctate inner choroidopathy: a 
mini review. Bull Soc Belge Ophtalmol 273:115-24. 
Dean, S., et al. 
 2017 "The patient is speaking": discovering the patient voice in ophthalmology. 
Br J Ophthalmol 101(6):700-708. 
Denniston, A. K., P. A. Keane, and S. K. Srivastava 
 2017 Biomarkers and Surrogate Endpoints in Uveitis: The Impact of Quantitative 
Imaging. Invest Ophthalmol Vis Sci 58(6):Bio131-bio140. 
Denniston, A. K., et al. 
 2014 An introduction to patient-reported outcome measures in ophthalmic 
research. Eye (Lond) 28(6):637-45. 
Dick, Andrew D., et al. 
  Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in 
Noninfectious Uveitis. Ophthalmology. 
Doria, A., et al. 
 2012 Autoinflammation and autoimmunity: bridging the divide. Autoimmun Rev 
12(1):22-30. 
Dreyer, R. F., and D. J. Gass 
 1984 Multifocal choroiditis and panuveitis. A syndrome that mimics ocular 
histoplasmosis. Arch Ophthalmol 102(12):1776-84. 
Dunlop, A. A., et al. 
 1998 Multifocal choroiditis: clinicopathologic correlation. Arch Ophthalmol 
116(6):801-3. 
Durrani, O. M., et al. 
 
 
276 
 
 
 
 
 2004 Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 
88(9):1159-62. 
Ehrenstein, M. R., et al. 
 2004 Compromised function of regulatory T cells in rheumatoid arthritis and 
reversal by anti-TNFalpha therapy. J Exp Med 200(3):277-85. 
Eldem, B., and C. Sener 
 1991 Punctate inner choroidopathy and its differential diagnosis. Ann 
Ophthalmol 23(4):153-5. 
Elkord, Eyad 
 2016 Helios Should Not Be Cited as a Marker of Human Thymus-Derived Tregs. 
Commentary: Helios(+) and Helios(−) Cells Coexist within the Natural FOXP3(+) T 
Regulatory Cell Subset in Humans. Frontiers in Immunology 7:276. 
Engel, G. L. 
 1977 The need for a new medical model: a challenge for biomedicine. Science 
196(4286):129-36. 
Essex, R. W., et al. 
 2010 Punctate inner choroidopathy: clinical features and outcomes. Arch 
Ophthalmol 128(8):982-7. 
Essex, R. W., et al. 
 2013 Idiopathic multifocal choroiditis: a comment on present and past 
nomenclature. Retina 33(1):1-4. 
Fairweather, D., et al. 
 2001 From infection to autoimmunity. J Autoimmun 16(3):175-86. 
Fairweather, DeLisa, et al. 
 2012 Autoimmune heart disease: role of sex hormones and autoantibodies in 
disease pathogenesis. Expert Review of Clinical Immunology 8(3):269-284. 
Fairweather, DeLisa, and Noel R. Rose 
 2004 Women and Autoimmune Diseases. Emerging Infectious Diseases 
10(11):2005-2011. 
Fan, Q., Y. Y. Teo, and S. M. Saw 
 2011 Application of advanced statistics in ophthalmology. Invest Ophthalmol Vis 
Sci 52(9):6059-65. 
Fisher, A., et al. 
 2011 Psychosocial correlates of objectively measured physical activity in 
children. Eur J Public Health 21(2):145-50. 
Fiske, S. T., A. J. Cuddy, and P. Glick 
 2007 Universal dimensions of social cognition: warmth and competence. Trends 
Cogn Sci 11(2):77-83. 
Fiske, S. T., et al. 
 
 
277 
 
 
 
 
 2002 A model of (often mixed) stereotype content: competence and warmth 
respectively follow from perceived status and competition. J Pers Soc Psychol 
82(6):878-902. 
Fiske, Susan T. 
 2012 Warmth and Competence: Stereotype Content Issues for Clinicians and 
Researchers. Canadian psychology = Psychologie canadienne 53(1):14-20. 
Flaxel, C. J., et al. 
 1998 The use of corticosteroids for choroidal neovascularisation in young 
patients. Eye (Lond) 12 ( Pt 2):266-72. 
Fleisher, T. A. & Oliveira, J. B. 
 2013 Flow cytometry. In Clinical Immunology: Principles and Practice 4th edition. 
R.R. Rich, Fleisher, T. A, Shearer W. T., Schroeder, H. W., Frew, A. J & Weyland C. 
M., ed: Elsevier Saunders. 
Floess, S., et al. 
 2007 Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 
5(2):e38. 
Fontenot, J. D., M. A. Gavin, and A. Y. Rudensky 
 2003 Foxp3 programs the development and function of CD4+CD25+ regulatory T 
cells. Nat Immunol 4(4):330-6. 
Foster, C. S., et al. 
 2016a The Ocular Immunology and Uveitis Foundation preferred practice patterns 
of uveitis management. Surv Ophthalmol 61(1):1-17. 
Foster, C. Stephen, et al. 
 2016b The Ocular Immunology and Uveitis Foundation preferred practice patterns 
of uveitis management. Survey of Ophthalmology 61(1):1-17. 
Foster, C. Stephen, and Albert T. Vitale 
 2002 Diagnosis and treatment of uveitis. Philadelphia, Pa. ; London: W.B. 
Saunders. 
Foussat, A., et al. 
 2017 Regulatory T Cell Therapy for Uveitis: A New Promising Challenge. J Ocul 
Pharmacol Ther 33(4):278-284. 
Fung, Adrian T. Mbbs MMed, et al. 
 2014 MULTIFOCAL CHOROIDITIS WITHOUT PANUVEITIS: Clinical Characteristics 
and Progression. Retina 34(1):98-107. 
Furtado, J. M., et al. 
 2016 Uveitis Associated with Zika Virus Infection. N Engl J Med 375(4):394-6. 
Garcia, A. L., et al. 
 2017 Evaluation of the "Eat Better Feel Better" Cooking Programme to Tackle 
Barriers to Healthy Eating. Int J Environ Res Public Health 14(4). 
 
 
278 
 
 
 
 
Gass, J. D. 
 1993 Acute zonal occult outer retinopathy. Donders Lecture: The Netherlands 
Ophthalmological Society, Maastricht, Holland, June 19, 1992. J Clin 
Neuroophthalmol 13(2):79-97. 
Gass, J. D., A. Agarwal, and I. U. Scott 
 2002 Acute zonal occult outer retinopathy: a long-term follow-up study. Am J 
Ophthalmol 134(3):329-39. 
Gass, J. D., and C. P. Wilkinson 
 1972 Follow-up study of presumed ocular histoplasmosis. Trans Am Acad 
Ophthalmol Otolaryngol 76(3):672-94. 
Gavin, M. A., et al. 
 2006 Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 
expression without regulatory T cell development. Proc Natl Acad Sci U S A 
103(17):6659-64. 
Géhl, Zsuzsanna, et al. 
 2014 Retinal and choroidal thickness measurements using spectral domain 
optical coherence tomography in anterior and intermediate uveitis. BMC 
Ophthalmology 14(1):1-7. 
Gerstenblith, A. T., et al. 
 2007 Punctate inner choroidopathy: a survey analysis of 77 persons. 
Ophthalmology 114(6):1201-4. 
Gilbert, Rose, et al. 
 2017 Statins as anti-inflammatory agents: A potential therapeutic role in sight-
threatening non-infectious uveitis. Porto Biomedical Journal 2(2):33-39. 
Gilbert, Rose M., et al. 
 2018 Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is 
Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards 
T-bet and TIGIT. Frontiers in Immunology 9(907). 
Gilbert, Rose, et al. 
 2016a Retinitis. In Encyclopedia of Ophthalmology. U. Schmidt-Erfurth and T. 
Kohnen, eds. Pp. 1-5. Berlin, Heidelberg: Springer Berlin Heidelberg. 
Gilbert, Rose, et al. 
 2016b TIGIT+ Tregs May Be Associated with Clinical Remission of Non-Infectious 
Uveitis. Investigative Ophthalmology & Visual Science 57(12):3313-3313. 
Glanz, K., Marcus Lewis, F. & Rimer, B.K. 
 1997 Theory at a Glance: A Guide for Health Promotion Practice. : National 
Institutes of Health. 
Glanz, K., Rimer, B.K. & Viswanath, K. (Eds) 
 
 
279 
 
 
 
 
 2008 HEALTH BEHAVIOR AND HEALTH EDUCATION: Theory, Research, and 
Practice: Jossey-Bass: A Wiley Imprint. 
GMC 
 2017 Medical and Social Models of Disability: General Medical Council. 
Godin, G., et al. 
 2008 Asking questions changes behavior: mere measurement effects on 
frequency of blood donation. Health Psychol 27(2):179-84. 
Gregersen, Peter K., and Timothy W. Behrens 
 2006 Genetics of autoimmune diseases — disorders of immune homeostasis. 
Nature Reviews Genetics 7:917. 
Gritz, D. C., and I. G. Wong 
 2004 Incidence and prevalence of uveitis in Northern California; the Northern 
California Epidemiology of Uveitis Study. Ophthalmology 111(3):491-500; 
discussion 500. 
Herbert, J., et al. 
 2014 Wider impacts of a 10-week community cooking skills program--Jamie's 
Ministry of Food, Australia. BMC Public Health 14:1161. 
Hirooka, K., et al. 
 2014 Increased macular choroidal blood flow velocity and decreased choroidal 
thickness with regression of punctate inner choroidopathy. BMC Ophthalmol 14:73. 
Hirooka, K., et al. 
 2006 Risk factors for elevated intraocular pressure after trans-tenon retrobulbar 
injections of triamcinolone. Japanese journal of ophthalmology 50(3):235-8. 
Hogg, R. E., et al. 
 2017 Mediterranean Diet Score and Its Association with Age-Related Macular 
Degeneration: The European Eye Study. Ophthalmology 124(1):82-89. 
Hori, S., T. Nomura, and S. Sakaguchi 
 2003a Control of regulatory T cell development by the transcription factor Foxp3. 
Science 299(5609):1057-61. 
Hori, S., T. Takahashi, and S. Sakaguchi 
 2003b Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv 
Immunol 81:331-71. 
Horwitz, D. A., et al. 
 2004 Regulatory T cells generated ex vivo as an approach for the therapy of 
autoimmune disease. Semin Immunol 16(2):135-43. 
Hu, Dan-Ning 
 2009 Photobiology of the Uvea. 
Hua, R., L. Liu, and L. Chen 
 
 
280 
 
 
 
 
 2014 Evaluation of the progression rate of atrophy lesions in punctate inner 
choroidopathy (PIC) based on autofluorescence analysis. Photodiagnosis Photodyn 
Ther 11(4):565-9. 
Huber, M., et al. 
 2016 Towards a 'patient-centred' operationalisation of the new dynamic concept 
of health: a mixed methods study. BMJ Open 6(1):e010091. 
Huber, Machteld, et al. 
 2011 How should we define health? BMJ 343. 
Huehn, J., J. K. Polansky, and A. Hamann 
 2009 Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell 
lineage? Nat Rev Immunol 9(2):83-9. 
Iacovou, M., et al. 
 2013 Social health and nutrition impacts of community kitchens: a systematic 
review. Public Health Nutr 16(3):535-43. 
Jabs, D. A. 
 2017 Immunosuppression for the Uveitides. Ophthalmology. 
Jabs, D. A., R. B. Nussenblatt, and J. T. Rosenbaum 
 2005a Standardization of uveitis nomenclature for reporting clinical data. results 
of the First International Workshop. Am J Ophthalmol 140. 
Jabs, D. A., et al. 
 2005b Standardization of uveitis nomenclature for reporting clinical data. Results 
of the First International Workshop. Am J Ophthalmol 140(3):509-16. 
Jabs, D. A., et al. 
 2000 Guidelines for the use of immunosuppressive drugs in patients with ocular 
inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 
130(4):492-513. 
Jampol, L. M., and A. Wiredu 
 1995 MEWDS, MFC, PIC, AMN, AIBSE, and AZOOR: one disease or many? Retina 
15(5):373-8. 
Janson, P. C., et al. 
 2008 FOXP3 promoter demethylation reveals the committed Treg population in 
humans. PLoS One 3(2):e1612. 
Janz, N. K., and M. H. Becker 
 1984 The Health Belief Model: a decade later. Health Educ Q 11(1):1-47. 
JLA 
 2017a About Priority Setting Partnerships: Crown Copyright. 
— 
 2017b Ocular Inflammatory Disease Top 10: Crown Copyright. 
 
 
281 
 
 
 
 
— 
 2017c Sight Loss and Vision: Crown Copyright. 
— 
 2017d Top 10s of priorities for research: Crown Copyright. 
Joller, N., et al. 
 2011 Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 
186(3):1338-42. 
Joller, N., et al. 
 2014 Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit 
proinflammatory Th1 and Th17 cell responses. Immunity 40(4):569-81. 
Jones, N. P. 
 2015 The Manchester Uveitis Clinic: the first 3000 patients--epidemiology and 
casemix. Ocul Immunol Inflamm 23(2):118-26. 
— 
 2016 Visual loss in uveitis. Eye. 
Kaiser, P. K., and E. S. Gragoudas 
 1996 The subretinal fibrosis and uveitis syndrome. Int Ophthalmol Clin 
36(1):145-52. 
Ke, Yan, et al. 
 2008 Ocular Regulatory T Cells Distinguish Monophasic from Recurrent 
Autoimmune Uveitis. Investigative ophthalmology & visual science 49(9):3999-
4007. 
Keane, P. A., et al. 
 2015a Automated Analysis of Vitreous Inflammation Using Spectral-Domain 
Optical Coherence Tomography. Transl Vis Sci Technol 4(5):4. 
Keane, Pearse A., et al. 
 2015b Automated Analysis of Vitreous Inflammation Using Spectral-Domain 
Optical Coherence Tomography. Translational Vision Science & Technology 4(5):4-
4. 
Kedhar, S. R., et al. 
 2007 Multifocal choroiditis with panuveitis and punctate inner choroidopathy: 
comparison of clinical characteristics at presentation. Retina 27(9):1174-9. 
Kempen, J. H., et al. 
 2015 Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone 
Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and 
Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment 
(MUST) Trial and Follow-up Study. Ophthalmology 122(10):1967-75. 
Kempen, J. H., et al. 
 
 
282 
 
 
 
 
 2011 Randomized comparison of systemic anti-inflammatory therapy versus 
fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the 
multicenter uveitis steroid treatment trial. Ophthalmology 118(10):1916-26. 
Khorram, K. D., L. M. Jampol, and M. A. Rosenberg 
 1991 Blind spot enlargement as a manifestation of multifocal choroiditis. Arch 
Ophthalmol 109(10):1403-7. 
Kim, Y., et al. 
 2016 The Role of Interleukin-22 and Its Receptor in the Development and 
Pathogenesis of Experimental Autoimmune Uveitis. PLoS One 11(5):e0154904. 
Kimberlee, Richard 
 2016 What is the value of social prescribing? 2016 3(3). 
Klack, K., R. M. Pereira, and J. F. de Carvalho 
 2011 Uveitis in celiac disease with an excellent response to gluten-free diet: third 
case described. Rheumatol Int 31(3):399-402. 
Klein, S., et al. 
 2010 CD127(low/-) and FoxP3(+) expression levels characterize different 
regulatory T-cell populations in human peripheral blood. J Invest Dermatol 
130(2):492-9. 
Koch, M. A., et al. 
 2009 The transcription factor T-bet controls regulatory T cell homeostasis and 
function during type 1 inflammation. Nat Immunol 10(6):595-602. 
Kramer, M., et al. 
 2007 Serum cytokine levels in active uveitis and remission. Curr Eye Res 32(7-
8):669-75. 
Kramer, M., and E. Priel 
 2014 Fundus autofluorescence imaging in multifocal choroiditis: beyond the 
spots. Ocul Immunol Inflamm 22(5):349-55. 
Krifa, F., et al. 
 2010 Uveitis responding on gluten free diet in a girl with celiac disease and 
diabetes mellitus type 1. Gastroenterol Clin Biol 34(4-5):319-20. 
Kung, Yung-Jen, et al. 
 2017 Kawasaki Disease Increases the Incidence of Myopia. BioMed Research 
International 2017:2657913. 
Kurtulus, S., et al. 
 2015 TIGIT predominantly regulates the immune response via regulatory T cells. 
J Clin Invest 125(11):4053-62. 
Lange, C., et al. 
 
 
283 
 
 
 
 
 2009 Resolving the clinical acuity categories “hand motion” and “counting 
fingers” using the Freiburg Visual Acuity Test (FrACT). Graefe's Archive for Clinical 
and Experimental Ophthalmology 247(1):137-142. 
Lee, R. W., and A. D. Dick 
 2012 Current concepts and future directions in the pathogenesis and treatment 
of non-infectious intraocular inflammation. Eye (Lond) 26(1):17-28. 
Lee, R. W., et al. 
 2009 Steroid refractory CD4+ T cells in patients with sight-threatening uveitis. 
Invest Ophthalmol Vis Sci 50(9):4273-8. 
Leung, S., et al. 
 2010 The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and 
regulatory T cells in autoimmune disease. Cell Mol Immunol 7(3):182-9. 
Leung, T. G., et al. 
 2014 Clinical features and incidence rate of ocular complications in punctate 
inner choroidopathy. Retina 34(8):1666-74. 
Levine, Andrew G., et al. 
 2017 Stability and function of regulatory T cells expressing the transcription 
factor T-bet. Nature 546(7658):421-425. 
Lewis, D. E., Harriman, G. R. & Blutt, S. E. 
 2013 Organisation of the Immune System. In Clinical Immunology: Principles and 
Practice. R.R. Rich, ed: Elseviser Saunders. 
Li, B, et al. 
 2005 Upregulation of T-bet expression in peripheral blood mononuclear cells 
during Vogt-Koyanagi-Harada disease. British Journal of Ophthalmology 
89(11):1410-1412. 
Li, Bin, et al. 
 2006 FOXP3 ensembles in T-cell regulation. Immunological Reviews 212(1):99-
113. 
Lightman, S., et al. 
 2014 Pegylated interferon-alpha-2b reduces corticosteroid requirement in 
patients with Behcet's disease with upregulation of circulating regulatory T cells 
and reduction of Th17. Ann Rheum Dis. 
— 
 2015 Pegylated interferon-alpha-2b reduces corticosteroid requirement in 
patients with Behcet's disease with upregulation of circulating regulatory T cells 
and reduction of Th17. Ann Rheum Dis 74(6):1138-44. 
Lin, Shuman, et al. 
 2014 Treg cells: a potential regulator for IL-22 expression? International Journal 
of Clinical and Experimental Pathology 7(2):474-480. 
 
 
284 
 
 
 
 
Liu, W., et al. 
 2006 CD127 expression inversely correlates with FoxP3 and suppressive function 
of human CD4+ T reg cells. J Exp Med 203(7):1701-11. 
Lochner, M., et al. 
 2008 In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ 
RORgamma t+ T cells. J Exp Med 205(6):1381-93. 
Lonergan, Mike, et al. 
 2017 Defining drug response for stratified medicine. Drug Discovery Today 
22(1):173-179. 
Maddux, James E., and Ronald W. Rogers 
 1983 Protection motivation and self-efficacy: A revised theory of fear appeals 
and attitude change. Journal of Experimental Social Psychology 19(5):469-479. 
Maggi, L., et al. 
 2010 CD161 is a marker of all human IL-17-producing T-cell subsets and is 
induced by RORC. Eur J Immunol 40(8):2174-81. 
Mantel, P. Y., et al. 
 2006 Molecular mechanisms underlying FOXP3 induction in human T cells. J 
Immunol 176(6):3593-602. 
Marques, Cintia, et al. 
 2015 Genetic and epigenetic studies of FOXP3 in asthma and allergy. Volume 1. 
Matthews, K., J. Nazroo, and J. Whillans 
 2017 The consequences of self-reported vision change in later-life: evidence 
from the English Longitudinal Study of Ageing. Public Health 142:7-14. 
Mazzoni, A., et al. 
 2015 Demethylation of the RORC2 and IL17A in human CD4+ T lymphocytes 
defines Th17 origin of nonclassic Th1 cells. J Immunol 194(7):3116-26. 
McCluskey, Peter J, Hamish MA Towle, and Susan Lightman 
 2000 Management of chronic uveitis. BMJ 320(7234):555-558. 
Medawar, P. B. 
 1956 The immunology of transplantation. Harvey Lect (Series 52):144-76. 
— 
 1991 The Nobel Lectures in Immunology. The Nobel Prize for Physiology or 
Medicine, 1960. Immunological tolerance. Scand J Immunol 33(4):337-44. 
Mendes de Leon, Carlos F. 
 2005 Social engagement and successful aging. European Journal of Ageing 
2(1):64-66. 
Michie, S., Atkins, L. & West R. 
 
 
285 
 
 
 
 
 2014 The Behaviour Change Wheel: A Guide to Designing Interventions. Great 
Britain: Silverback Publishing. 
Michie, Susan, Maartje M. van Stralen, and Robert West 
 2011 The behaviour change wheel: A new method for characterising and 
designing behaviour change interventions. Implementation Science : IS 6:42-42. 
Milne, S., S. Orbell, and P. Sheeran 
 2002 Combining motivational and volitional interventions to promote exercise 
participation: protection motivation theory and implementation intentions. Br J 
Health Psychol 7(Pt 2):163-84. 
Molins, B., et al. 
 2015 Regulatory T cell levels and cytokine production in active non-infectious 
uveitis: in-vitro effects of pharmacological treatment. Clin Exp Immunol 179(3):529-
38. 
Morgan, C. M., and H. Schatz 
 1986 Recurrent multifocal choroiditis. Ophthalmology 93(9):1138-47. 
Morikawa, H., et al. 
 2014 Differential roles of epigenetic changes and Foxp3 expression in regulatory 
T cell-specific transcriptional regulation. Proc Natl Acad Sci U S A 111(14):5289-94. 
Mosmann, T. R., and R. L. Coffman 
 1989 TH1 and TH2 cells: different patterns of lymphokine secretion lead to 
different functional properties. Annu Rev Immunol 7:145-73. 
Mrejen, S., et al. 
 2014 Acute zonal occult outer retinopathy: a classification based on multimodal 
imaging. JAMA Ophthalmol 132(9):1089-98. 
Murphy, K. M., and B. Stockinger 
 2010 Effector T cell plasticity: flexibility in the face of changing circumstances. 
Nat Immunol 11(8):674-80. 
Nature 
 2018 "Chronic Inflammation", Vol. 2017: MacMillan Publishers Ltd, Springer 
Nature. 
Nguyen, D. X., and M. R. Ehrenstein 
 2016 Anti-TNF drives regulatory T cell expansion by paradoxically promoting 
membrane TNF-TNF-RII binding in rheumatoid arthritis. J Exp Med 213(7):1241-53. 
NICE 
 2007 Behaviour change: general approaches 
National Insitute for Health and Social Care Excellence. 
— 
 
 
286 
 
 
 
 
 March 2016 Community engagement: improving health and wellbeing and 
reducing health inequalities, NICE guideline [NG44]. N.I.f.H.a.C. Excellence, ed. 
Niederer, R. L., et al. 
 2017 Risk Factors for Developing Choroidal Neovascular Membrane and Visual 
Loss in Punctate Inner Choroidopathy. Ophthalmology. 
Nozik, R. A., and W. Dorsch 
 1973 A new chorioretinopathy associated with anterior uveitis. Am J Ophthalmol 
76(5):758-62. 
Nussenblatt, R. B., et al. 
 1985 Standardization of vitreal inflammatory activity in intermediate and 
posterior uveitis. Ophthalmology 92(4):467-71. 
Ogden, Jane 
 2003 Some problems with social cognition models: A pragmatic and conceptual 
analysis. Health Psychology 22(4):424-428. 
Ohkura, N., et al. 
 2012 T cell receptor stimulation-induced epigenetic changes and Foxp3 
expression are independent and complementary events required for Treg cell 
development. Immunity 37(5):785-99. 
Ohnmacht, Caspar, et al. 
 2015 The microbiota regulates type 2 immunity through RORγt<sup>+</sup> T 
cells. Science 349(6251):989-993. 
Omenetti, Sara, and Theresa T. Pizarro 
 2015 The Treg/Th17 Axis: A Dynamic Balance Regulated by the Gut Microbiome. 
Frontiers in Immunology 6(639). 
Ooi, K. G., et al. 
 2006a Cytokines and chemokines in uveitis: is there a correlation with clinical 
phenotype? Clin Med Res 4(4):294-309. 
Ooi, K. G., et al. 
 2006b Multiplex cytokine detection versus ELISA for aqueous humor: IL-5, IL-10, 
and IFNgamma profiles in uveitis. Invest Ophthalmol Vis Sci 47(1):272-7. 
Ouellette, J. A. & Wood, W. 
 1998 Habit and Intention in Everyday Life: The Multiple Processes By Which Past 
Behaviour Predicts Future Behaviour. Psychol Bull 124(1):54-74. 
Ozbay, F., et al. 
 2007 Social support and resilience to stress: from neurobiology to clinical 
practice. Psychiatry (Edgmont) 4(5):35-40. 
Pachydaki, S. I., et al. 
 
 
287 
 
 
 
 
 2012 Surgical management and ultrastructural study of choroidal 
neovascularization in punctate inner choroidopathy after bevacizumab. J 
Ophthalmic Inflamm Infect 2(1):29-37. 
PHE 
 2017 Cell Counting with a Haemocytometer. 
Polansky, J. K., et al. 
 2008 DNA methylation controls Foxp3 gene expression. Eur J Immunol 
38(6):1654-63. 
Polley M.J., Pilkington K. 
 2017 A review of the evidence assessing impact of social prescribing on 
healthcare demand and cost implications. Technical Report. U.o. Westminster, ed. 
Povoleri, Giovanni, et al. 
 2013 Thymic Versus Induced Regulatory T Cells – Who Regulates the Regulators? 
Frontiers in Immunology 4(169). 
Powrie, F, and D Mason 
 1990 OX-22high CD4+ T cells induce wasting disease with multiple organ 
pathology: prevention by the OX-22low subset. The Journal of Experimental 
Medicine 172(6):1701-1708. 
Prochaska, J. O. & DiClemente, C. C. 
 1984 The Transtheoretical Approach: Crossing Traditiional Boundaries of 
Therapy. Homewood, IL: Dow Jones Irwin. 
Quartilho, A., et al. 
 2016 Leading causes of certifiable visual loss in England and Wales during the 
year ending 31 March 2013. Eye 30(4):602-607. 
Ramesh, R., et al. 
 2014 Pro-inflammatory human Th17 cells selectively express P-glycoprotein and 
are refractory to glucocorticoids. J Exp Med 211(1):89-104. 
Raven, M. L., et al. 
 2017 Multi-modal imaging and anatomic classification of the white dot 
syndromes. Int J Retina Vitreous 3:12. 
Reddy, C. V., et al. 
 1996 Enlarged blind spots in chorioretinal inflammatory disorders. 
Ophthalmology 103(4):606-17. 
Restif, Olivier, and Andrea L. Graham 
 2015 Within-host dynamics of infection: from ecological insights to evolutionary 
predictions. Philosophical Transactions of the Royal Society B: Biological Sciences 
370(1675). 
Rich, Robert R. 
 
 
288 
 
 
 
 
 2013 The human immune response In Clinical Immunology: Principles and 
Practice. R. Rich, R., ed: Elsevier Saunders. 
Richardson, B. 
 2003 DNA methylation and autoimmune disease. Clin Immunol 109(1):72-9. 
Rose, Gilbert, et al. 
 2018 Blended learning: e‐patients and patient perspectives in ophthalmology. 
Medical Education 52(5):553-554. 
Rosenblum, Michael D., Kelly A. Remedios, and Abul K. Abbas 
 2015 Mechanisms of human autoimmunity. The Journal of Clinical Investigation 
125(6):2228-2233. 
Rosenstock, Irwin M. 
 1974 Historical Origins of the Health Belief Model. Health Education Monographs 
2(4):328-335. 
Rowe, Fiona, et al. 
 2014 The Sight Loss and Vision Priority Setting Partnership (SLV-PSP): overview 
and results of the research prioritisation survey process. BMJ Open 4(7). 
RUBIN, GARY S., et al. 
 1994 Visual Impairment and Disability in Older Adults. Optometry and Vision 
Science 71(12):750-760. 
Ruggieri, S., et al. 
 2012 Treg lymphocytes in autoimmune uveitis. Ocul Immunol Inflamm 
20(4):255-61. 
Russ, Tom C, et al. 
 2012 Association between psychological distress and mortality: individual 
participant pooled analysis of 10 prospective cohort studies. BMJ : British Medical 
Journal 345. 
Saito, A., et al. 
 2007 Indocyanine green angiography in a case of punctate inner choroidopathy 
associated with acute zonal occult outer retinopathy. Jpn J Ophthalmol 51(4):295-
300. 
Sakaguchi, S, T Takahashi, and Y Nishizuka 
 1982 Study on cellular events in post-thymectomy autoimmune oophoritis in 
mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of 
oophoritis. The Journal of Experimental Medicine 156(6):1577-1586. 
Sakaguchi, S., et al. 
 2013 The plasticity and stability of regulatory T cells. Nat Rev Immunol 
13(6):461-7. 
Sangwan, V. S. 
 2010 Treatment of uveitis: beyond steroids. Indian J Ophthalmol 58(1):1-2. 
 
 
289 
 
 
 
 
Scheider, A. 
 1993 Multifocal inner choroiditis. Ger J Ophthalmol 2(1):1-9. 
Schewitz-Bowers, L. P., et al. 
 2015 Glucocorticoid-resistant Th17 cells are selectively attenuated by 
cyclosporine A. Proc Natl Acad Sci U S A 112(13):4080-5. 
Schewitz, L. P., et al. 
 2009 Glucocorticoids and the emerging importance of T cell subsets in steroid 
refractory diseases. Immunopharmacol Immunotoxicol 31(1):1-22. 
Sefik, Esen, et al. 
 2015 Individual intestinal symbionts induce a distinct population of RORγ+ 
regulatory T cells. Science (New York, N.Y.) 349(6251):993-997. 
Serhan, Charles N., et al. 
 2007 Resolution of inflammation: state of the art, definitions and terms. FASEB 
journal : official publication of the Federation of American Societies for 
Experimental Biology 21(2):325-332. 
Shakoor, A., and A. T. Vitale 
 2012 Imaging in the diagnosis and management of multifocal choroiditis and 
punctate inner choroidopathy. Int Ophthalmol Clin 52(4):243-56. 
Shantha, J. G., S. Yeh, and Q. D. Nguyen 
 2016 Ebola virus disease and the eye. Curr Opin Ophthalmol 27(6):538-544. 
Sharief, Lazha Ahmed Talat, Sue Lightman, and Oren Tomkins-Netzer 
 2018 Using Local Therapy to Control Noninfectious Uveitis. Ophthalmology 
125(3):329-331. 
Sheeran, P., and C. Abraham 
 2003 Mediator of moderators: temporal stability of intention and the intention-
behavior relation. Pers Soc Psychol Bull 29(2):205-15. 
Shen, Z., et al. 
 2011 Comparison on clinical characteristics of multifocal choroiditis and 
punctate inner choriodopathy. Eye Sci 26(3):161-5. 
Shevach, E. M., and A. M. Thornton 
 2014 tTregs, pTregs, and iTregs: similarities and differences. Immunol Rev 
259(1):88-102. 
Shimada, H., et al. 
 2008 Pathological findings of multifocal choroiditis with panuveitis and punctate 
inner choroidopathy. Jpn J Ophthalmol 52(4):282-8. 
Shoda, H., et al. 
 
 
290 
 
 
 
 
 2015 Dietary Omega-3 Fatty Acids Suppress Experimental Autoimmune Uveitis in 
Association with Inhibition of Th1 and Th17 Cell Function. PLoS One 
10(9):e0138241. 
Silva, L. M., et al. 
 2013 Visual impairment from uveitis in a reference hospital of Southeast Brazil: a 
retrospective review over a twenty years period. Arq Bras Oftalmol 76(6):366-9. 
Silva, P. S., et al. 
 2015 Peripheral Lesions Identified on Ultrawide Field Imaging Predict Increased 
Risk of Diabetic Retinopathy Progression over 4 Years. Ophthalmology 122(5):949-
56. 
Silva, Paolo S., et al. 
 2012 Nonmydriatic Ultrawide Field Retinal Imaging Compared With Dilated 
Standard 7-Field 35-mm Photography and Retinal Specialist Examination for 
Evaluation of Diabetic Retinopathy. American Journal of Ophthalmology 
154(3):549-559.e2. 
Silver, Phyllis, et al. 
 2015 Retina-Specific T Regulatory Cells Bring About Resolution and Maintain 
Remission of Autoimmune Uveitis. The Journal of Immunology 194(7):3011. 
Simonetta, F., et al. 
 2010 Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. 
Eur J Immunol 40(9):2528-38. 
Smith, H, et al. 
 1991 Effector and regulatory cells in autoimmune oophoritis elicited by neonatal 
thymectomy. The Journal of Immunology 147(9):2928-2933. 
Spaide, R. F., N. Goldberg, and K. B. Freund 
 2013 Redefining multifocal choroiditis and panuveitis and punctate inner 
choroidopathy through multimodal imaging. Retina 33(7):1315-24. 
St Claire, Lindsay and He, Yuequn 
 2009 How Do I Know if I Need a Hearing Aid? Further Support for the Self-
Categorisation Approach to Symptom Perception. Applied Psychology: An 
International Review 58(1):24-41. 
Steele, C. M., and J. Aronson 
 1995 Stereotype threat and the intellectual test performance of African 
Americans. J Pers Soc Psychol 69(5):797-811. 
Stein-Streilein, J., and J. W. Streilein 
 2002 Anterior chamber associated immune deviation (ACAID): regulation, 
biological relevance, and implications for therapy. Int Rev Immunol 21(2-3):123-52. 
Steptoe, A. (Ed) 
 2011 Handbook of Behavioral Medicine: Methods and Practice: Springer. 
 
 
291 
 
 
 
 
Steptoe, A., et al. 
 2013 Social isolation, loneliness, and all-cause mortality in older men and 
women. Proc Natl Acad Sci U S A 110(15):5797-801. 
Stevens, Rebekah, Hannah Bartlett, and Richard Cooke 
 2015 Dietary analysis and nutritional behaviour in people with and without age-
related macular disease. Clinical Nutrition ESPEN 10(3):e112-e117. 
Streilein, J. W. 
 1995 Immunological non-responsiveness and acquisition of tolerance in relation 
to immune privilege in the eye. Eye (Lond) 9 ( Pt 2):236-40. 
Streilein, J. W., and S. W. Cousins 
 1990 Aqueous humor factors and their effect on the immune response in the 
anterior chamber. Curr Eye Res 9 Suppl:175-82. 
Sun, M., et al. 
 2010 Contribution of CD4+CD25+ T cells to the regression phase of experimental 
autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 51(1):383-9. 
Suri-Payer, E., et al. 
 1998 CD4+CD25+ T cells inhibit both the induction and effector function of 
autoreactive T cells and represent a unique lineage of immunoregulatory cells. J 
Immunol 160(3):1212-8. 
Suttorp-Schulten, M. S., and A. Rothova 
 1996 The possible impact of uveitis in blindness: a literature survey. The British 
journal of ophthalmology 80(9):844-8. 
Swainson, L., De Barros, S.C., Craveiro, M., Zimmerman, V.S. and Taylor, N. 
 2013 T-cell Development In Clinical Immunology: Principles and Practice. R. Rich, 
R., ed: Elsevier Saunders. 
Taira, K., et al. 
 2006 Acute zonal occult outer retinopathy in the fellow eye 5 years after 
presentation of punctate inner choroidopathy. Graefes Arch Clin Exp Ophthalmol 
244(7):880-2. 
Takase, H., et al. 
 2006 Cytokine profile in aqueous humor and sera of patients with infectious or 
noninfectious uveitis. Invest Ophthalmol Vis Sci 47(4):1557-61. 
Taylor, S. R., et al. 
 2011 Behcet disease: visual prognosis and factors influencing the development 
of visual loss. Am J Ophthalmol 152(6):1059-66. 
Teshima, Takanori 
 2011 Th1 and Th17 join forces for acute GVHD. Blood 118(18):4765-4767. 
Thornton, A. M., et al. 
 
 
292 
 
 
 
 
 2010 Expression of Helios, an Ikaros transcription factor family member, 
differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J 
Immunol 184(7):3433-41. 
Tomkins-Netzer, O., et al. 
 2014 Long-term clinical outcome and causes of vision loss in patients with 
uveitis. Ophthalmology 121(12):2387-92. 
Tomkins-Netzer, O., S. R. Taylor, and S. Lightman 
 2012 Corticosteroid-sparing agents: new treatment options. Dev Ophthalmol 
51:47-56. 
Torun, N., et al. 
 2005 Serum cytokine receptor levels in noninfectious uveitis. Ophthalmic Res 
37(2):112-6. 
Tran, D. Q., H. Ramsey, and E. M. Shevach 
 2007 Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell 
receptor stimulation is transforming growth factor-beta dependent but does not 
confer a regulatory phenotype. Blood 110(8):2983-90. 
von Toerne, C., et al. 
 2010 Effector T cells driving monophasic vs. relapsing/remitting experimental 
autoimmune uveitis show unique pathway signatures. Mol Immunol 48(1-3):272-
80. 
Vuong, V. S., et al. 
 2016 Repeatability of Choroidal Thickness Measurements on Enhanced Depth 
Imaging Optical Coherence Tomography Using Different Posterior Boundaries. Am J 
Ophthalmol 169:104-12. 
Wachtlin, J., et al. 
 2003 Long-term results after photodynamic therapy with verteporfin for 
choroidal neovascularizations secondary to inflammatory chorioretinal diseases. 
Graefes Arch Clin Exp Ophthalmol 241(11):899-906. 
Wang, J., et al. 
 2007 Transient expression of FOXP3 in human activated nonregulatory CD4+ T 
cells. Eur J Immunol 37(1):129-38. 
Ward, Stephen T., Ka-Kit Li, and Stuart M. Curbishley 
 2014 A method for conducting suppression assays using small numbers of tissue-
isolated regulatory T cells. MethodsX 1(Supplement C):168-174. 
Watzke, R. C., et al. 
 1984 Punctate inner choroidopathy. Am J Ophthalmol 98(5):572-84. 
Webb, T. L., et al. 
 
 
293 
 
 
 
 
 2010 Using the internet to promote health behavior change: a systematic review 
and meta-analysis of the impact of theoretical basis, use of behavior change 
techniques, and mode of delivery on efficacy. J Med Internet Res 12(1):e4. 
Webb, T. L., and P. Sheeran 
 2006 Does changing behavioral intentions engender behavior change? A meta-
analysis of the experimental evidence. Psychol Bull 132(2):249-68. 
Weinhold, Bob 
 2006 Epigenetics: The Science of Change. Environmental Health Perspectives 
114(3):A160-A167. 
Weinstein, Neil D. 
 2007 Misleading tests of health behavior theories. Annals of Behavioral Medicine 
33(1):1-10. 
West, R. 
 2006 Theory of Addiction. Oxford: Wiley-Blackwell. 
WHO 
 1946 Constitution of the World Health Organization: Principles. 
Wilkinson, S., Joffe, H. & Yardley, L. 
 2004 Qualitative Data Collection: Interviews and Focus Groups. In Research 
Methods in Clinical and Health Psychology. D.F.Y. Marks, L., ed. London, UK: SAGE 
Publications. 
Williams, G. J., et al. 
 2007 The prevalence of sight-threatening uveitis in Scotland. Br J Ophthalmol 
91(1):33-6. 
Wilson, C. B., E. Rowell, and M. Sekimata 
 2009 Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 
9(2):91-105. 
Witte, K. 
 1992 PUTTING THE FEAR BACK INTO FEAR APPEALS: THE EXTENDED PARALLEL 
PROCESS MODEL  
  COMMUNICATION MONOGRAPHS 59:329-349. 
Wu, J., et al. 
 2015 Intakes of Lutein, Zeaxanthin, and Other Carotenoids and Age-Related 
Macular Degeneration During 2 Decades of Prospective Follow-up. JAMA 
Ophthalmol 133(12):1415-24. 
Xu, H., et al. 
 2005 Differentiation to the CCR2+ inflammatory phenotype in vivo is a 
constitutive, time-limited property of blood monocytes and is independent of local 
inflammatory mediators. J Immunol 175(10):6915-23. 
Xu, H., et al. 
 
 
294 
 
 
 
 
 2004 Recruitment of IFN-gamma-producing (Th1-like) cells into the inflamed 
retina in vivo is preferentially regulated by P-selectin glycoprotein ligand 1:P/E-
selectin interactions. J Immunol 172(5):3215-24. 
Yeh, S., et al. 
 2009 CD4+Foxp3+ T-regulatory cells in noninfectious uveitis. Arch Ophthalmol 
127(4):407-13. 
Yeo, T. K., et al. 
 2013 Causes of visual loss associated with uveitis in a singapore tertiary eye 
center. Ocul Immunol Inflamm 21(4):264-9. 
Yu, X., et al. 
 2009 The surface protein TIGIT suppresses T cell activation by promoting the 
generation of mature immunoregulatory dendritic cells. Nat Immunol 10(1):48-57. 
Zarranz-Ventura, J., et al. 
 2014 Characterization of punctate inner choroidopathy using enhanced depth 
imaging optical coherence tomography. Ophthalmology 121(9):1790-7. 
Zhang, Huiyun, et al. 
 2014 Subsets of regulatory T cells and their roles in allergy. Journal of 
Translational Medicine 12(1):125. 
Zhang, X., et al. 
 2013a Spectral-domain optical coherence tomographic findings at each stage of 
punctate inner choroidopathy. Ophthalmology 120(12):2678-83. 
Zhang, Xiaozhe, et al. 
 2016 Levels of corticosteroids positively correlate with IL-10+FoxP3+CD25+CD4+ 
T regulatory cells but not with CD4+IL-17+ Th17 cells in Behçet’s Disease. 
Investigative Ophthalmology & Visual Science 57(12):494-494. 
Zhang, Y., et al. 
 2013b Genome-wide DNA methylation analysis identifies hypomethylated genes 
regulated by FOXP3 in human regulatory T cells. Blood 122(16):2823-36. 
Zhao, Jun, et al. 
 2017 Serum Th1 and Th17 related cytokines and autoantibodies in patients with 
Posner-Schlossman syndrome. PLOS ONE 12(4):e0175519. 
Zheng, S. G., et al. 
 2004 Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop 
suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 172(9):5213-
21. 
Zheng, Y., et al. 
 2010 Role of conserved non-coding DNA elements in the Foxp3 gene in 
regulatory T-cell fate. Nature 463(7282):808-12. 
Zhuang, Z., et al. 
 
 
295 
 
 
 
 
 2017 Imbalance of Th17/Treg cells in pathogenesis of patients with human 
leukocyte antigen B27 associated acute anterior uveitis. Sci Rep 7:40414. 
Zirm, E. K. 
 1989 Eine erfolgreiche totale Keratoplastik (A successful total keratoplasty). 
1906. Refract Corneal Surg 5(4):258-61. 
 
 
  
 
 
296 
 
 
 
 
Appendix: Supplementary Material for Chapter 3 
Experimental Laboratory and Clinical Study Methods 
 
Materials for experimental lab studies 
  
 
Table 23: List of  materials for lab work, with product code and supplier (excluding 
antibodies) 
 
Product Product Code Supplier 
Cell Stimulation Cocktail 
(containing PMA and 
Ionomycin) 
 
00-4970-03 eBiosciences UK 
Cell Strainer 35µm in 
12x75mm Polystyrene Tube  
 
352235 
 
BD Falcon/ SLS UK 
Cytofix/ Cytoperm kit 
Fixation/Permeabilization 
Solution Kit   
 
554714 BD Biosciences UK 
DMSO, Hybri-Max, Sterile 
filtered, Bioreagent 
 
D2650 Sigma Aldrich 
DNeasy Blood and tissue kit 
(50) 
 
69504 
 
Qiagen 
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Dulbecco’s PBS – modified, 
without sodium chloride and 
magnesium chloride, liquid, 
sterile filtered 
 
D8537 Sigma Aldrich 
DRAK7 dead cell dye, for flow 
cytometry 
 
424001 BioLegend 
 
Dynabeads Human T-Activator 
CD3⁄CD28 for T Cell 
Expansion and Activation 
 
11131D Thermofisher Scientific 
DynaMag 96 Side-skirted 
Magnet 
 
12027 Thermofisher Scientific 
EZ DNA Methylation Kit 
 
D5002 Zymo Research/ 
Cambridge 
Biosciences 
Flow Cytometry Staining 
Buffer 
 
00-4222-26 eBiosciences UK 
FoxP3/ transcription factor 
fix/perm concentrate and 
diluent 
 
00-5521-00 eBiosciences UK 
Heat inactivated foetal calf 
serum 
4-101-500 LabTech International 
UK 
Histopaque-1077, sterile-
filtered, density: 1.077 g/mL  
10771 Sigma Aldrich UK 
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Human Serum, from human 
male AB plasma, USA origin, 
sterile-filtered  
 
H4522 Sigma Aldrich UK 
Regulatory T Cell Isolation Kit 
II, CD4+CD25+CD127dim/neg, 
human 
 
130-094-775 Miltenyi Biotech 
Regulatory T Cell Staining Kit 
#1 
(CD4+CD25+FoxP3+), human/ 
primate 
 
88-4999 eBiosciences UK 
 
IL-2 IS, human, research grade 130-097-742 
 
Miltenyi Biotech  
Legendplex Human Th 
Cytokine Panel 
740001 
 
BioLegend  
Luminex Assays, human 
magnetic, premixed multiplex 
L120101 R&D Systems 
Non-filled 50ml LeucoSep 
tubes, sterile 
 
227290 Greiner Bio-one Ltd. 
OneComp ebeads, 
compensation beads for flow 
cytometry 
 
01-1111-42 eBiosciences UK 
Protein transport inhibitor 
cocktail (containing brefeldin) 
 
00-4950-03 eBiosciences UK 
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Quantikine ELISA human TGF-
β1 
 
DB100B R&D Systems 
RPMI-1640 with sodium 
bicarbonate, without L-
glutamine, liquid, sterile-
filtered, suitable for cell 
culture  
 
R0883 Sigma Aldrich UK 
SAFETY Blood Collection Set 
+ Luer Adapter 23G x 3/4" 
tubing length 7 1/2" (19cm), 
single-packed, sterile, latex-
free 
 
450082 Greiner Bio-one Ltd 
Sample Activation kit 1 
(acidification of samples for 
ELISA) 
 
DY010 
 
R&D Systems 
SYTOX Blue dead cell stain, 
for flow cytometry 
 
S34857 ThermoFisher 
Scientific  
 
UltraComp eBeads, 
compensation beads for flow 
cytometry (compatible with 
UV and violet laser) 
 
01-2222-42 eBiosciences UK 
VACUETTE 9ml NH Sodium 
Heparin NR GRN/GRN  
455051 Greiner Bio-one Ltd 
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Violet proliferation dye 450 
 
562158 
 
BD Biosciences UK 
X-VIVO 15 with Gentamicin 
and Phenol Red 
L2BE02-060F Lonza Cambridge/SLS 
Zombie Near Infra Red Fixable 
Viability  
Dye, for flow cytometry 
423106 BioLegend 
 
Table 24: List of primary human antibodies used for lab studies 
 
Antibody Clone Host Isotype Source 
CD127 BV605 
 
A019D5 Mouse IgG1 BioLegend 
CD14 APC-Fire  
 
63D3 Mouse IgG1 BioLegend 
CD3, purified NA/LE HIT3a Mouse IgG2a BD 
CD3 Vioblue BW264/56 Mouse IgG2a Miltenyi 
Biotech 
CD3 BV785 
 
OKT3 Mouse IgG2a BioLegend 
CD4 BUV395 RPA-T4 Mouse IgG1 BD 
CD4 FITC OKT4 Rat 
 
IgG2a eBiosciences 
CD4 PerCP-Cy5.5 OKT4 Mouse IgG2b BioLegend 
CD8a AF700  HIT8a Mouse IgG1 BioLegend 
CD25 APC 
 
BC96 Rat 
 
IgG2a eBiosciences 
CD25 BV711 2A3 Mouse IgG1 BD 
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CD25 PE-Dazzle594 
 
M-A251 
 
Mouse IgG1 BioLegend 
CD28, purified 
NA/LE 
CD28.2 Mouse IgG1 BD 
FoxP3 AF647 259D/C7  Mouse IgG2a BD 
FoxP3 PE PCH101 Rat IgG2a eBiosciences 
IFN-γ BV605 B27 Mouse IgG1 BD 
IL-10 BV605 
 
JES3-9D7  Rat IgG1 BD 
IL-10 CF594 JES3-19F1 Rat IgG2a BD 
IL-17A PE-Vio770 CZ8-23G1 Mouse IgG1 Miltenyi Biotech 
ROR-γt AF488 
 
Q21-559  Mouse IgG2b BD 
TIGIT PE 
 
A15153G 
 
Mouse  IgG2a  BioLegend  
T-bet PerCP-Cy5.5 4B10 Mouse IgG1 BioLegend 
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Titration and optimisation of antibody concentrations for flow 
cytometry 
 
Below is an example of the staining protocol (shown for an anti-CD4 FITC 
antibody) used to titrate and optimise flow cytometry antibody concentrations 
for both stimulated and unstimulated cells (PBMC): 
 
Number of samples required for titration experiment: 
 
1) Stimulated - Unstained 
2) Stimulated – Live/Dead  
3) Stimulated – Live/Dead + CD4-FITC @ 1:12.5 
4) Stimulated – Live/Dead + CD4-FITC @ 1:25 
5) Stimulated – Live/Dead + CD4-FITC @ 1:50 
6) Stimulated – Live/Dead + CD4-FITC @ 1:100 
7) Stimulated – Live/Dead + CD4-FITC @ 1:200 
8) Stimulated – Live/Dead + CD4-FITC @ 1:400 
9) Stimulated – Live/Dead + CD4-FITC @ 1:800 
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Staining Calculations 
 
Antibodies: 
Fixable Live/Dead Dye    1:1000 
CD4-FITC      To be titrated 
 
1. Stimulated - Unstained Control 
Sample: 1  
 
2. Stimulated – Live/Dead (post - CD4 stain) 
 Samples: 2 → 16 
200 uL of Live/Dead dye dilution per sample of 1.0 x106 cells 
15 samples require the Live/Dead dye 
 3000 uL of Live/Dead @ (1:1000) 
→3000 uL = 3.0 uL of Live/Dead (1:1000) + 2997.0 uL of PBS (no protein)*** 
 
3. Stimulated – Live/Dead + CD4-FITC @ (1:12.5) 
 Sample: 3 
→100 uL = 8.0 uL of CD4-FITC (1:12.5) + 92.0 uL of Staining Media  
200 uL needed for serial dilution (2x)  
→200 uL = 16.0 uL of CD4-FITC (1:12.5) + 184.0 uL of Staining Media 
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4. Stimulated – Live/Dead + CD4-FITC @ (1:25) 
  Sample: 4 
→200 uL = 100.0 uL of CD4-FITC (1:12.5) + 100.0 uL of Staining Media 
 
5. Stimulated – Live/Dead + CD4-FITC @ (1:50) 
  Sample: 5 
→200 uL = 100.0 uL of CD4-FITC (1:25) + 100.0 uL of Staining Media 
 
6. Stimulated – Live/Dead + CD4-FITC @ (1:100) 
  Sample: 6 
→200 uL = 100.0 uL of CD4-FITC (1:50) + 100.0 uL of Staining Media 
 
7. Stimulated – Live/Dead + CD4-FITC @ (1:200) 
  Sample: 7 
→200 uL = 100.0 uL of CD4-FITC (1:100)+ 100.0 uL of Staining Media 
 
8. Stimulated – Live/Dead + CD4-FITC @ (1:400) 
  Sample: 8 
→200 uL = 100.0 uL of CD4-FITC (1:200)+ 100.0 uL of Staining Media 
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9. Stimulated – Live/Dead + CD4-FITC @ (1:800) 
  Sample: 9 
→200 uL = 100.0 uL of CD4-FITC (1:400)+ 100.0 uL of Staining Media 
 
Calculations: 
 
Dilution: _________________ 
 
Human PBMCs: Total # of cells: 
 
% Viable ________________________________          
x = _______________ cells/mL x __________________ mL 
 
Viable cells/mL ________________________            
x = ______________________ cells 
 
Total cells/mL _______________=   1.0 x106 cells/mL  x____________ mL 
                   
        
x    =   __________________  mL   or       
x    =   _____________________ ul 
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NHS R&D-approved proforma for collection of clinical study 
data 
Patient Details 
Date of Birth  
(dd mm yyyy) 
__ __ / __ __ / __ __ __ __ 
Gender Male   Female   
 
Weight __ __ __ . __ __ kg 
Baseline Details 
Date of Visit  
(dd mm yyyy) 
__ __ / __ __ / __ __ __ __ 
Uveitis Diagnosis  
Affected Eye(s) Right  Left   Both   
 
Best Corrected VA 
Right   __ __              
Left   __ __                            
 
Uveitis 
Classification 
(SUN) 
Intermediate  Posterior   Panuveitis   
 
Duration of 
Disease Since 
Diagnosis 
__ __  years__ __  months  
Right Lens Clear   IOL   Significant  Aphakia   
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Left Lens Clear   IOL   Significant  Aphakia   
 
Ocular Activity (in either eye) 
Uveitis activity 
status 
Active   Quiescent   
 
If Quiescent, state 
time since last 
flare 
__ __ Years    __ __  Months 
If Active please complete the following: 
AC cells Yes   No   
 
Vitreous cells Yes   No   
 
Macular oedema Yes   No   
 
Disc oedema Yes   No   
 
Ischaemic 
vasculitis 
Yes   No   
 
Retinitis/ 
choroiditis 
Yes   No   
 
If active, 
prednisolone 
commenced? 
Yes   No   
 
  
_ ___ G 
  
 
If Quiescent, list previous medications Duration of treatment 
Prednisolone Yes   No   
 
__ __Years     
__ __ Months 
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Mycophenolate Yes   No   
 
__ __Years     
__ __ Months 
Methotrexate Yes   No   
 
__ __Years       
__ __ Months 
Ciclosporin Yes   No   
 
__ __Years      
__ __ Months 
Biological Agents Yes   No   
 
 
 _________________ 
__ __Years      
__ __ Months 
Other 2nd Line 
Agents 
Yes   No   
 
If Yes Specify 
(one or more) 
__________________ 
__ __Years      
 __ __ Months 
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Standard curves for ELISA and Luminex Assays 
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Primer sequences used in the NGS sequencing  
 
Genomic FOXP3 TDSR sequence 
 
CAGAAGCTGGGGGAGAGGCCTGGAGCAGCTTCTCCCTTATGGCCCCCAGA 
AGGAACCAACCCTGGCAACACCTTGATCTTGGACTCTGGCCTCCAGAACT 
GTGAGATGATCAATTTCTGTTGCTGAAGCCACTCAGTTGTGGTACTTTGT 
TATAGCAGCCAGAACAAACTAATACCGATTTCGGTGCAAATGGATGTTTT 
CCACCACTCTGGCCTGGCCCATGTGGCTGGCCTGTGGTCACTTCTGAAGC 
TGCCTGGACACTTGGCCAGAGCTAAGAATTCTCCCCAAACACATGTGGGA 
TGGCCTGACTCAGCAAAGCATAGATACATTCTCAGACAGGGACATGGAGA 
TGATCTGTCTGGGGGTAGAGGACCTAGAGGGCCGGGCTGGGCAGCCGGCT 
TCCTGCACTGTCTGTTGGGACGTCCCTTTCTGACTGGGTTTCTCAGAAGC 
TGAATGGGGGATGTTTCTGGGACACAGATTATGTTTTCATATCGGGGTCT 
GCATCTGGGCCCTGTTGTCACAGCCCCCGACTTGCCCAGATTTTTCCGCC 
ATTGACGTCATGGCGGCCGGATGCGCCGGGCTTCATCGACACCACGGAGG 
AAGAGAAGAGGGCAGATACCCCACCCCACAGGTTTCGTTCCGAGAACTGG 
CTGCCCTGTCCTGCAGCAGGCTTGGCCCAGGTGGGGTGACATGGGTGCTG 
GTGGATGTGGTAGGTGATGTCCATCTGGCCACTATGACAAGCCCCTAGCT 
CTGAAGACCTGGCCCTTCTTGGGTTGTGGAGAGGACCCAGGTTTGAAGCT 
CTGAGAGTGCCAGGCAGGCTCCACAGATACTGGGACCCCTGGGGTCTTCA 
AATAGTATAACACCAGGACCTCAGAATCATAGAACAGCATTTCTTAGATT 
TAAAGGATCCTAGAATCTCAAAACCACAGACTGTGGGGTCTACGGTCCCA 
AAGTCTCAGTATGTGTAGGCCAGTGTCCCTGGTGTCCAAACTCCTTGGAA 
CCATCTGAAAGTCAGGCAGCTTGCTGCTTCATAGGGCCTCTTGCCTACCA 
GGCCTGGAAACAGAGCCAGCCTCCCTAGGGCCTCAGTCTCCCTGTCCACT 
CTGGAACAACGTTCCCAAATACATGGCCACTCCGCCAGAGATGGCAACAG 
GGGGAGGAGGAGGTTGAGGCTGGTGTGCCTTTGGTCTGGGCCTCATGGGG 
GGAGCTGGAAAAGCCTCAGCCTTCGCCAATACAGAGCCCATCATCAGACT 
CTCTAGAGGGGCCCCACAATCAAGGTTTTCGGGGACCAGCACCAGCTCTG 
ACAAATGTGTCTGAGATAATTAGGGAGAAGATAAAGTTATTGAGTGAATA 
GTCAGTCCATTATCCCAACAACCCCTCCCTGCCCAGTTTGAAATGTCACC 
 
Figure 75: Example process of primer design and sequence check showing the 
genomic FoxP3 TSDR sequence with the FoxP3 TSDR primer sequences highlighted 
in yellow 
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Bisulfite converted FOXP3 TDSR sequence 
 
GTGAGATGATTAATTTTTGTTGTTGAAGTTATTTAGTTGTGGTATTTTGT 
TATAGTAGTTAGAATAAATTAATATTGATTTTGGTGTAAATGGATGTTTT 
TTATTATTTTGGTTTGGTTTATGTGGTTGGTTTGTGGTTATTTTTGAAGT 
TGTTTGGATATTTGGTTAGAGTTAAGAATTTTTTTTAAATATATGTGGGA 
TGGTTTGATTTAGTAAAGTATAGATATATTTTTAGATAGGGATATGGAGA 
TGATTTGTTTGGGGGTAGAGGATTTAGAGGGTTGGGTTGGGTAGTTGGTT 
TTTTGTATTGTTTGTTGGGATGTTTTTTTTTGATTGGGTTTTTTAGAAGT 
TGAATGGGGGATGTTTTTGGGATATAGATTATGTTTTTATATTGGGGTTT 
GTATTTGGGTTTTGTTGTTATAGTTTTTGATTTGTTTAGATTTTTTTGTT 
ATTGATGTTATGGTGGTTGGATGTGTTGGGTTTTATTGATATTATGGAGG 
AAGAGAAGAGGGTAGATATTTTATTTTATAGGTTTTGTTTTGAGAATTGG 
TTGTTTTGTTTTGTAGTAGGTTTGGTTTAGGTGGGGTGATATGGGTGTTG 
GTGGATGTGGTAGGTGATGTTTATTTGGTTATTATGATAAGTTTTTAGTT 
TTGAAGATTTGGTTTTTTTTGGGTTGTGGAGAGGATTTAGGTTTGAAGTT 
TTGAGAGTGTTAGGTAGGTTTTATAGATATTGGGATTTTTGGGGTTTTTA 
AATAGTATAATATTAGGATTTTAGAATTATAGAATAGTATTTTTTAGATT 
 
Figure 76: Example process of primer design and sequence checking, showing the 
annotated bisulphite-converted genomic FoxP3 sequence with the primer sequence 
highlighted in yellow. 
 
 
 
Figure 77: Example screenshot of BLAST sequence search used to check primer 
sequence for FoxP3 TSDR  
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Table 25: Primer sequences used in the assay (the Fluidigm CS1 and CS2 tags are 
highlighted in bold). 
Target 
name 
Forward primer 
(5’-3’) 
Reverse Primer 
(5’3’) 
Annealing 
temperature* 
TBX21 
down  
ACACTGACGAC
ATGGTTCTACA
GGGAAGGTGTT
AGTT 
 
TACGGTAGCAGA
GACTTGGTCTAAA
ACCCCAAACTACC 
 
53°C 
RORC2 
up 
ACACTGACGAC
ATGGTTCTACA
TTTGTTTTTGAA
GTTATTTGGTAA
AGAG 
 
TACGGTAGCAGA
GACTTGGTCTCCC
CACCCCCAAAAAA
TACAAT 
 
60°C 
RORC2 
down 
ACACTGACGAC
ATGGTTCTACA
GGGGGGTTGTT
ATTTGGTTATT 
 
TACGGTAGCAGA
GACTTGGTCTACT
CACACTATTCCCA
AAACATC 
 
60°C 
TIGIT ACACTGACGAC
ATGGTTCTACA
GGAGGATGTTA
GAGGAGTTTAG
TTAATAG 
 
TACGGTAGCAGA
GACTTGGTCTACA
CAAACTACATAAA
ATAAACCACAAAA 
 
53°C 
FOXP3 
TDSR 
ACACTGACGAC
ATGGTTCTACA
GTAGAGGATTT
AGAGGGTTG 
TACGGTAGCAGA
GACTTGGTCTAAA
CCTACTACAAAAC
AAAAC 
53°C 
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FOXP3 
Promotor 
ACACTGACGAC
ATGGTTCTACA
TGGTGAAGTGG
ATTGATAGAAAA
GG 
 
TACGGTAGCAGA
GACTTGGTCTTAT
AAAAACCCCCCCC
CACC 
 
60°C 
 
Table 26: Unique Fluidigm barcodes added to the PCR products in the assay 
 
Fluidigm Barcode 
sequences (5’-3’) 
TGGTACTCGC 
GAAGTCGCTG 
GCGTTGTGGT 
CGTCGTAGCT 
TGTGATCTGG 
CGGTGGTGAT 
CGCTGGTACA 
GAGGTCTAGT 
GAACGTGTCG 
CTGGAGCGAT 
TTCGTCTCAG 
GTTAGCTTCG 
TTGGCGTGTG 
TGATCGCCGT 
GATGGCTAGA 
TGCCGCTGTT 
TTGTTGCGCC 
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GGAGCGATCA 
GTCGAGGATC 
TGTCTACTGG 
GTTGTACTGC 
GGCTCTGGTA 
TGCAGGCTGT 
GTCACGTGGT 
GTAGGATCGG 
TCGCTGATGG 
GCTTAGTCAC 
CTGGACATCT 
TACGGAGGTA 
CGTAGAGAGG 
GCTCGATCTT 
GTGCCAGAGT 
CTTGGTGCTG 
 
